 
 
 
SPONSOR   
Pharma Mar, S.A.  
Avda de los Reyes, 1   
Polígono Industrial “La Mina”  
[ZIP_CODE] Colmenar Viejo (Madrid), Spain  
Phone:  + 34 918 466 000  
Fax:  + [ADDRESS_772247] 
[LOCATION_001], NY [ZIP_CODE] 
[LOCATION_003] 
Phone: [PHONE_2225]  309 8737  
Fax: +[PHONE_9081]  
 
 
 
 
CLINICAL TRIAL PROTOCOL  
 
 
Randomized, Multicenter, Open -label, Phase III Study of Plitidepsin in Combination 
with Dexamethasone vs. Dexamethasone Alone in Patients with Relapsed/Refractory 
Multiple Myeloma  
 
 
INVESTIGATIONAL MEDICINAL PRODUCTS: plitidepsin (Aplidin®) and 
dexamethasone.  
Protocol No.:  APL -C-001-[ADDRESS_772248] No.: 2009- 016138- [ADDRESS_772249] Code: 01102426  
 
 
 
Protocol version 4.0:  [ADDRESS_772250]-C-001-09
SPONSOR
Pharm aMar S.A.
Avenida de los Reyes, 1 
Polígono Industrial “La Mina”
[ZIP_CODE] Colmenar Viejo, Madrid, Spain.
Phone: + 34 91 846 6000 /  Fax : + [ADDRESS_772251]
New  York, Ne w York [ZIP_CODE], [LOCATION_003]
Phone: + [PHONE_9288]
Fax : + [PHONE_9289]
CLINICA LTRIA L PROTOCOL
APL -C-001-09
(ADMYRE: Aplidin –Dexamethasone in RElapsed/Refractory MYeloma)
Randomized, Multicenter, Open -label, Phase III Study of Plitidepsin in 
Combination with Dexamethasone vs.Dexamethasone Alone in Patients with 
Relapsed/Refractory Multiple Myeloma 
INVESTIGATIONAL MEDICINAL PRODUCT: Aplidin®(plitidepsin)
Combination with: Dexamethasone
Protocol Code: APL -C-001-[ADDRESS_772252]: 2009 -016138 -29
Protocol Version 4.0
Substant ial Amendment # 3(edition 10July 2017) is included
This study will be conducted in compliance with the protocol, Good Clinical Practice (GCP) and 
the applicable regulatory requirements. 
Confidentiality statement
Information and data included in this protocol contain trade secrets and privileged or confidential 
information which is the property of the Sponsor. No person is authorized to make it public 
without written permission of the Sponsor.  These restrictions on disclosure will apply equally to 
all future information supplied to you which is indicated as privileged or confidential. This 
material may be disclosed to and used by [CONTACT_587135].
CL_0092 5.[ADDRESS_772253]-C-001-09STUDY CONTACTS NAME [CONTACT_587215] ,FAX NUMBER, AND E -
MAIL ADDRESS
Sponsor: 
Pharm aMar S.A.
Pharm aMar [LOCATION_003], Inc.Avda .de los Reyes, 1
Polígono Industrial “La Mina”
[ADDRESS_772254]
New  York , [LOCATION_001] [ZIP_CODE], 
[LOCATION_003]Phone: + 34 91 846 6000
Fax: + 34 91 846 6003
Phone: + [PHONE_9288]
Fax: + [PHONE_12195]
Responsible Physicians José Rodríguez , MD.
Clinical Oncology.
Clinical Development. 
Pharm aMar S.A.
Sara Martínez González , MD
Clinical Oncology.
Clinical Development. 
Pharm a Mar S.A.Phone: [PHONE_12206]
Fax: + 34 91 823 4504
E-mail: [EMAIL_11191]
Phone: [PHONE_12207]
Fax: + 34 91 823 4504
E-mail: smgonzalez @pharmamar.com
Project Manager Pi[INVESTIGATOR_587094]ía Paramio , PhD.
Clinical Operations.
Clinical Development. 
Pharm a Mar S.A.Phone: + 34 91 823 4597
Fax: + 34 91 846 6003
E-mail: [EMAIL_11192]
Study Coordinator Eva Jiménez Martínez .
Clinical Operations.
Clinical Development. 
Pharm a Mar S.A.Phone: + 34 91 823 4566
Fax: + 34 91 846 6003
E-mail: [EMAIL_11193]
Clinical Trial Monitor Pharm a Mar CRA.
Clinical Operations.
Clinical Development. 
Pharm a Mar S.A.Phone: + 34 91 846 6000
Fax: + [ADDRESS_772255] Research 
Organizations (CROs)ICON Clinical Research .
South County Business Park.
Leopardstown, Dublin 18.
Ireland.
(Only in Greece):
Qualitis Ltd.
Clinical Research & Medical 
Consulting.
32 Olaf Palme str.
Zografou 157 71.
Attiki, Greece.Phone:   +353 (0) 1 291 2000 
Fax:       +3 53 (0) 1 291 2700
Phone: + 30 [PHONE_12196]
Mobile: + 30 [PHONE_12197]
Fax: + 30 [PHONE_12198]
Pharm acovigilance Contact [CONTACT_587136].
Pharm acovigilance (PhV).
Clinical Development. 
Pharm a Mar S.A.Phone:    + 34 91 823 4557
Fax: + 34 91 846 6004
E-mail:[EMAIL_8329]
Out of office hours (GMT)
PhV service phone:
+ [ADDRESS_772256] 
Farm ingdale, NY [ZIP_CODE] 
[LOCATION_002] Phone:   +353 (0) 1 291 2000 
Fax:       +353 (0) 1 291 2201
Phone:   +[PHONE_12199] 
Fax:       +[PHONE_12200]
Clinical Pharmacology 
Contact[CONTACT_587137] , MD.
Clinical Pharmacology. 
Clinical Development.
Pharm a Mar S.A.Phone: + 34 91 8234521
Fax: + 34 91 823 4504
E-mail:sfudio @pharmamar.com
Central Laboratory for 
Pharm acokinetic SamplesKristine W agner -Caruso .
ICON Development Solutions.
[ADDRESS_772257] . 
Whitesboro, NY [ZIP_CODE], US.Phone: + [PHONE_12201]
E-mail: Kristine.Wagner -
[EMAIL_11194]
Central Laboratory for 
Troponin I AnalysisJosep Mª Mestres Alomar.
Tele-Test Analytika.
Montseny 11.
[ZIP_CODE] Barcelona.
Spain.Phone: + 34 93 415 44 27
Fax: + 34 93 416 02 63
E-mail: [EMAIL_11195]
QTc Substudy Contact [CONTACT_587137], MD.
Clinical Pharmacology. 
Clinical Development.
Pharm a Mar S.A.Phone: + 34 91 823 4521
Fax: + 34 91 823 4504
E-mail:sfudio @pharmamar.com
Central Laboratory for ECG 
Readings (QT Substudy)ERT.
Peterborough Business Park. 
Lynch Wood.
Peterborough, PE2 6FZ.
[LOCATION_008].Phone: + 44 (0) [PHONE_12202]
Fax: + 44 (0) [PHONE_12203]
QT-Related Polymorphisms 
Assessments LaboratoryTransgenomic, Inc.
Five Science Park.
New  Haven, CT06511.
[LOCATION_003].Phone: +[PHONE_12204]
Fax: +[PHONE_12205]
A list of additional study  contacts will be supplied as an additional document.
CL_0092 5.[ADDRESS_772258] OF ABBREVIATION S AND DEFINITION OF TERMS ................................ .......................... 25
1 INTRODUCTION ................................ ................................ ................................ ............................ 29
1.1 OVERVIEW OF THE DISEASE ................................ ................................ ................................ ....29
1.2 CURRENT TREATMENT FOR MULTIPLE MYELOMA ................................ ............................... 29
1.2.1 Plitidepsin ................................ ................................ ................................ ............................. 30
1.3 INFORMATION ON STUDY DRUG:PLITIDEPSIN ................................ ................................ .......31
1.3.1 Name [CONTACT_188113] ................................ ................................ ....................... 31
1.3.2 Non-clinical Data ................................ ................................ ................................ ................. 31
1.3.3 Clinical Data ................................ ................................ ................................ ........................ 39
1.3.4 Safety Issues ................................ ................................ ................................ ......................... 42
1.4 INFORMATION ON STUDY DRUG:DEXAMETHASONE ................................ ............................. [ADDRESS_772259]-C-001-097.1.1 Quantitative and Qualitative Composition ................................ ................................ .......... 64
7.2 ADMINISTRATION OFSTUDY MEDICATION ................................ .............................. 64
7.3 CRITERIA FOR TREATMEN T CONTINUATION AND RETREATMENT ................................ ......... 64
7.4 DOSE REDUCTION CRITER IA................................ ................................ ................................ ....66
7.5 CONCOMITANT MEDICATION ................................ ................................ ................................ ..68
7.5.1 Prophylactic Medication ................................ ................................ ................................ ......68
7.5.2 Allowed Medications/Therapi[INVESTIGATOR_014] ................................ ................................ .......................... 68
7.5.3 Prohibited Medications/Therapi[INVESTIGATOR_014] ................................ ................................ ...................... 69
7.5.4 Drug Accountability ................................ ................................ ................................ ............. 69
7.6 VERIFICATION OF COMPLIANCE WITH TREATMENT REGIMEN ................................ ............. 69
8 STUDY EVALUATIONS ................................ ................................ ................................ ................. 69
8.1 EFFICACY ................................ ................................ ................................ ................................ .69
8.2 SAFETY ................................ ................................ ................................ ................................ .....71
8.3 EVALUATION OF PHARMACOKINETICS ................................ ................................ ................... 71
9 ADVERSE EVENTS REPOR TING ................................ ................................ ................................ 71
9.1 DEFINITIONS ................................ ................................ ................................ ............................. 71
9.1.1 Adverse Event ................................ ................................ ................................ ...................... 71
9.1.2 Serious Adverse Event (SAE) ................................ ................................ .............................. 71
9.1.3 Unlisted /Unexpected Adverse Event ................................ ................................ ................... [ADDRESS_772260] ING................................ ................................ ............. 80
11.3 PATIENT INFORMED CONSENT ................................ ................................ ................................ 81
11.4 CONFIDENTIALITY /PATIENTS IDENTIFICAT ION................................ ................................ ......81
11.5 CASE REPORT FORMS ................................ ................................ ................................ ............... 81
11.6 INSURANCE ................................ ................................ ................................ ............................... 82
11.7 RECORDS RETENTION ................................ ................................ ................................ .............. 82
11.8 USE OF INFORMATION AN D PUBLICATION ................................ ................................ ............... 82
12 REFERENCES ................................ ................................ ................................ ................................ 83
13 APPEND ICES ................................ ................................ ................................ ................................ ..89
APPENDIX 1:CLINICAL MANAGEMENT OF HYPERSENSITIVITY REACTIONS TO PLITIDEPSIN®........ 89
APPENDIX 2:PERFORMANCE STATUS (ECOG) ................................ ................................ ........... 91
APPENDIX 3:COCKCROFT AND GAULT ’S FORMULA ................................ ................................ ............ 92
APPENDIX 4:DIAGNOSTIC CRITERIA ................................ ................................ ................................ ...93
APPENDIX 5:INTERNATIONAL MYELOMA WORKING GROUP UNIFORM RESPONS E CRITERIA FOR 
MULTIPLE MYELOMA ................................ ................................ ................................ ............................ 94
APPENDIX 6:STAGING SYSTEMS ................................ ................................ ................................ .......... [ADDRESS_772261]-C-001-09APPENDIX 7:LISTS OF DRUGS THAT PROLONG THE QT INTERVAL AND/OR INDUCE TORSADES DE 
POINTES VENTRICULAR ARRHYTHMIA ................................ ................................ ................................ 98
APPENDIX 8:QTC SUBSTUDY PROTOCOL ................................ ................................ .......................... 103
TABLES
Table 1. Plitidepsin: single -agent phase I trials in adult patients ................................ ......................... 40
Table 2. Final pharm acokinetic param eter es timates for plitidepsin. ................................ ................. 46
Table 3. Pre -treatm ent period ................................ ................................ ................................ ................. 56
Table 4. Evaluation during treatm ent................................ ................................ ................................ ....59
Table 5. Sampling points for pharm acokinetic evaluations. ................................ ................................ .63
Table 6. Criteria for continuation of treatm ent................................ ................................ ..................... 65
Table 7. Dose reduction criteria for plitidepsin and dexamethasone. ................................ .................. 67
FIGURES
Figure 1. MM1.S cell line, 48 h incubation ................................ ................................ ............................. 33
Figure 2. Activity of the combination plitidepsin + dexamethasone in MM cell lines ........................ [ADDRESS_772262]-C-001-09SYNOPSIS
TITLE Randomized, Multicenter, Open -label, Phase III Study of Plitidepsin in 
Combination with Dexamethasone vs.Dexamethasone Alone in Patients 
with Relapsed/Refractory Multiple Myeloma 
CODE APL -C-001-09
LOCATION OF 
INVESTIGATORS 
AND SITESThe complete listof investigators is available in a separate document.
NUMBER OF SITES Approximately 40-80 centers worldwide.
CLINICA L TRIAL 
OBJECTIVES
Primary To compare the efficacy of plitidepsin in combination with
dexamethasone vs. dexamethasone alone as measured by
[CONTACT_3988] -free survival (PFS) in patients with relapsed/refractory 
multiple mye loma ( MM).
Secondary To evaluate tumor response according to the International Myeloma 
Working Group (IMWG) criteria.
To assess duration of response ( DR)and overall survival ( OS).
To asses sefficacy in patients who undergo crossover from 
dexamethasone a lone to plitidepsin and dexamethasone combination .
To characteriz eand compar ethe safety profile on both arms in this 
population.
To characteriz e thepharmacokinetics (PK) and pharmacokinetic
/pharmacodynamic (PK/PD) relationship.
PATIENT 
ELIGIBILITY 
Inclusion Criteria1.Age ≥ 18 years.
2.Eastern Cooperative Oncology Group (ECOG) Performance 
Status (PS) ≤ 2(see Appendix 2 ).
3.Life expectancy ≥ 3 months.
4.Patient spreviously diagnosed with multiple myeloma based on 
IMWG diagnos ticcriteria (see Appendix 4). 
5.Patients must have relapsed or relapsed and refractory multiple 
myeloma (MM) (Appendix 5) after at least three but not more 
than sixprior therapeutic regimens for MM, including induction 
therapy and stem cell transplant in candidate patients, which 
will be considered as only one regimen.
CL_0092 5.[ADDRESS_772263] received previous bortezomib -containing and 
lenalidomide -containing regimens (or thalidomide where 
lenalidomide is not available ), unless unable to tolerate either of 
them.
7.Patients must have measurable disease defined as: 
a)For secretory MM: any quantifiable serum monoclonal 
protein value and, where applicable, urine light-chain 
excretion ≥ 200 mg/24 hours. 
b)For oligo-or non-secretory MM: presence of soft tissue 
(not bone) plasmacytomas ,as determined by [CONTACT_587138] [i.e., magnetic 
resonance imaging (MRI), computed tomography (CT) -
scan] ,and/orby [CONTACT_587139] (sFLC): involved FLC level ≥ 10 mg/dl provided 
the serum FLC ratio is abnormal. 
8.At least two-week washout period since the end of last therapy 
(six weeks ifprevious nitrosoureas -containing regimen) , given 
recovery to grade ≤ 1 from any non-hematological related 
adverse event (AE) derived from previous treatment (excluding 
alopecia ).
9. Adequate bone marrow (BM), renal, hepatic, and metabolic 
function (assessed ≤ 7 days before inclusion in the study):
a)Absolute neutrophil count (ANC) ≥ 1.0x 109/l (≥ 0.5 x 
109/l if due to extensive and documented BM involvement
by≥ 50% of plasma cell sin BMbiopsy) .
Screening of ANC should be independent of 
granulocyte -and granulocyte/macrophage -colony 
stimulating factor (G-CSF and GM-CSF) support for at 
least one week and of pegylated G-CSF for at least two 
weeks.
b)Platelet count ≥ 50 x 109/l (≥25 x 109/lif due to extensive 
and documented BM disease involvement).
c)Hemoglobin ≥ 8.5g/dl. 
Patients may receive red blood cells(RBC) and/or 
erythropoietin (EPO) ,and/or platelets transfusions in 
accordance with institutional guidelines .
d)Aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) ≤ 3.0x the upper limit of normal
(ULN).
e)Total bilirubin ≤ 1.[ADDRESS_772264] bilirubin ≤ 1.[ADDRESS_772265] 
when total bilirubin is above the upper limit of normal. 
f)Calculated creatinine clearance (CrCl) ≥ 30 ml/minute (by 
[CONTACT_587140]´s formula) (see Appendix 3 ).
g)Creatine phosphokinase (CPK) ≤ 2.[ADDRESS_772266].
h)Albumin ≥ 2.5 g/dl.
10.Left ventricular ejection fraction (LVEF) by [CONTACT_6751] 
(ECHO) or multiple -gated acquisition scan (MUGA) above the 
lower limit of normal (LLN) .
CL_0092 5.[ADDRESS_772267] 
agree to use a medically acceptable method of contraception 
throughout the treatment period and for six months after 
discontinuation of treatment.                   
12.Voluntarily signed and dated written informed consent prior to 
any specific study procedure.
PATIENT 
ELIGIBILITY 
Exclusion Criteria1.Concomitant diseases/conditions:
a)History or presence of angina, myocardial infarction, clinically 
relevant valvular heart disease , cardiac amyl oidosis or 
congestive heart failure within the last 12 months .
b)Symptomatic arrhythmi a(excluding anemia -related sinusal
tachycardia grade ≤ 2)or any arrhythmia requiring ongoing 
treatment, and/or prolonged QT-QTc grade ≥ 2; or presence of 
unstable atrial fibrilation. Patients with stable atrial fibrillation 
on treatment are allowed provided they do not meet any other 
cardiac or prohibited drug exclusion criterion.
c)Active uncontrolled infection.
d)Morphologic alor cytological features of myelodysplasia and/or 
post-chemotherapy aplasia on BMassessment.
e)Myopathy > grade 2 or any clinical situation that causes 
significant and persistent elevation of CPK (>2.[ADDRESS_772268] in two 
different determinations performed one week apart).
f)Known human immunodeficiency virus (HIV) infection (HIV 
testing is not required unless infection is clinically suspected).
g)Known active hepatitis B or C virus (HBV or HCV) infection.
h)Limitation of the patient’s ability to comply with the treatment 
or follow -up requirements.
i)Any other major illness that, in the Investigator’s judgment, will 
substantially increase the risk associated with the patient’s 
participat ion in this study.
j)Peripheral neuropathy > grade 2.
2.Women who are pregnant or breast feeding.
3.Concomitant medications that include corticosteroids,
chemotherapy, or other therapy that is or may be active against MM, 
within two weeks prior to Cycle 1 Day 1. Concurrent corticosteroids 
are allowed, provided they are administered at an equivalent 
prednisone dose of ≤ 10 mg daily, as premedication for blood 
products only.
4.Known history of peptic ulcer and/or major upper gastrointestinal 
bleeding epi[INVESTIGATOR_587095] g during last year before study entry 
and/or related to prior steroid -based therapy.
5.Relevant history of mood -disturbances changes associated with 
previous steroid -based therapy.
CL_0092 5.[ADDRESS_772269]-C-001-096.Disease -related symptomatic hypercalcemia despi[INVESTIGATOR_247482].
7.Known hypersensitivity to any involved study drug or any of its 
formulation components.
PATIENT 
ELIGIBILITY 
Number of patientsApproximately, 210 progression or death events will be needed for the 
evaluation of the primary endpoint (PFS). A total of approx imately 250
patients will be randomized in a 2:1 ratio to:
1. Arm A (plitidepsin + dexamethasone combination): approximately 
167 patients .
2.Arm B (dexamethasone single agent): approximately 83 patients .
An early futility analysis will be performed with t he data collected when 
40 patients in Arm A are evaluable for response.
Patients without valid disease evaluation during treatment will not be 
replaced for the main analysis , and will be analyzed as per ITT 
according to randomization.
CLINICA LTRIA L
DESIG NProspective, open -label, two-arm, 2:1 randomized phase III study. The 
efficacy of plitidepsin in combination with dexamethasone vs.
dexamethasone alone will be studied by [CONTACT_587141], and the evaluatio n of secondary 
efficacy endpoints. Patients in the control arm (dexamethasone alone, 
Arm B) who have documented disease progression according to 
Investigator’s criteria, after a minimum of eight weeks from 
randomization ,should be offered crossover to the combination arm
(plitidepsin + dexamethasone, Arm A) upon Sponsor agreement.
An Independent Review Committee (IRC) consisting of medical 
specialists directly involved in the care of patients with MM but not 
taking part inthis trial as investigators or subinvestigators, will review 
all efficacy data and will assign the date of progression/censoring and 
objective response according to their independent evaluation. This IRC 
will be blinded regarding to treatment arm allocation and identity of the 
cases revie wed.
An Independent Data Monitoring Committee (IDMC), including 
specialists in MM and in m edical statistics , will review the results of the 
protocol -specified analyses performed by [CONTACT_55467], 
including investigators and IRC efficacy asses sments and safety 
information. Then, the IDMC will provide advice on the conduct of the 
study.
Operational details for the IRC and IDMC will be detailed in the 
corresponding charters .
CL_0092 5.[ADDRESS_772270]-C-001-09Duration of study 
period (per patient)Patients will be evaluated at scheduled visits in up to three study 
periods:
Pre-treatment :from signature [CONTACT_587216].
Treatment :up to [ADDRESS_772271] dose of study 
drug administration, unless the patient starts any new antitumor 
therapy outside this clinical trial or dies, in which case the date of 
administration of this new therapy or the date of death will be 
considered the date of treatment discontinuation. An end-of-
treatment visit will be performed within 30 days ( ± two days) after 
last dose administration , unless the patient starts any new antitumor 
therapy outside this clinical trial, in which case the end-of-treatment 
visit should be performed immediately before the start of the new 
therapy (ideally the day befor e or the same day).
Follow -up: after treatment discontinuation, patients will be 
followed every four weeks until resolution of toxicities if any. 
Patients who discontinued treatment without progression will be 
followed every four weeks until disease progre ssion orother 
antitumor therapy ,whichever occurs first. After progression, all 
patients will be followed every three months for survival until death, 
or until the date of study term ination, whichever occurs first.
Patients will be considered to be on-study from the signature [CONTACT_587217] -up period. Patients will be 
considered to be on-treatment for the duration of their treatment and [ADDRESS_772272] treatment dose .Those patients in the control arm 
(Arm B) who cross ed over to the combination arm (Arm A) after 
disease progression will be considered on-treatment for the duration of 
their whole treatment (dexamethasone alone + dexamethasone in 
combination with plitidepsin) and during [ADDRESS_772273]. Specifically, treatment will continue until:
Disease progression (except for those patients treated with 
dexamethasone alone and eligible to beoffered crossover to 
combination therapy) .
Unacceptable toxicity .
Intercurrent illness of sufficient magnitude to preclude safe 
continuation of the study .
Patient refusal and/or non compliance with study requirements .
Protocol deviation with an effect on the risk/benefit ratio of the 
clinical trial .
Treatment delay >2 weeks from the theoretical treatment date
(except in case of clear clinical benefit, with the Sponsor’s 
approval) .
Requirement of > [ADDRESS_772274]-C-001-09INVESTIGATIONA L
DRUG
FormulationPlitidepsin will be supplied as a powder and solvent forconcentrate 
for solution for infusion .The 2-mgvialshould be reconstituted with
a 4-ml ampoule of reconstitution solution. The composition of 
reconstitution solution is Cremophor EL/ethan ol/water for injection 
(15/15/70% v/v/v).
Commercial lyavailable dexamethasone formulations will be used .
Mode of 
administration , dose 
and schedule1.Arm A: 
a)Dexamethasone: 40 mg orally on Day 1, 8, 15 and 22 every four 
weeks (q4wk) at least one hour befor e plitidepsin infusion.
b)Plitidepsin: 5 mg/m2intravenously (i.v.) diluted to a total 
volume of 250 ml in 0.9% saline (or 5% glucose )via a central 
venous catheter (suggested) or diluted to a total volume of 500 
ml in 0.9% saline (or 5% glucose )via a perip heral line. Infusion 
will be performed through a pump device over three hours 
(fixed rate) on Day 1 and 15 q4wk.
2.Arm B: 
a)Dexamethasone: 40 mg orally on Day 1, 8, 15 and 22 q4wk.
A cycle is defined as a four-week period.
Criteria for treatment 
continuationBefore the administration of each dose (re-treatment), patients must 
fulfill the baseline criteria defined in the following table:
Plitidepsin  
(Arm A)Dexam ethasone 
(Arm A and B)
  Day 1a& 15 bDay 1 a & 15
ANC
1.0 x 109/l or retur n to baseline 
values if extensive BM involvement -
Platelets 50 x 109/l or return to baseline 
values if extensive BM involvement-
Hemoglobin 8.5 g/dl 8.5 g/dl
Direct bilirubin if total 
bilirubin is above the 
upper normal limit1.[ADDRESS_772275] /ALT Grade 2 -
Muscular toxicity 
(myalgia, muscular 
weak ness, CPK 
increase) Grade 2 ≤ Grade 2
Other non -
hematological drug -
related AEs (except for 
increased GGT and/or 
AP, not optimally 
treated nausea and 
vomiting or 
hypertension, alopecia)c≤ Grade 1 ≤ Grade 1
ECG, ECHO/MUGAdSame as baseline Same as baseline
a. If a patient does not meet the requirements for treatment continuation on Day [ADDRESS_772276]-C-001-09drug, a dose decrease of 20% is mandatory; up to a maximum of two individual dose 
reductions are allowed. Patients needing additional dose reductions must be withdrawn from 
the trial.
b. If a patient does not meet the requirements for treatment continuation on Day 15, the 
administration of plitidepsin will be omitted. Patients requiring frequent dose omissions may 
have a dose reduction of 20% upon Investigator and Sponsor agreement. In no case more 
than two dose reductions are allowed. 
c. Any grade accepted for increased GGT and/or AP, and up to grade 2 peripheral neuropathy.
d. To be performed every three months unless more frequent assessments are clinically 
indicated.
AEs: adverse event(s); ANC: absolute neutrophil count; AP: alkaline phosphatase; BM: bone 
marrow; AST/ ALT: aspartate aminotransferase/alanine aminotransferase; CPK: creatine 
phosphokinase; GGT: -glutamyltranspeptidase; ECG: electrocardiogram; ECHO/MUGA: 
echocardiogram/multiple -gated acquisition scan.
Dose reduction criteria Patients experiencing frequent dose omissions and/or unacceptable 
toxicity, defined as
less than 50% compliance with treatment schedule, and/or 
grade ≥ 3 febrile neutropenia, or 
grade 4 neutropenia and infection, or
grade 4 neutropenia lasting > 7 days (except for patients with 
extensive BM involvement), and/or 
grade 4 thrombocytopenia (except for patients with extensive BM 
involvement), and/or 
grade 4 thrombocytopenia with grade ≥3 bleeding (in patients 
with extensive BM involvement), and/or
any grade ≥ 3 clinically relevant non-hematological toxicity other 
than non-optimally treated nausea and vomiting, diarrhea lasting < 
48 hours and/or grade ≥ 3 asthenia/fatigue lasting < 5 day s,
may continue treatment after reducing 20% of the dose of plitidepsin 
(first reduction to 4 mg/m2, and second reduction to 3.2 mg/m2), upon 
Sponsor agreement, if patient benefit is perceived. 
Dexamethasone doses are to be reduced by 50%, up to a maximum of 
two consecutive dose reductions (first one, 20 mg Days 1,8,15 and 22, 
and second, 20 mg Days 1 and 15 of each 28-day cycle), if a patient 
experiences 
muscular toxicity of grade ≥ 3 (weakness, myalgia and/or CPK 
elevations), or 
drug-related grade ≥ 3 fatigue, or 
mood disturbances or 
agitation of grade ≥ 2 or 
grade ≥ 3 fluid retention or 
grade 4 clinically documented infection 
these dose reductions are to be implemented independently from 
plitidepsin dose reductions, if required.
Once a dose reduction has been implemented, dose will not be re-
escalated thereafter. No more than two dose reductions (of either 
compound, if required) are allowed. Patient s needing additional dose 
reductions must be withdrawn from the trial. 
CL_0092 5.[ADDRESS_772277]-C-001-09Dose reduction criteria for both study drugs, plitidepsin and 
dexamethasone, are summarized in the following table:
Toxicity Worst 
gradePlitidepsin Dexam ethasone
Less than 50%  compli ance 
with treatment scheduleDecrease to 4 mg/m2, 
then to 3.2 mg/m2No reduction
Febrile neutropenia ≥ 3 Decrease to 4 mg/m2, 
then to 3.2 mg/m2No reduction
Neutropenia lasting > 7 
days
(except for patients with 
extensive BM involvement)4 Decrease to 4 mg/m2, 
then to 3.2 mg/m2No reduction
Thrombocytopenia 
(except for patients with 
extensive BM involvement )4 Decrease to 4 mg/m2, 
then to 3.2 mg/m2No reduction
Toxicity Worst 
gradePlitidepsin Dexam ethasone
Thrombocytopenia
with grade ≥ 3 bleeding 
(in patients with extensive 
bone marrow involvement)4 Decrease to 4 mg/m2, 
then to 3.2 mg/m2No reduction
Any clinically relevant 
and/or non -hematological 
toxicity (except non -
optimally treated nausea 
and vomiting, diarrhea < 
48 hours and/or 
asthenia/f atigue lasting < 5 
days)≥ 3 Decrease to 4 mg/m2, 
then to 3.2 mg/m2No reduction
Muscular toxicity 
(weakness, myalgia and/or 
CPK elevations)≥ [ADDRESS_772278] epi[INVESTIGATOR_1865]: decrease 
to 4mg/m2, then reduce 
dexamethasone; if 
toxicity recurs, reduce 
to 3.2 mg/m2First reduce 
plitidepsin; if 
persistence, decrease 
dexamethasone to 20 
mg Days 1,8,15,22, of 
each cycle; if toxicity 
recurs, decrease again 
first plitidepsin and, if 
persistence, then 
decrease 
dexamethasone dose to 
20 mg Days 1 and 15 
of each cycle. Two 
dose reductions are 
allowed for eit her 
agent (only for 
muscular toxicity).
Mood 
disturbances/agitation≥ [ADDRESS_772279] reduction to 20 
mg Days 1,8,15,22 of 
each cycle, then to 20 
mg Days 1 and 15 of 
each cycle.
Fluid retention ≥ [ADDRESS_772280]-C-001-09Prophylactic 
medication1.Arm A: 
All patients must receive the following prophylactic medication 
20-30 minutes befor e infusion of plitidepsin:
Ondansetron 8 mg i.v. or equivalent (granisetron 3 mg i.v. 
preferred when available).
Diphenhydramine hydrochloride 25 mg i.v. or equivalent, and
Ranitidine 50 mg i.v. or equivalent.
Oral metoclopramide and/or extended oral ondan setron (or their 
equivalents) may be used as per Investigator’s criteria/institutional 
guidelines.
2.Arm B: No prophylactic medication specified.
Allowed 
medications/therapi[INVESTIGATOR_014]1.Platelet and red cells transfusions. 
2.Erythropoietin.
3.Bisphosphonates according to the American Society of Clinical 
Oncology (ASCO) guidelines.
4.Therapi[INVESTIGATOR_587096]/or emergent medical 
conditions not specifically forbidden as per protocol elsewhere.
5.Antiemetics (excluding steroids) according to institutional or ASCO
guidelines.
6.Granulocyte colony stimulating factor (G-CSF)/granulocyte -
macrophage colony stimulating factor (GM -CSF) according to 
institutional or ASCO guidelines.
7.Palliative local radiation of a plasmacytoma. The irradiated lesion 
will then not be c onsidered an area of measurable/evaluable disease.
8.Systemic and/or local therapi[INVESTIGATOR_587097], particularly 
in the case of diarrhea or skin toxicity.
9.Patients in the plitidepsin + dexamethasone arm who develop grade 
≥ 2 muscular toxicity may be empi[INVESTIGATOR_587098] L-
carnitine at a total daily amount of up to 3 g, divided into three 
doses, until it decreases to grade ≤ 1.
10.Adequate analgesic medication, including opi[INVESTIGATOR_587099].
11.Drugs known to prolong QT interval and/or induce Torsades de 
Pointes should be avoided whenever possible (see Appendix 7, 
drugs labeled as 1). 
Prohibited 
medications/therapi[INVESTIGATOR_014]1.Concomitant administration of any othe r antineoplastic therapy.
2.Other investigational agents.
3.Immunosuppressive therapi[INVESTIGATOR_014], except single bolus hydrocortisone 
used eventually as treatment for hypersensitivity reactions, if 
required.
4.Primary prophylaxis with colony -stimulating factors such as G-CSF 
CL_0092 5.[ADDRESS_772281]-C-001-09and GM -CSF.
EVALUATION 
CRITERIAPrimary endpoint:
Efficacy :
PFS, according to IRC assessment, as per intention -to-treat 
(ITT) analysis.
Secondary endpoints:
Efficacy : objective response rate (RR); best overall response 
including rate of minor respons e (MR) or better (according to the 
IMWG response criteria), RR to combination treatment in patients 
who crossed over after progression on dexamethasone alone; time-
to-event endpoints: DR, and OS. Intrapatient response and PFS 
comparison of patients who crossed over from Arm B to Arm A. 
Both IRC and Investigator’s assessment will be used for the 
determination of RR, DR and PFS.
Safety :patients are evaluable for general safety if they received at 
least one dose of study treatment. Safety will be evaluated ineach 
arm separately. AEs will be graded according to the National Cancer 
Institute Common Term inology Criteria for Adverse Events 
(CTCAE), version 4.
The primary study analysis will be based on externally assessed PFS 
data in the ITT efficacy population , defined as all patients randomized 
to either treatment arm.
PFS will be calculated from randomization to the first evidence of 
progressive disease (PD) (IMWG criteria) or death due to any cause. If 
the patient receives further antitumor therapy before PD and within the 
timeframe expected for first follow -up, PFS will be censored on the date 
of the last disease assessment prior to the administration of this 
antitumor therapy. If the patient is lost to follow -up for the assessment 
of progression, or has more than one missing follow -up between the date 
of last tumor assessment and the date of progression, death or further 
antitumor therapy, the PFS will be censored at the date of last valid 
tumor assessment before the missing evaluations.
DR will be calculated from the date of first documentation of response 
to the date of disease progression or death. The same censoring rules 
described above for PFS calculation will be also considered for DR.
OS isdefined as the time from the date of randomization to the date of 
death or last contact. 
An external IRC, blinded to treatment arm, will assign the objective 
response and a progression or censoring date for each patient based on 
laboratory data, radiologic and bone marrow assessments when required, 
andevaluation ofall relevant clinical information, according to a 
predefined algorithm provided in a separate charter.
By [CONTACT_8345], disease response will be assessed every four weeks 
symmetrically across treatment arms irrespectively of treatment delays 
or omissions. Disea se assessments (e.g., serum or urine M protein, 
sFLC) and evaluation of extent of disease will be done within two weeks 
CL_0092 5.[ADDRESS_772282] scans, MRI (in 
case of soft tissue plasmacytoma) and any other documented means to 
evaluate tumor response or progression should be available for IRC 
review.
PHARMACO -
KINETIC 
EVALUATION SPlitidepsin pharmacokinetics (PK) will be evaluated in a minimum of 
100 patients included in the plitidepsin/dexamethasone arm (Arm A).
A total of [ADDRESS_772283] three 
infusions [infusions 1 and 2 of Cycle 1 (Days 1 and 15), and infusion 1 
of cycle 2 (Day 1)] using a sparse sampling schedule. Last sample will 
be collected immediately previous to infusion 2 of cycle 2 (Day 15) (see 
details in Table 5of this protocol).  
Pharmac okinetic parameters will be calculated with population methods, 
using the population PK model previously developed with PK data from 
411 patients treated with single -agent plitidepsin. 
QT SUBSTUDY The primary objective of the QT substudy is to assess thepotential 
effects of plitidepsin administered at a therapeutic dose on the duration 
of the QT/QTc interval, measured by [CONTACT_397910], in patients with 
relapsed/refractory multiple myeloma. Secondary objectives are: to 
evaluate QTc changes over the treatment perio d; to characterize the 
plitidepsin (real and estimated) whole blood concentration/QTc 
relationship (or PK/PD relationship); and to explore related ECG 
parameters.
This substudy will be conducted on patients included in study APL -C-
001-09 and randomized to the experimental arm (plitidepsin + 
dexamethasone), who voluntarily sign and date the informed consent 
form to participate in the QT substudy, and who fulfill the following at 
screening for the main study:
A 12-lead ECG consistent with normal cardiac condu ction and 
function, showing sinus rhythm, pulse rate between 45 and 100 
bpm, QRS interval <120 ms, and PR interval <200 ms.
Blood pressure between 90 and 150 mmHg systolic, inclusive, 
and not higher than 90 mmHg diastolic.
Serum electrolyte levels ≤ grade 1 (i.e. Ionic Ca++:  1.0 –1.5 
mmol/L; K+: 3 –5.5 mmol/L; Mg++:  0.5 –1.23 mmol/L). 
Prior exposure to anthracyclines at a cumulative dose of 
doxorubicin or equivalent, ≤ 450 mg/ m². 
Patients who at screening are not on medica tion that is known to 
CL_0092 5.[ADDRESS_772284] of plitidepsin on QTc:
ECGs will be obtained digitally using an ECG continuous 12-lead 
digital recorder on Day 1 and Day 15. The change in QTc from  baseline 
to each postdose time point on Day 1 and Day 15 (ΔQTc) will be 
evaluated. The QTc measurements at each of the scheduled time points 
along with their corresponding real and estimated whole blood 
plitidepsin concentration will be compared to explore any concentration -
effect relationship for plitidepsin.
STATISTICAL 
CONSIDERATIONSRandomization
Eligible patients will be stratified according to their ECOG -PS score (0 
and1 vs.2) and Durie -Salmon stage (I/II vs.III) and then randomized 
using a 2:1 randomization procedure to Arm A (plitidepsin in 
combination with dexamethasone) or Arm B (dexamethasone alone). 
Patients will be assigned to each group by [CONTACT_587142], so that a 
patient will have a two-thirds chance of getting Arm A (plitidepsin in 
combination with dexamethasone) and a one-third chance ofgetting 
Arm B (dexamethasone alone). The random permuted blocks method 
will be used; the size of the blocks in the randomization list will be fixed 
and not accessible to the investigators. To select the blocks, a uniform 
(0, 1) variable with a random seed will be used.
Sample size
Approximately [ADDRESS_772285] a HR of 0.625 in favor of the combination arm (equivalent 
to an increase of 60% in PFS, i.e., from 10 to 16 weeks, from 12 to 19.2 
weeks, from 16 to 25.6 weeks, etc.) with 90% power and 1-sided 2.5% 
significance level. As a preliminary hypothesis, it is estimated that up to 
[ADDRESS_772286] 40 patients evaluable for response in 
Arm A will be included in an early futility analysis. A response rate 
(IMWG criteria) of at least 30% (twelve or more responses by [CONTACT_587143]) will be taken as threshold for continuation of the study. A 
minimum response rate of 30% has been considered as clinically 
significant in this setting. This result will ensure that the lower limit of 
the exact binomial 95% Confidence Interval for the response rate will be 
greater than 15% (95% CI in case of 12 responses would be 16.6% -
46.5%). 
No claim for superiority in efficacy will be formulated in this interim 
analysis and no alpha -spending for the analysis of PFS is foreseen.
CL_0092 5.[ADDRESS_772287]-C-001-09The main analy sis will be conducted after 210 progression and/or death 
events are observed. The PFS assessed by [CONTACT_587144], while the Investigator assessment will be used for the 
secondary analysis of PFS.
An interim analysis of OS will be performed concomitantly with the 
final PFS analysis. A final analysis of OS will be performed when 80% 
of death events (approximately 200 death events) have occurred, or [ADDRESS_772288].
Note: Two years after the last patient accrual, on 19 May 2017, the final OS 
analysis was done based on a total of 195 death events (i.e., 76.5% of the 255 
randomized patients): 123 events in Arm A (plitidepsin plus dexamethasone) 
and 72 events in Arm B (dexame thasone). Then, the duration of this study is 
prolonged for six additional months, until 19 November 2017, in order to 
continue follow -up in the alive patients , and then to be able to reach the pre-
specified total of 80% of death events (approximately 204 death events) or even 
more.If the required death events are not achieved on [ADDRESS_772289] for the main endpoint (PFS) will be 
performed as supportive analysis. 
Secondary time -to-event endpoints (DR, OS) will be analyzed according  
to the Kaplan -Meier method and compared between treatment groups 
using the log -rank test. 
Counts and percenta ges, with their corresponding exact 95% confidence 
intervals, will be calculated for the response rate (IMWG criteria and, 
separately, minor response). The Fisher’s exact test will be used to 
compare the RRs of Arm A and B.
Both the IRC and Investigator’s assessments will be used for RR, PFS 
and DR.
Efficacy parameters vs. baseline covariates will be analyzed and 
appropriate tests will be used (i.e., Fisher's exact test and logistic 
regression for categorical variables; the log-rank test or Cox regression 
for time -to-event variables, etc.).
Exploratory intrapatient comparison of response and PFS (before and 
after crossover) will be performed for patients who switch from Arm B 
to Arm A after disease progression.
ANTICIPATED 
STUDY DATESProtocol submission: 1 Q2010.
Planned start date (first patient on study): 2Q2010.
Complete enrollment: 60months (2Q2010 -2Q201 5).
Planned study termination date: it will be set after the occurrence of 
80% of death events, [ADDRESS_772290] 
randomized patie nt, or IDMC recommendation (whichever occurs 
first).
Note: Two years after the last patient accrual, on 19 May 2017, the final 
OS analysis was done based on a total of 195 death events (i.e., 76.5% of 
the 255 randomized patients): 123 events in Arm A (plitidepsin plus 
dexamethasone) and 72 events in Arm B (dexamethasone). Then, the 
CL_0092 5.[ADDRESS_772291]-C-001-09duration of this study is prolonged for six additional months, until 19 
November 2017 , in order to continue follow -up in the alive patients ,and 
then to be able to reach the pre-specified total of 80% of death events 
(approximately 204 death events) or even more.If the required death 
events are not achieved on 19 November 2017, the study might be further
extended by [CONTACT_587145].
The futility analysis is foreseen after 40patients evaluable for response 
are recruited in Arm A, approximately 12 months after the recruitment 
start.
All patients on active treatment at the date of study termination will be 
offered to continue to receive plitidepsin -based treatment off-study 
according to the Investigator’s criteria and upon Sponsor agreement.
CL_0092 5.[ADDRESS_772292] cycleTreatment 
Subsequent cyclesEnd of 
treatmentFollow -
up16
1 8 15 22 29=1 8 15 22
Written infor med consent Before any 
procedures- - - - - - - - - -
Demographic data -14  to  0 - - - - - - - - - -
Medical history/ Baseline condition -14  to  0 - - - - - - - - - -
Primary diagnosis / Prior 
treatment(s)-14  to  0 - - - - - - - - - -
Assessment o f signs and symptoms1-14  to  0 - - - - - - - - - -
Complete physical examination, 
including weight and height1and 
BSA.-14  to  0 - - - -  - - -  -
Performance status (ECOG) -14  to  0  -  -  -  -  
Vital signs (heart rate, blood 
pressure, te mperature)-14  to  0 -  -  -  -  -
Hematology2,3-7  to  0 - -  -  -  -  -
Coagulation tests2,4-7  to  0 - - - -  - - -  -
Biochemistry A2-7  to  0 - -  -  -  -  -
Biochemistry B2-7  to  0 - - - -  - - -  -
Pregnancy test (if appl icable)5-7  to  0 Repeat if applicable -
ECG (before treatment on both 
arms) 6-7  to  0 -  -  -  -  -
LVEF by [CONTACT_12079] 7-14 to 0 Every 12 weeks ( ± 2 week tolerance)  -
Pharmacokinetics8-    - - - - -
Intercurrent events, concomit ant 
diseases and treatments-14  to  0 Throughout study -
Adverse events NA Throughout study 14
Local serum and Urine proteins9-28 to 0 - - - - - - - - - -
Central Lab Serum protein10NA  - - -  - - -  15
Central Lab Urine protein11NA  - - -  - - -  15
Serum β -2 microglobulin -14  to  0 Every 8 weeks 15-
Bone marrow12
-28  to  0 To confirm a presumed CR If  
clinically 
indicatedIf 
clinically 
indicated 
Radiological tumor assessment only 
if soft tissue plasmacytoma is 
present at baseline13-28  to  0 Every 8 weeks orif response is observed orif 
clinically indicated 13
Skeletal evaluation 17-28  to  0
(+1 week 
tolerance)If clinical symptoms suggest new bone lesions If 
clinically 
indicated 
Plitidepsin treatment (Arm A only) -  -  -  -  - - -
Dexamethasone treatment (both 
arms)-         - -
QT substudy 18 See Appendix [ADDRESS_772293]-C-001-09Note: windows for laboratory assessments on ly apply prior to the scheduled infusion (e.g., 2 -day window = within 48 
hours before the next scheduled infusion, etc.). Windows for radiological tumor assessment and LVEF assessment by 
[CONTACT_587146].
1. Repeat prior to first infusion, if treatment will be administered more than [ADDRESS_772294] infusion, if treatment will be administered more than 1 week (2 days tolerance) after 
the screening tests. IfCTCAE Grade ≥[ADDRESS_772295](s) should be assessed at least every 2-[ADDRESS_772296] every 2-3 days in the case of grade 4 non-febrile neutropenia and every day in case of grade 4 
febrile neutropenia.
4. Close monitoring of patient s taking oral anticoagulants is required. 
5. Serum human chorionic gonadotropin (HCG). Repeat during treatment if applicable, always prior to study  
drug administration.
6. It should allow rhythm definition (at least 30 seconds of duration). Before each study drug administration, 
symmetrically on both arms. After the first two cycles, ECG will be performed only on Day 1 of each 
cycle.
7. During treatment, LVEF (when due) will be performed within 7 days of plitidepsin administration, except 
in non -primarily cardiac o rigin acutely ill hospi[INVESTIGATOR_9643], until resolution. 
8. Plitidepsin pharmacokinetics (PK) will be evaluated in at least [ADDRESS_772297] three infusions [infusions 1 
and 2 of Cycle 1 (Days 1 and 15), and infusion 1 of Cycle 2 (Day 1)] using a sparse sampling schedule. 
Last sample will be collected immediately previous to infusion 2 of Cycle 2 (Day 15)(see details in Table 
5).
9. Serum and urine protein analysis performed at the institution to assess/document disease relapse after last 
treatment will be used for screening (tests performed within 4 weeks prior to registration will be allowed).
10. Serum protein electr ophoresis, immunoglobulins quantification, M -protein identification and quantification, 
serum free light chains (sFLC) ratio and immunofixation will be performed in the Central Lab starting on 
Day 1 of Cycle 1 prior to treatment (complete protein panel). P atients with secretory MM will be followed 
with serum electrophoresis, immunoglobulins quantification and M protein quantification; patients with 
oligo or non -secretory MM will be followed with sFLC ratio, in case it has been abnormal at study entry; in 
case of M protein disappearance, immunofixation will be done to confirm CR, and if CR is confirmed, 
sFLC ratio will be performed, to determine stringent complete response (sCR). All protein assays will be 
done symmetrically every four weeks (i.e., Day 1 of e ach 4 -week cycle, with a window of ± 2 days) in both 
treatment arms, irrespectively of treatment delays or omissions.
11. Urine immunoelectrophoresis and immunofixation in Central Lab: on Day 1 of Cycle 1, and afterwards, 
only if Bence -Jones proteinuria was present at entering the study. To be done symmetrically every 4 weeks 
(with a window of ± 2 days) in both treatment arms, irrespectively of treatment delays or omissions.
12. At screening (within 4 weeks prior to registration). In all patients, BM evaluation is mandatory at screening 
and while on treatment in case of CR (including flow cytometry or immunohistochemistry, to demonstrate 
the presence of clonal plasma cells, only in those patients with presumed CR). In patients with non-
secretory MM, it must be repe ated [ADDRESS_772298] 
administration of study drug, only those procedures that are relevant to any persisting toxicities need to be 
performed.
15. Only in patients who discontinued treatment without documented disease progression.
16. Bone marrow evaluation, radiological tumor assessment and skeletal evaluation will be performed only on 
pre-treatment and treatment evaluations. These evaluations will not be performed after the end of treatment. 
After the end of treatment, all patients will be followed every three months for survival until death, or until 
the date of study termination. The follow -up visits will be performed by [CONTACT_587147]/her disease. This will only apply to patients who 
are followed up after discontinuing treatment due to disease progression.
17. May be evaluated using CT -scan or X -ray, provided the same procedure is used throughout the study.
18. Optional substudy (a separate ICF needs to be signe d).
Note: One patient was still undergoing treatment on 19 May 2017 . However, as the primary endpoint of the study 
(progression -free survival) was fulfilled, and this extended follow -up is focused only on survival, no information such 
as central laboratory data or images will be sent for independent review. Nevertheless, laboratory determinations or 
images will be done locally, if clinically indicated, in order to perform tumor assessment.    
CL_0092 5.[ADDRESS_772299]-C-001-09Hematology: Differential white blood cells (WBC), hemoglobin, h ematocrit and platelets.
Biochemistry A:AST, ALT, total bilirubin, direct bilirubin in case total bilirubin is above ULN, alkaline 
phosphatase (AP), creatinine, calculated creatinine clearance (Cockcroft and Gault´s formula; see Appendix 3), 
glucose, serum electrolytes (Na+, K+, Mg++, Ca++), creatine phosphokinase (CPK), CPK-MB fraction (should be 
measured only if CPK is abnormally high) and troponin I. 
Biochemistry B : Uric acid, lactate dehydrogenase (LDH), total proteins a nd albumin.
Coagulation tests : PT, PTT and INR.
CL_0092 5.[ADDRESS_772300] OF ABBREVIATION S AND DEFINITION OF TERMS
ABP Arterial Blood Pressure
AE(s) Adverse Event(s)
ALL Acute Lymphoblastic Leukemia
ALT Alanine Aminotransferase
ANC Absolute Neutrophil Count
ANOVA Analys is Of Variance
AP Alkaline Phosphatase
ASCO American Society of Clinical Oncology
ASH American Society of Hematology
AST Aspartate Aminotransferase
AUC Area Under The Curve
βhCGs Beta Human Chorionic Gonadotrophins
BM Bone Marrow
Bmax Maximal Pliti depsin Concentration into Red Blood Cells
BP Blood Pressure
BPM Beats Per Minute
BSA Body  Surface Area
CBP CREB binding protein
CDK Cyclin-dependent Protein Kinase
C Cycle
CI Confidence Interval
CL Clearance
Cmax Maximum Plasma Concentration
CPK Creatine Phosphokinase
CPK -MB Serum CPK Isoenzymes (Found In Cardiac Muscle)
CR Com plete Response
CrCl Creatinine Clearance
CRF Case Report Form
CRO Contract Research Organization
CTCAE National Cancer Institute Common Terminology Criteria for Advers e Events
CT-scan Com puted Tom ography Scan
CV Cardiovascular
d/D Day(s)
DI Dose Intensity
DLT Dose -Limiting Toxicity
DNA Deoxyribonucleic Acid
DR Duration of Response
ECG Electrocardiogram
CL_0092 5.[ADDRESS_772301]-C-001-09ECHO Echocardiogram
ECOG Eastern Cooperative Oncology Grou p
EOI End of Infusion
EPO Erythropoietin
ER Endoplasmic Reticulum
EU European Union
GC Glucocorticoids
GCP Good Clinical Practice
G-CSF Granulocyte Colony Stimulating Factor
GGT -Glutamyltranspeptidase
GI Gastrointestinal
GM-CSF Granulocyte/Macr ophage Colony Stimulating Factor
GMT Greenwich Mean Time
GR GC Receptor
GSH Gluthation eReduced
h Hour(s)
HAT Histone Acetyltransferase
Hb Hem oglobin
HBV Hepatitis B Virus
HCG Human Chorionic Gonadotropin
HCV Hepatitis C Virus
HDAC Histone Deacet ylase
HIV Human Immunodeficiency Virus
HBR Heart Beating Rate
HR Hazard Ratio ; Heart Rate
IB Investigator Brochure
IC50 Half Maximal Inhibitory Concentration
ICF Informed Consent Form
ICH International Conference on Harmonization
IDMC Independent D ata Monitoring Committee
IEC Independent Ethics Committees
Ig Immunoglobulin
IMWG International Myeloma Working Group
IMP Investigational Medicinal Product
INR International Normalized Ratio
IRB Institutional Review Board
IRC Independent Review Comm ittee
ISS International Staging System
i.v. Intravenous
CL_0092 5.[ADDRESS_772302]
MM Multiple Myeloma
MP Melphalan plus Prednisone
MR MinorResponse
MRI Magnetic Resonance Imaging
ms Milliseconds
MTD Maximum Toler ated Dose
MTT 3-(4,5-Dimethyl thiazol -2-yl)-2,5-diphenyl tetrazolium bromide
MUGA Multiple -gated Acquisition Scan
NCI National Cancer Institute
NCI-CTC National Cancer Institute Common Toxicity Criteria
NHL Non-Hodgkin Lymphoma
NSCLC Non-Small Cell Lung Canc er
ORR Overall Response Rate
OS Overall Survival
PCR Polymerase Chain Reaction
PD Progressive Disease ; Pharmacodynamics
PFS Progression -free Survival
PK Pharm acokinetics
p.o. Per os, Oral(ly)
PR Partial Response
PS Performance Status
PT Prothromb in Time
PTT Partial Thromboplastin Time
PTCL Peripheral T -Cell Lymphoma 
Q2 Intercompartmental Exchange Flow  for the Shallow Compartment
Q3 Intercompartmental Exchange Flow  for the Deep Compartment
q4w Every Four Weeks
qPCR Quantitative Polymerase Ch ain Reaction
RBC Red Blood Cell
RD Recommended Dose
RNA Ribonucleic Acid
CL_0092 5.[ADDRESS_772303]-C-001-09RP-HPLC Reversed -Phase High Performance Liquid Chromatography
RR Response Rate
RT Plasma -to-blood Ratio; Reverse Transcription, Room Temperature
SAE(s) Serious Adverse Event(s)
SCLC Small Cell Lung Carcinoma
sCR Stringent Complete Response
SCT Stem Cell Transplantation
SD Stable Disease
sFLC Serum Free Light Chains
SOI Start Of Plitidepsin Infusion
SPC Summary of Product Characteristics
t1/[ADDRESS_772304] Upper Limit of Norm al
UV light Ultraviolet Light
US Ultrasound (Cardiac)
V1 Central Volume of Distribution
V2 Volume of Distribution of the Shallow Compartment
V3 Volume of Distribution of the Deep Compartment
VEGF Vascular Endothelial Growth Factor
VEGFR -[ADDRESS_772305]-C-001-091INTRODUCTION
Despi[INVESTIGATOR_587100] (MM), most patients 
ultimately  relapse. The disease remains incurable and there is an urgent need for 
developi[INVESTIGATOR_587101]. The addition of 
corticosteroids to active ne w investigational drugs in MM is a major way  to improve the 
outcome, particularl y because this agent has non-cross -resistance and a different 
toxicity  profile when compared to other agents commonly  used for MM treatment.
1.1 OVERVIEW OF THE DISEASE
MM is a malignant plasma -cell disorder characterized by [CONTACT_587148] a 
monoclonal protein from plasma cells in the bone marrow (BM). Information from the 
National Cancer Institute (NCI) indicates that,in the [LOCATION_003], 19,920 new cases of MM 
will be diagnosed in 2009 and 10,690 patients will die from theirdisease (1).Similar 
figures occur in Europe, with an incidence of 6.0/100,000 habitants per year and a 
mortality  rate of 4.1/100,000 habitants per year (2).In the Western hemisphere, about 
1% of cancer -related deaths are due to myeloma. Traditionally , MM has beenstaged 
according to the Durie -Salmon system ,based on the amount of abnormal monoclonal 
immunoglobulin in the blood or urine; blood calcium levels; the amount of bone 
damage shown by X-rays,blood hemoglobin levels , and renal function (3). More 
recentl y,the International Staging System (ISS), which relies on the levels of albumin 
and beta -2-microgl obulin , has been validated (4). Neverthe less, though both sy stems are 
based on easily obtained clinical and laboratory  parameters, and predict for survival, it 
has recently  been suggested that newer parameters should be included in the prognostic 
initial evaluation of MM patients (5, 6). The present recommendation is to include both 
classifications in clinical trials, as they  provide complementary  information (6).
Recent advances have identified new prognostic markers, such as the complete deletion 
of chromosome 13 or its long arm asdetected by [CONTACT_93106][INVESTIGATOR_007] ,the t(4;14) or t(14;16) 
translocation s,and the increased bone marrow microvascular densit y.
The disease primaril y affects elderly  individuals ,with a median age of [ADDRESS_772306] a median survival of 24–30 months. Twent y-five 
percent of patients survive five years or longer, and the 10-year survival is 
approximately  3% (1).
1.[ADDRESS_772307] -dose chemotherap y to cure this disease has led to study  the use of 
dose intensified chemotherap y regimens. Conditionings may  involve ablative or reduced 
intensity , non-myeloablative regimens, and may be followed by [CONTACT_587149] -cell rescue. Despi[INVESTIGATOR_587102], the 
morbidity  and mortality related to intensified chemotherap y regimens are still of 
concern, particularl y in the aged and frail population; therefore, this treatment option 
has been reserved onl y for younger patients with adequate performance status (7).
CL_0092 5.[ADDRESS_772308] treatment for suitable MM patients aged <65 years is induction 
chemotherap y followed by [CONTACT_20375] -cell transplantation (SCT), which has been 
associated with increased response rates (complete response of30-40%), overall 
survival (54-62 months )and event -free survival (25-43 months )when compared to 
traditional chemotherap y(7),although these results are currentl y being challenged by 
[CONTACT_587150] “novel agents”, 
which are increasingl y being used as part of first -line combinations.
In elderl y patients, namely  those over [ADDRESS_772309] -dose melphalan plus prednisone (MP) or prednisone alone 
(but at higher doses) have become a widel y-accepted standard of care (8). However, MP 
is now challenged, as new therapeutic options like thalidomide, lenalidomide and 
bortezomib, initially  approved in the relapsed/refractory  setting, are now moving 
upfront as part of new combinatio n regimens. Two recentl y finished randomized trials 
have shown the superiority  of adding thalidomide to MP compared to MP alone in 
elderl y patients (9, 10).Likewise , the VISTA trial has shown superiority  when 
bortezomib was added to MP in a similar patient population (11).
In patients with relapsed or refractory  MM, thalidomide ,lenalidomide and bortezomib 
have been used as single agents ,with responses of 30%,38% and 27%, respectivel y
(12-14). However, in these and other studies evaluating therapi[INVESTIGATOR_587103]/refractor y 
MM patients (15-18),progression -free survival (PFS) and time to progression (TTP) 
were in the range of 4-[ADDRESS_772310] 
treatment is available and therapeutic options are limited, thus representing a clear 
unmet medical need. Options may include palliative care, steroid treatment, oral 
alkylating agents, or participation in clinical trials. Of note, a previous exploratory 
phase II trial in which plitidepsin was administered with or without the addition of 
dexamethasone has provided evidence of activity in this patient population (see details 
in Section [IP_ADDRESS] ).
In conclusion, all these innovative approaches have significantly  changed the available 
therapeutic options, especiall y in elderl y patients and in patients with 
relapsed/refractory  MM, as they are not likely to show cross -resistance or the toxicities 
commonly  seen with traditional chemotherap y regimens based on alkylators and 
anthracy clines. Nonetheless, newer toxicity  patterns are also emerging, such as an 
increased thrombo ticrisk and neurotoxicity , which may be cumulative. These new 
drugs are being combined with classic agents, such as melphalan, prednisone and 
anthracy clines, as an upfront treatment; however, their exact role and sequence in the 
changing landscape of MM therap y remains to be defined.
1.2.[ADDRESS_772311]-C-001-09Aplidium albicans . Although the main mechanism of action by [CONTACT_587151]/or induces cell death remains to be fully characterized, the 
major effects of plitidepsin can be at least partially  attributed to a cell cy cle block in the 
G0/G1 phases and the induction of apoptosis (19-21)via activation of the JNK pathway; 
this activation leads to a decreased production of intracel lular glutathione, an increase in 
reactive oxygen species and an alteration of the mitochondrial membrane potential, 
ultimately  leading to both caspases -dependant and independent apoptosis. In addition to 
the pro-apoptotic properties of plitidepsin, the molecule has demonstrated 
antiangiogenic properties in several pre-clinical models via direct activity  on vascular 
endothelial growth factor (VEGF) -stimulated angiogenesis. In fact, plitidepsin has been 
demonstrated to reduce the secretion of VEGF and its receptor type 1 (VEGFR -1) from 
MOL T-4 human leukemia cells in vitro (22). It seems that the majority  of the 
pharmacologic activit y of plitidepsin can be attributed to a combination of these cellular 
effects in vivo.
Antitumor activity  has been display ed by [CONTACT_587152]. In 
addition, this observation has been sustained in early clinical trials as single agent, 
showing clinical responses in patients with hematologic almalignancies as well as solid 
tumors. The toxicity  of plitidepsin innormal hematopoietic tissue is several folds lower 
than in tumor cells. More importantly , this observation translates into a lack of clinicall y 
significant hematologic altoxicity  in clinical trials to date, even in leukemia/ly mphoma 
patients with limited bone marrow reserve capacity . Consequently , plitidepsin may 
display  a positive profile for combination with other agents in chemotherapy  regimens, 
avoiding overlappi[INVESTIGATOR_5171] .
1.3 INFORMATION ON STUDY DRUG:PLITIDEPSIN
Please refer to the Investigator's Broc hure (IB) for full information on plitidepsin.
1.3.1 Name [CONTACT_587218]®is the trade name [CONTACT_587219] [leucine, 1-(1,2-dioxopropy l) prolyl-N-
methy l-leucy lthreony l-4-amino -3-hydroxy-6-methy lheptanoy l-4-hydroxy-2,5-dimethy l-
3-oxohexanoy l-N,0-dimethy ltyrosylprolyl, O-lactone)], a cyclic depsipeptide originall y 
isolated from a Mediterranean marine tunicate, Aplidium albicans , which iscurrentl y 
manufactured b y total synthesis. 
1.3.2 Non-clinical Data
[IP_ADDRESS] Mechanism of Action in Cell Lines
The major effects of plitidepsin can be specifically  attributed to the induction of 
apoptosis secondary  to oxidative stress and activation of JNK activity . Exposure of 
cultured human cervical cancer (HeLa) cells to plitidepsin induced oxidative stress 
resulting in cellular apoptosis (23), and a rapid and sustained activation of JNK, p38 
MAPK and ERK in human breast cancer cells (MDA -MB-231) (24). In fact, genetically 
engineered mouse embryo fibrobla st (MEFs) which did not express any JNK isoforms 
were at least an order of magnitude less sensitive to plitidepsin (21). JNK has been 
shown as a critical component in plitidepsin -induced cytotoxicity  through a decrease in 
the intracellular reduced glutathione (GSH) levels which, in turn, increases the levels of 
CL_0092 5.[ADDRESS_772312]-C-001-09reactive oxygen species (24). Plitidepsin effects on the Rac1, a pleiotropic regulato ry 
protein, would contribute to the sustain edactivation of JNK (19, 25) . Additi onally  a cell 
cycle inhibitor, p27 (kip1), has been shown to determine plitidepsin sensitivity  in vitro, 
on a panel of mouse sarcoma cells from resected tumors (26). Data on human renal cell 
carcinoma lines (A-498 and ACHN) confirmed the oxidative operating mechanism and 
recent studies on human melanoma cell lines (SK-MEL -28 and UACC -257) have again 
involved a Rac1/JNK pathway  in the apoptotic cell arrest induced by [CONTACT_587153] (24, 
25), thus demonstrating a common mechanism in cells of different tumor origins. Latest 
studies have shown that plitidepsin is able to increase levels of cell membrane 
phospholipid oxidation and deox yribonucleic acid (DNA) oxidation in vitro (19).
Apart from its pro-apoptotic properties, plitidepsin has also demonstrated 
antiangiogenic effects. The addition of the drug reduces the active secretion of VEGF 
and the expression of its receptor (VEGFR -1) on human leukemia (MOLT -4) cells in 
vitro (22), suggesting that the block of cell growth might be mediated by  [CONTACT_587154]. Supporting these findings, plitidepsin has been shown highl y 
cytotoxic on acute myelogenous leukemia cells, both on regular cultures (K-562, HEL 
and HL -60) and on blasts obtained from patients (27). Furthermore, plitidepsin was able 
to reduce the secretion of VEGF in a dose-dependent manner, thus confirming previous 
observations. At the functional level, plitidepsin inhibited spontaneous and growth 
factor -induced angiogenesis, prevented proliferation, migration and invasiveness, and 
hampered formation of capi[INVESTIGATOR_1396] -like tridimensional structure s, in in vivo and in vitro
models (28).
In summary , it appears that the pharmacologic activity  of plitidepsin can be attributed, 
at least in part, to a combination of pro -apoptotic and antiangiogenic effects in vivo .
[IP_ADDRESS] In vitro and in vivo Data as Single Agent
In vitro studies demonstrated antiproliferative activity  against a broad spectrum of 
tumor types, namel y bladder cancer, breast cancer, stomach cancer, lung cancer, 
melanoma, neuroblastoma, prostate cancer, thyroid cancer (with IC50values ranging 
from 10-7to 10-9M), and leukemia, myeloma and lymphoma (with IC50values ranging 
from 10-8to 10-9M) (29). 
In addition, a model in MM has been explored (30). Plitidepsin exhibited, at clinically  
achievable concentrations, potent in vitro activit y against primary  MM tumor cells and a 
broad spectrum of human MM cell lines, including cells resistant to conventional (e.g., 
dexamethasone, alkylating agents, and anthracyclines) or novel (e.g., thalidomide and 
bortezomib) anti -MM agents. Plitidepsin was active against MM cells in the presence of 
proliferat ive/antiapoptotic cy tokines or BMstromal cells and had additive or sy nergistic 
effects with some of the established anti-MM agents. The anti-MM effect of plitidepsin 
was associated with suppression of a constellation of proliferative/antiapoptotic genes 
and up -regulation of several potential regulators of apoptosis. 
In conclusion, plitidepsin showed consistent cytotoxic activity  against a broad selection 
of human -derived solid tumors cell lines such as lung, breast, thy roid, prostate, stomach, 
bladder, an d kidney , as well as human malignant cell lines of hematologic alorigin.
In the hollow fiber in vivo model, in which athymic rats were treated with i.v. 
plitidepsin, tumors of the bladder, stomach, and prostate were shown to be susceptible 
CL_0092 5.[ADDRESS_772313] human renal and pancreatic 
tumors when injected to athymic mice. 
Additionally , the antitumor and antiangiogenic effects of plitidepsin were evaluated in 
the 5T33MM syngeneic orthotopic model of MM (31). In vitro, plitidepsin inhibited 
DNA synthesis and induced an arrest in transition from G0 /G1 to S phase. Furthermore, 
plitidepsin induced apoptosis by [CONTACT_587155]. For 
the in vivo experiment, i.p.-injected plitidepsin was well tolerated by [CONTACT_587156] 42% (p<0.001), while BM invasion with 
myeloma cells was decreased by  35% (p<0.001). Plitidepsin also reduced the my eloma -
associated angiogenesis to basal values. This antiangiogenic effect was confirmed in 
vitro and may be explained by [CONTACT_587157]. In summary , these data indicate that plitidepsin is well tolerated in vivo and 
its antitumor and antiangiogenic effects support the use of the drug in MM (32).
[IP_ADDRESS] In vitro and in vivo Data in Combination
Clinical experience in the manag ement of MM patients supports the concept that drug 
combinations induce higher response rates than single agents. The ability  of plitidepsin 
to increase the activity  of other established anticancer agents was assessed in several 
human tumor cell lines. Thecombination of plitidepsin with dexamethasone that was 
selected for further development in solid tumors and preclinical data is summarized 
below.
[IP_ADDRESS].1 Non-clinical Data of the Plitidepsin -Dexamethasone Combination
The combination of plitidepsin with dexametha sone was explored regarding the 
viability  of MM1.S and U266 -LR7 cells. Both non-constant ratio (for suboptimal doses 
of drugs) and constant ratio experimental designs were used. The effects of single and 
combined treatments after [ADDRESS_772314] of dexamethasone. The combination 
was additive but tended to be sy nergistic at higher doses (30) (Figure 1).
0.2 0.4 0.6 0.8 [IP_ADDRESS].0Plitidepsin  + Dexamethasone CR
Combination.
index
Fraction affected
Figure 1. MM1.S cell line, 48 h incubation
Similar results were obtained in a stu dy by [CONTACT_587158]. (Internal Report, March 2008), 
where the combination of plitidepsin and dexamethasone (at a fixed plitidepsin to 
dexamethasone ratio of 1:50) was tested in four MM cell lines (MM1.S, ARP, RPMI -
CL_0092 5.[ADDRESS_772315]-C-001-098226 and MM1.R (dexamethasone -resistant). As shown in Figure 2, the combination 
(Apl+Dex) resulted in a significant increase in cell toxicity  when adde d to the MM cell 
lines MM1.S, ARP, and RPMI -8226 compared to either drug alone (Apl/Dex). In 
contrast, only plitidepsin had an effect on the dexamethasone -resistant cell line, 
MM1.R.  
Figure 2. Activit y of the combination plitidepsin + dexamethasone in MM cell lines
This combination was synergistic for the cell lines MM1.S, ARP, and RPMI -8226 at all 
tested (nanomolar) concentrations of the drugs, while it was additive for MM1.R at high 
concentrations.
[IP_ADDRESS].[ADDRESS_772316] important for its antitumo r activity ; however ,
they offer a potentiall y unique mechanism of action and a major therapeutic advantage. 
In particular, they may account for the synchronized targeting of different specific 
proliferative/antiapoptotic pathway s in MM tumor cells. In fact, gene expression 
profiling results in tumor cells provide a framework for designing a combinatorial 
therap y to potentiate each individual antitumor effect. It is likely that their pleiotropic 
and synergistic effects in vitro over MM cells may neutralize the pathways thatenable 
tumors to evade cell death and to become resistant to anticancer treatment.
Glucocorticoids (GCs), such as dexamethasone, induce apoptosis in the hematologic al
lineage, while support ingthe survival of several non-hematologic altissues, such as the 
mammary  gland, ovary , liver or fibroblasts (33-35). GCs exert their action through 
interaction with the intracellular GC receptor (GR), a ligand regulated transcription [ADDRESS_772317]+Dex
AplidinnM
DexnM 7.[ADDRESS_772318]+Dex
AplidinnM
DexnM 7.[ADDRESS_772319]+Dex
AplidinnM
DexnM 7.[ADDRESS_772320]+Dex
AplidinnM
DexnM 7.[ADDRESS_772321]+Dex
AplidinnM
DexnM 7.[ADDRESS_772322]+Dex
AplidinnM
DexnM 7.[ADDRESS_772323]+Dex
AplidinnM
DexnM 7.[ADDRESS_772324]+Dex
AplidinnM
DexnM 7.[ADDRESS_772325]-C-001-09factor thatpositively  or negativel y alters the expression of specific target genes. In turn, 
GR either induces gene transcription by [CONTACT_587159] -enhancer regions of responsive genes or reduces gene transcription by 
[CONTACT_587160] n (35-38). 
Thus , dexamethasone acts over genes responsible for the induction of apoptosis in 
lymphoid cells, in which seems a plitidepsin comple ment arypathway , therefore
enhancing plitidepsin cytotoxicity (39-42). 
Like plitidepsin, GCs may  induce apoptosis by  [CONTACT_587161] s. Death receptors (CD95 and TRAIL) and downstream 
effectors have been found deregulated by [CONTACT_587162] . 
Regarding the intrinsic and mitochondria -mediated pathway s, which lead to release of 
pro-apoptotic molecules upon depolarization of the mitochondrial membrane potential, 
the apoptotic response is tightly  regulated by [CONTACT_587163]-and anti-
apoptotic Bcl-2 family  members. Additionall y, both, plitidepsin and dexamethasone, 
upregulate pro-apoptotic genes (TRAIL -Rl/DR4 and TRAIL -R2/DR5, Bax, Bak, Bad, 
Fas, FasL, TRAIL, Noxa, PIG3, Bim, Bik and Puma, Bcr-Abl (in CML), c-Myc, and
HDAC3), while they downregulate pro-survival genes (c-FLIP, MCl-I, Bel-X, and Bcl-
2)(36, 43) .
On the other hand, both agents have been found to disrupt cellular redox state (e.g., 
ROS), and damage mitochondria in cells undergoing apoptosis, as an effect of the 
depolarization of mitochondrial membrane, which will enhance the expression of death 
receptors and ligands resulting again in the activation of the caspase scascade.
Moreover, plitidepsin -induced suppression of caspase sinhibitors (FLIP, survivin) may 
contri bute to the increased sensitivity  of plitidepsin -treated MM cells to caspase s-
dependent apoptosis by [CONTACT_149618]. Both agents deregulate Hsp90 complexes such 
as receptor, FKBP5, HSPs and DNAJs. 
Other molecules and pathway s involved in the antiproliferat ive effect of both 
dexamethasone and plitidepsin, could yet contribute to the synergism of the 
combination. Plitidepsin downregulates genes with a documented role in oncogenic 
transformation in MM: Myb, Myc or Ras families, frequently  mutated in MM cells, 
effect also seen after dexamethasone administration (44). Likewise, both had a 
synergistic effect on NF -kappaB (survival transcription factor) and its inhibitor (45, 46) .
Besides , a sy nergistic effect may  occur on the cell cy cle, where the arrest induced by  [CONTACT_587164] (p21WAF1/CI P1, p27 KIP), INK4 famil y of proteins (p15INK4b, 
p18INK4c, p19INK4d), cycA, cycD1 and D2, suppression of CDK4, suppression of 
p107, or hy pophosphory lation of Rb (35).
CL_0092 5.[ADDRESS_772326]-C-001-09Figure 3. Plitidepsin -dexa methasone molecular model of apoptosis
Plitidepsin treatment also reduces Erk (an extracellular signal -regulated kinase, ERK 
1/2) activation but increases activation of p38MAPK, enhancing GC sensitivity  by [CONTACT_587165]. Similarly , MAPK pathwa y activation by [CONTACT_587166].
Combined treatment with plitidepsin and dexamethasone suppresses genes involved in 
cytokine -induced proliferative/antiapoptotic signaling pathway s and oncogenic 
transformation triggering MM proliferation: IGF-1R, IL -6R, gp130, CXCR -4 etc.
In addition to the documented effects induced by [CONTACT_587167], some 
of the effects of dexamethasone seem to be non-specific, i.e., a non-genomic activity , 
with a quick activation of protein kinases, including the MAPK cascade, 
phosphatidy linositol -3 kinase (PI3K) and Akt. These non-specific effects could explain 
the short -term rapid synergism of the combination, since plitidepsin has also shown a 
rapid effect over the same pathway s.
GR reduces gene trans cription by  [CONTACT_587168]-1 (Fos-Jun heterodimers) and NF-kB (p65-p50 heterodimers). Both require 
the coactivator CREB binding protein (CBP) for maximal activity . Therefore, these data 
also suggest that alterations in chromatin structure may be important in modulating GC 
actions. 
On this regard, the direct inhibition of CBP -associated histone acetyltransferase (HAT) 
activity  and the active recruitment of a histone deacet ylase complex 2 (HDAC2) 
induced in cell lines treated with dexamethasone appear crucial (47, 48). Both 
complexes are closel y related to chromatin remodeling and consequently , to the 
modulation of gene expression induced b y dexamethaso ne. 
Plitidepsin
Plitidepsin
CL_0092 5.[ADDRESS_772327]-C-001-09
Figure 4. Glucorticoids and the chromatin complex
Glucocorticoids induce the acetylation of specific lysine residues (K5 and K16) in 
histone H4. The consequences of this epi[INVESTIGATOR_587104], e.g. preventing other 
transcription factors, such as activator protein 1 (AP-1) and nuclear factor қB(NF-қB), 
from activating their target genes by [CONTACT_587169] H4. This may also have an antiangiogenic potential (reducing VEGF 
expression). 
Therefore, histone H4 K5 acetylation can be considered as a marker of dexamethasone 
transactivation. Dexamethasone predominantly  targeted acetylation on histone H4 K5 
and K16 in all subjects. However, GR complex inhibits acetylation of K8 and K12 by 
[CONTACT_587170] a direct inhibitor of CBP -associated histone acety lation and by [CONTACT_587171]2 to the p65-CBP HAT complex. Thus, it has been described that both HAT and 
HDAC activities coexist within same complex in the presence of p65 and GR and that 
they can each act independently .  This mechanism for glucocorticoid repression is novel 
and establishes that inhibition of histone acety lation brings an additional level of control 
of inflammatory /antiproliferative/apoptotic gene expression. This furth er suggests that 
pharmacological manipulation of specific histone acetylation status is a potentially 
useful approach for the treatment of dexamethasone -sensitive diseases. On this regard, 
the effects of dexamethasone have been shown to improve in the presence of 
trichostatin A (TSA ), a classical potent in vitro HDAC inhibitor, and in the presence of 
SAHA, recentl y approved for its use in vivo at the clinical setting. HDACs were also 
pointed out to play ing a role in dexamethasone repression. 
Further analy sis of the epi[INVESTIGATOR_587105] 3 at Ser10 (inhibited in response to TNFα) and histone 3 
methy lation at Ly sine 4 (H3K4 methy lation). These two markers of the histone code are 
targets for rapid hyperacet ylation upon treatment with the HDAC inhibitor sodium 
butyrate or with TSA . Moreove r, most, if not all, available Lys in the H3 tail become s
acetylated when they  are marked with K4 methy lation or S10 phosphory lation.
Such specificity  suggest s that the activation of HATs after treatment with 
dexamethasone together with an HDAC inhibitor is not at random.  
[IP_ADDRESS] Toxicology
Plitidepsin, given by i.v. injection in daily x1 (dx1), dx5 or 3-cycle dx5 regimens, 
produced toxicological effects typi[INVESTIGATOR_587106]. Tissues containing 
cells with a high turnover were especially  targeted. In the dx1 and dx5 studies, the 
principal organs affected were the reticuloendothelial system and the gastrointestinal 
tract in all species, testes in the mo use and rat, and pancreas in the dog. The main organs 
CL_0092 5.[ADDRESS_772328]-C-001-09additionally  affected were: epi[INVESTIGATOR_587107], pancreas, heart, mammary  gland and skeletal 
muscle in the rat and mouse, and liver, thy mus and testes in the dog. In all three species, 
toxic effects were dose -related and generally  fully or partially  reversible. Most toxicities 
were reversible at the maximum tolerated dose (MTD) level at the end of an acute 
toxicity  evaluation.
Of interest is the observation that the toxicity  of plitidepsin in normal hematopoiet ic 
tissue (IC50: 150-2250 nM) was 1-3 orders lower than in tumor cells (IC 50: 0.2-27 nM) 
(49). These and other data (50) indicate that plitidepsin might be a potential compound 
in multidrug chemotherapy  regimen, assuming that it does not increase hematotoxicity  
significantl y, which is often the dose -limiting toxicity  of these regimens.
[IP_ADDRESS] Safety Pharmacology
[IP_ADDRESS].[ADDRESS_772329] iovascular (CV) safet y pharmacology  evaluation of plitidepsin involved both in 
vitro and in vivo studies.
Briefl y, no inhibition of the hERG tail current was found after a 15-min exposure of 
HEK293 cells stably  transfected with hERG cDNA to a concentration of 1M of 
plitidepsin. Moreover, increasing concentrations of plitidepsin (10, 100 and 1000 nM) 
did not produce changes in the action potential morphology  of isolated cardiac Purkinje 
fibers from dogs.
The effect of plitidepsin on CV parameters [arterial blood pressure (ABP), heart beating 
rate (HBR) and electrocardiogram (ECG) variables -PR interval, QRS duration, RR 
interval, and QT interval] was evaluated in conscious, telemetered dogs. Infusion of 
plitidepsin at doses up to 0.03 mg/kg (0.6 mg/m2) did not affect ABP. HBR increased 
from 2 to 48 hours after administration of 0.03 mg/kg (0.6 mg/m2) of plitidepsin. There 
were no significant effects on corrected QT (QTcF) at the studied plitidepsin doses. No 
ECG abnormalities were observed during or up to 8 hours after discontinuation of the 
plitidepsin infusion.
[IP_ADDRESS].2 Respi[INVESTIGATOR_587108] 0.50 mg/kg (3 mg/m2) of plitidepsin to male rats did 
not significantly  affect either respi[INVESTIGATOR_587109]. Significant decreases in 
tidal volume and respi[INVESTIGATOR_587110] [ADDRESS_772330] -dosing with 1.50 mg/kg 
(9 mg/m2).
[IP_ADDRESS].3 Neurotoxicity
Intravenous administration of up to 0.50 mg/kg (3 mg/m2) of plitidepsin to male rats did 
not produce gross behavioral or physiological state changes at any observation period. 
In rats treated with 1.5 mg/kg (9 mg/m2) occasional cage dispersion, increased 
cutaneous blood flow, diarrhea, and vocalization were observed. 
CL_0092 5.[ADDRESS_772331]-C-001-091.3.3 Clinical Data
To date, plitidepsin has been evaluated in adult patients as single-agent or in 
combination with other antineoplastic drugs, and as single -agent in pediatric patients.
As of March 2009, more than 700 patients had been recruited into clinical trials with 
plitidepsin (PharmaMar internal data):
A phase I program using single-agent plitidepsin in adult patients with solid 
malignancies or non -Hodgkin l ymphoma (NHL) has been completed. 
There are several finished or ongoing studies of plitidepsin in combination 
with other agents: 
-Phase I trial of plitidepsin with carboplatin in patients with advanced 
solid malignancies or l ymphoma: completed.
-Phase Ib trial of plitidepsin in combination with bortezomib and 
dexamethasone in relapsed/refractory  multiple myeloma: closed 
recruitment.
-Phase Ib trial of plitidepsin in combination with sorafenib or 
gemcitabine in patients with solid tumors or lymphomas: open 
recruitment.
-Phase Ib trial of plitidepsin in combination with bevacizumab or 
docetaxel in patients with solid tumors: open recruitment.
-Phase I -II trial of plitidepsin in combina tion with dacarbazine as first -
line treatment in patients with unresectable advanced melanoma :the 
phase I part has been already  completed. 
Phase II studies with single -agent plitidepsin have been conducted to 
evaluate its activity  against different solid tumors and hematological 
malignancies.
Particularl y of interest is a phase II trial of plitidepsin alone and/or with the addition of 
dexamethasone in patients with suboptimal response in relapsed/refractory  multiple 
myeloma that has been recentl y complete d. Thefinal results of this trial were presented 
during the American Society  of Hematology  (ASH) meeting in December 2008 in San 
Francisco, [LOCATION_003] (Abstract # 3700).
[IP_ADDRESS] Single -Agent Phase I Trials
Results obtained in single -agent phase I trials in adult patient s are summarized in Table 
1.
CL_0092 5.[ADDRESS_772332]-C-001-09Table 1. Plitidepsin: single -agent phase I trials in adult patients
24 h i .v.
d1,8,15
q4w3 h i.v.
d1,15 
q4w1 h i.v.
d1,8,15
q4w24 h c.i.v.i. d1,15 q4w 1 h i.v.
d1-5 
q3wPlitidepsin 
alonePlitidepsin +
L-carnitine
No. patients [ADDRESS_772333] dose 
(mg/m2)4.[ADDRESS_772334] (m g/m2) 3.[ADDRESS_772335] 
(mg/m2/week)2.8 2.5 2.4 2.5 3.5 2.0
24 h i.v. d 1,8,15 q4w: 24 -hour intravenous infusion for three weeks every four weeks; c.i.v.i.: continuous intravenous infusion; 
DI: Dose intensity; DLT, dose-limiting toxicity; NCI-CTC, National Cancer Institute Common Toxicity Criteria; RD: 
recommended dose.
Hepatic = I ncreased values of serum enzymes (grade 3 -4 CTCAE)
Muscular = myalgia, muscular weakness or elevated CPK (grade 3 -4 NCI -CTC)
Of note, the proposed recommended do se (RD) for further developments as single agent 
after the extensive phase I program consistently  delivered a similar dose intensity , 
around 2.5 mg/m2/week and a similar pattern of DLTs, without unexpected toxicities 
independentl y of schedule.
[IP_ADDRESS] Single -Agent Phase II Trials
As single -agent in phase II clinical trials and up to March 2009, plitidepsin has been 
administ ered to patients with:
Unresectable advanced renal cancer or advanced colorectal cancer in objective 
progression (81 patients) .
Unresectable adv anced medullar thy roid carcinoma (16 patients) .
Unresectable advanced carcinoma of the exocrine pancreas ( 19patients) .
Advanced non-small cell lung cancer (NSCLC) progressing after first-line 
chemotherap y (21 patients) .
Advanced or metastatic transitional cell carcinoma of the urothelium relapsing 
or progressing after first-line chemotherap y (21 patients) .
Small -cell lung carcinoma (SCL C) relapsing or progressing after first-line 
chemotherap y (19 patients) .
Advanced or metastatic melanoma relapsing or progressing after first-line 
systemic therapy  (37 patients ).
Locally  advanced or metastatic squamous cell carcinoma of the head and neck 
(10 patients) .
Relapsing or refractory androgen -independent prostate adenocarcinoma (8 
patients) .
Relapsed or refractory  indolent NHL (8 patients) .
Relapsed or refractory  aggressive NHL (51 patients) .
Relaps edor refractory  multiple my eloma (5 1patients) .
CL_0092 5.[ADDRESS_772336]-C-001-09Relapsed or refractory  acute ly mphoblastic leukemia (ALL) (17 patients) .
The results from completed and ongoing phase II tr ials confirmed the preliminary  safet y 
profile described from the subset of patients treated at the proposed RD in phase I trials. 
For the [ADDRESS_772337] 
of the AEs and laboratory  abnormali ties which constituted DLTs consisted of transient 
liver biochemical disorders without clinical manifestations and muscular events, mainly  
myalgia, muscular weakness and creatine phosphokinase (CPK) elevations ,without 
myoglobin increase or signs/s ymptoms of rhabdomy olysis. These events were in most 
cases mild, and reverted upon dose modification or drug discontinuation. Other 
common events were mild emesis and diarrhea and cutaneous events (erythema, 
pruritus, rash). Mild hy persensitivity  reactions have be en reported to be probably  related 
to the Cremophor oil contained in the formulation. Of these, less than 3% had been 
serious (i.e., anaph ylactic shock) and all reactions have been reversible after stoppi[INVESTIGATOR_587111]. No fatal events have 
occurred. Yet, allergic prophy laxis (Appendix 1) has been made mandatory  in all 
subsequent trials since 2005. Of note, hematologic altoxicity  was almost absent from 
plitidepsi n single agent trials.
Non-serious cardiac events (rhythm alterations, ECG abnormalities )have been 
occasionall y reported in association with plitidepsin treatment; however, severe and 
life-threatening cardiovascular events were rare and causalit y was usually confounded 
by [CONTACT_587172] -existing conditions. No chronic or dose -cumulative cardiac 
toxicity  has been observed so far. Regular assessment of cardiac function and cardiac 
parameters (i.e., troponin I) and mandatory  ECG monitoring have been implemented in 
all ongoing and planned trials in order to closely evaluate the cardiac safety  profile of 
plitidepsin.
Regarding efficacy , plitidepsin alone has shown consistent antitumor activity  in 
pretreated patients with renal cancer, melanoma, neurob lastoma, non-cutaneous mature 
aggressive peripheral T-cell lymphoma (PTCL) and multiple myeloma. In addition 
clinically  meaningful stabilizations (≥ 3 months) have been achieved in patients with 
several others solid tumor types (i.e., colorectal cancer, neuroendocrine tumors, 
NSCL C, hepatocellular carcinoma, etc.). 
Based on the aforementioned results and its relative good tolerance, the clinical 
development of plitidepsin as a single agent in multiple my eloma, PTCL  and melanoma, 
as well as combined with several agents (including dacarbazine for advanced malignant 
melanoma, bortezomib or lenalidomide for relapsed/refractory  multiple myeloma, and 
sorafenib or gemcitabine for advanced solid tumors or lymphomas), is currently 
underway .
[IP_ADDRESS] Phase II Trial of Plitide psin in Combination with Dexamethasone
The safet y and efficacy  of plitidepsin in patients with relapsed or refractory  MM have 
been investigated in a phase II study  and final results have been reported (51). This was 
an open -label study  of plitidepsin given as a 3-h infusion every  two weeks, with the 
addition of dexamethasone allowed in patients with suboptimal response to plitidepsin 
alone (defined as PD after 3 cycles or SD after 4 cycles of plitidepsin) . Primary 
endpoint was the objective response rate (ORR = CR+ PR [partial response] + MR 
CL_0092 5.[ADDRESS_772338]-C-001-09[minimum response]) according to strict Bladé criteria (52). Secondary  endpoints were
time to progression (TTP) and safet y. 
Between June 2004 and March 2008, 53 relapsed/refractory  MM patients were included 
and 51 received plitidepsin -based therap y. The results showed a promising activit y in 
this heavily  treated subset of patients ,resulting in an ORR of 12%, and up to 21% when 
dexamethasone was added (primary  efficacy  endpoint: ORR in the intent -to-treat 
population according to Myeloma Response Criteria ). This benefit was a lso translated in 
terms of TTP. 
Patients received a median number of four prior lines of therapy  (range: 1 -18) and [ADDRESS_772339] phase of the study , 21patients
received plitidepsin as monotherap y. The overall response rate (ORR) for the first stage 
was 9%. During the second phase, 26 additional patients were evaluable for response. 
ORR to plitidepsin as monotherap y in this second cohort was 11%.
Dexamethasone was subsequently  added to plitidepsin treatment in 18 patients 
evaluable for efficacy , being the response in this subgroup of 21%.
Overall, pooled data of all evaluable patients (n=47) receiving plitidepsin as 
monotherap y in the two stages resulted in an ORR of 12% (1 PR, 2 MR). Median time 
to progression (TTP) was 3 months (95% CI: 0.9-2.8months ) and median overall 
survival (OS) for the first 21 treated patients was 17 months. The addition of 
dexamethasone also increased median TTP to 4.2months (95% CI: 3.4-7.7months ), 
which represented a 40% increase comp ared to plitidepsin alone (TTP of 3 months). 
The safety  profile was acceptable and was not significantly  changed after 
dexamethasone addition. Particularl y the incidence of grade 3-4 drug-related 
hematological toxicity  was very low,with only 11% and 21% of the patients 
experiencing grade 3-4 neutropenia and thrombocy topenia respectively  with the 
combination (similar figures for plitidepsin alone) 
1.3.4 Safety Issues
[IP_ADDRESS] Relevant Safety Information from Phase II Trials
The results from completed and ongoing phase II trials confirmed the preliminary  safet y 
profile described from the subset of patients treated at the proposed recommended dose 
in phase I trials. The majority  of AEs and laboratory  abnormalities which constituted 
dose-limiting toxicities consisted of transient liver biochemical disorders without 
clinical manifestations and muscular events, mainly  myalgia, muscular weakness and 
creatine phosphokinase (CPK) elevations without myoglobin increase, or 
signs/sy mptoms of rhabdom yolysis. These events were in most cases mild, and reverted 
upon dose modification or drug discontinuation. Other common events were mild 
emesis and diarrhea and cutaneous events (erythema, pruritus, and rash) or 
hypersensitivity  reactions. Serious hematological toxicity  was negligible.
Non-serious cardiac events (rhythm alterations, ECG abnormalities )have been 
occasionall y reported in association with plitidepsin treatment, however, severe and life -
threatening cardiovascular events were rare and causality  was usuall y confounded by 
[CONTACT_587172]-existing conditions. A close monitoring of cardiac function is 
being implemented in ongoing trials to reassess the cardiac safet y profile of plitidepsin.
CL_0092 5.[ADDRESS_772340]-C-001-[IP_ADDRESS] Clinical Safety
For each AE, figures represent the frequency  of its worst grade by  [CONTACT_587173] y. 
[IP_ADDRESS].[ADDRESS_772341] muscular AEs found in patie nts treated with the 1 -hour infusion in the phase I trial 
were mild or moderate and consisted of myalgia (50%) and muscle weakness (17%), 
and only one grade 3-4 event was reported (muscle weakness, 7%). As for the other 
schedules, most muscular adverse events reported in patients in the three 1-hour 
infusion phase II trials, were mild or moderated myalgia (25%) and muscle weaknesses 
(15%). Grade ≥ 3 events were reported in eight occasions: two cases of myalgia and 
four of muscle weakness, one of muscle cramp and one of back pain (n=87).
[IP_ADDRESS].2 Biochemical Laboratory  Abnor malities
Grade ≥ [ADDRESS_772342] (aspartate aminotransferase) were reported in 
27.5% in the 1-hour Day 1, 8, [ADDRESS_772343] majority  of 
cases. Other severe biochemical disorders were rare and no remarkable differences in 
incidence of biochemical or metabolic abnormalities wereobserved as compared to 
other schedules.
[IP_ADDRESS].[ADDRESS_772344] frequent 
gastrointestinal event. Its incidence was higher with the 24-hour infusion schedule 
(64%) as compared to the 3 -hour (47%) and the 1 -hour inf usion (35%) schedules. Grade 
3-4 emesis was rare in patients treated with 1 -hour infusion.
[IP_ADDRESS].[ADDRESS_772345] patients 
without other abnormalities. There was no apparent correlation between dose level of 
plitidepsin and strength testing abnormalities in this trial. No grade 3 events were 
reported. Overall, the incidence of neurological AEs was generall y low. 
[IP_ADDRESS].[ADDRESS_772346] common hematologic alabnormality  in the 1-hour Day 
1, 8, 15 q4w schedule in phase II trials was hemoglobin decrease (90%). Lymphocyte 
decrease occurred in 66% of the patients, and thrombocy topenia was observed in 60% 
(26% of them were grade ≥ 3). However, taking into account the prior clinical 
experience with plitidepsin and its preclinical toxicology  profile, it was concluded that 
most of these epi[INVESTIGATOR_587112]_0092 5.[ADDRESS_772347]-C-001-09to the underly ing disease (acute leukemia, lymphoma and multiple myeloma). In fact, 
several patients alread y suffer edfrom leukopenia and/or thrombocy topenia at baseline. 
In general, these events did not wor sen after plitidepsin treatment, but rather their values 
improved significantly  in patients showing objective response to treatment.
[IP_ADDRESS].[ADDRESS_772348] frequently  found in patients in phase II studies 
with singl e-agent plitidepsin. A total of 31% of patients treated with the 1 -hour infusion 
had asthenia, with 8% of cases being grade 3-4. However, its significance may be 
confounded, since the underly ing malignancy  is frequently  a cause of asthenia in cancer 
patien ts. 
Other severe AEs reported within this schedule were grade 3 edema in one patient (1%) 
and pyrexia also in one (1%) patient. Mild grade 1-2 pyrexia was reported in other 
schedules, particularl y in the 3-hour i.v. infusion every  two weeks (69% of patien ts). It 
was usuall y associated with shivering and developed within [ADDRESS_772349] likely  as a consequence of the 
underly ing disease.
[IP_ADDRESS].7 Infusion Site Events
When central venous acce ss was not used, local problems related to drug administration 
were frequent, including ery thema, pain during infusion and phlebitis. 
Injection site reactions were more common in patients receiving plitidepsin as a 24 -hour 
infusion than with any other schedule. Shortening the infusion time was associated with 
a marked reduction in the incidence of injection site reactions. A total of 2% of patients 
reported infusion site reactions with the 3 -hour infusion and 5 mg/m2dose (1/3 of which 
were grade ≥ 3), and1% of patients with mild-moderate events were found with the 1-
hour infusion schedule. In all cases, plitidepsin should be administered through infusion 
pumpswith special filter -containing infusion lines ,via central venous access.
[IP_ADDRESS].8 Cardiac Safety
An upda te of the safet y information on cardiac events occurred during clinical trials 
evaluating plitidepsin as single -agent treatment in adult patients with advanced solid 
tumors or hematological malignancies was done using a cutoff for data analy sis of 20 
Novem ber 2008 (see Investigator Brochure). Forty-six of the 578 patients (8.0%) 
treated with plitidepsin as a single agent up to that cutoff date had at least one cardiac 
AE. Eleven of these 46 patients (1.9% of the total of 578 patients) had cardiac AEs 
relate d to plitidepsin and eight among them were reported as serious adverse events 
(SAEs). The majority  of cardiac events occurred in phase II studies (37 of 46 for overall 
events), and particularl y in two studies, APL -B-003-02 (pancreatic cancer) and APL -B-
011-02 (prostate cancer) with a higher than expected incidence. 
Cardiac AEs observed to date in plitidepsin trials are clinically  heterogeneous; the most 
frequent type is harmless rhythm alterations, asno life-threatening ventricular 
arrhythmias occurred , while the rest of events are relativel y infrequent. No fatal 
CL_0092 5.[ADDRESS_772350]-C-001-09outcome was reported as a consequence of all cardiac AEs analyzed. Relevant 
predisposing factors identified in univariate and multivariate anal yses are mostly  related 
with patient’s baseline chara cteristics and disease -related characteristics rather than with 
drug exposure or treatment -related characteristics, the analy zed cardiac events do not 
follow a dose cumulative pattern of occurrence, and none among all PK parameters 
explored did show a correlation, although other potential relevant factors remain yet to 
be identified and further characterized. As of [ADDRESS_772351] 
become mandatory  in all current and future plitidepsin protocols, including serial ECG 
and troponin I determination and periodic left ventricular ejection fraction (LVEF) 
measurement by [CONTACT_6751] (ECHO) or multiple -gated acquisition scan (MUGA) 
testing. In addition, patients with a cardiovascular background or any  prior interventions 
predisposing to cardiac toxicity  are excluded from these pro tocols.
[IP_ADDRESS].[ADDRESS_772352] chemotherap y. 
Overall, the currentl y available clinical data provide reassurance that the toxicity  of 
plitidepsin appears to be acceptable in the clinical setti ng.
[IP_ADDRESS] Summary of Pharmacokinetic Results
Pharmacokinetic data have been collected from patients in phase I and II studies 
following i.v. administration of plitidepsin using the following schedules: 24-hour 
infusion every  week ( Day 1 and 15 q4wk), 3 -hour infu sion every  other week ( Day 1 and 
15 q4wk), 1-hour infusion every  week (Day 1, 8, 15 q4wk), 24-hour infusion every 
other week (Day 1 and 15 q4wk) and 1-hour infusion for five consecutive days every 
three weeks ( Day 1-5 q3wk). 
After non-compartmental analy sis, plitidepsin was found to be widely  distributed, with 
apparent volumes of distribution in steady  state (Vss) of about 500 to 1350 l based on 
plasma, and from about 100 to 225 l based on whole blood, thus suggesting that blood 
cells are an important distribution compartment. Concentrations were about 3-fold 
higher in whole blood than in plasma. 
This initial characterization was updated after analy zing data from phase II clinical 
trials, with samples collected at later time points than in the phase I trials. Furthermore, 
patients included in phase II trials had samples taken for pharmacokinetic (PK)
evaluation during both the first andthird treatment cycle, allowing for a more extensive 
analysis. Population methodology  was used, as the phase II studies h ad sparse sampling.
Thus, the population PK analy sis of plitidepsin was performed based on data from 13 
clinical studies, including all four adult patients, single -agent phase I studies (APL -A-
001-98, APL -A-002-98, APL -A-003-[ADDRESS_772353] -A-004-98) and nine phase II studies 
CL_0092 5.[ADDRESS_772354]-C-001-09(APL -B-001-01, APL -B-002-02, APL -B-005-02, APL -B-006-02, APL -B-007-02, APL -
B-011-02, APL -B-013-02, APL -B-014-03, APL -B-015-04), using the NONMEM 
software. Blood and plasma concentration -time data from phase I studies with extensive 
sampling were pooled with sparse PK sampling from patients with advanced cancer 
included in phase II studies. In these studies, patients received i.v.plitidepsin as 
monotherap y at doses ranging from 0.13 to 8.0 mg/m2and given as 1-hour or 24-hour 
infusions weekl y; 3-hour or 24 -hour q2wk ,or 1-hour infusion daily  for five consecutive 
days every  21 days. In total, 411 patients and 5585 plitidepsin concentration 
measurements, including 2900 blood and 2685 plasma concentrations, were pooled in 
the population PK analy sis.
An open, three -compartment disposition model with linear elimination and linear 
distribution from the central compartment to peripheral compartments was used to 
describe the PK of plitidepsin in plasma. The model was parameterized in terms of 
clearanc e (CL), central (V1) and peripheral volumes of distribution for the shallow (V2) 
and the deep (V3) compartments, intercompartmental exchange flows for shallow (Q2) 
and the deep (Q3) compartments. The concentration of plitidepsin into red blood cells 
was modeled as a non-linear function ,where Bmaxcorresponds to the maximal 
plitidepsin concentration into red blood cells and kdis the plitidepsin plasma 
concentration at which the plitidepsin bound to red blood cells is half-maximal. 
Between and within subjec t variabilities were assumed to be log -normall y distributed. 
Final parameter estimates describing the PK of plitidepsin in cancer patients are 
presented in Table 2. The plitidepsin initial fast distribution half-life was about 21
minutes followed by a dominant elimination half-life of about 8.9 hours and a terminal 
half-life of about 88 hours that constituted on average 27.2% of the overall area under 
the plasma concentration vs.time curve.
Table 2. Final pharmacokinetic parameter estimates for plitidepsin .
Pharm acokinetic 
param eterTypi[INVESTIGATOR_119885]*Variability
Between patients 
(%)Within patients 
(%)
V1(l) 103 (8.87) 74.2 (30.5) --
CL (l/h)a,b28.7 (4.77) 55.0 (16.6) 38.3 (25.6)
V2(l)b417 (5.68) 55.1 (16.1) --
Q2(l/h) 136 (6.46) 64.0 (20.4) --
V3(l) 1320 (7.17) 88.7 (32.8) --
Q3(l/h)a18.1 (6.13) -- 53.4 (19.1)
Bmax (g/l) 309 (10.2) 60.8 (12.9) 21.8 (27.5)
kd(g/l) 23.5 (11.8) -- --
*Results expressed as parameter (RSE: relative standard error of parameter estimate, %).
a. Correlation between IIV of Cl and Q 3set to 1. Expansion factor of Q 3is 0.757 (RSE=17.2%).
b. Correlation between IIV of Cl and V 2 is 0.521 (RSE= 19.1%).
Residual variability, expressed as percentage: 
-Blood: 24.5 (R SE = 7.35 %).
-Plasma: 38.1 (RSE =9.86 %).
Bmax: maximal plitidepsin concentration into red blood cells; kd: plitidepsin plasma concentration at 
which the plitidepsin bound to red blood cells is half -maximal; V 1: central volume of distribution; V 2: 
volume of distribution of the shallow compartment; V3: volume of distribution of the deep 
compartment; CL: clearance, Q2: intercompartmental exchange flow for the shallow compartment, 
Q3: intercompartmental exchange flow for the deep compartment.
As a summary , the main conclusions of the population PK report are:
CL_0092 5.[ADDRESS_772355]-C-001-09A three -compartment disposition model with linear elimination is suitable to 
describe the plasma PK profiles of plitidepsin after i.v. administration to 
cancer patients.
Non-linear binding to red blood cells is evident from blood concentrations. 
However, its clinical relevance is limited since the plasma concentrations 
achieved with the dosing regimens used in phase II program are below the 
estimated k dvalue and the effect of the hematocrit on blood con centrations is 
limited. 
No evidence of time-dependent kinetics was observed. Actually , plitidepsin 
systemic exposure following repeat i.v. administration q2wk evidenced 
minimal accumulation in plasma.
The subject -related covariates, including age, body  weight, sex, laboratory  liver 
function parameters (AST, ALT, ALP and total bilirubin) and renal function (creatinine 
clearance), total protein, serum albumin, hemoglobin levels and leukocy tes counts had 
no discernable impact on the PK parameters of plitidepsin within the range of values 
evaluated and, consequently , pliti depsin dose adjustment on the basis of these covariates 
is not warranted.
Between and within patients variability  in PK is moderate to large, but similar to other 
anticancer drugs.
The followi ng Section detail sthe individual PK results from the relevant phase I clinical 
trial in which the 3 -hour infusion every  two weeks was used.
[IP_ADDRESS].1 Three -hour Every  Two Weeks Intravenous Infusion Regimen of Plitidepsin 
(Study  APL -A-001b -98)
Median half -life value s were 35.3, 31.7, 31.5 and 38.5 hours following administration of 
plitidepsin at 3, 4, 5 and 6 mg/m2, respectivel y.  Corresponding clearance values were 
5.3, 4.1, 5.9 and 1.7 l/h, respectivel y and corresponding Vssvalues were 171, 148, 199 
and 130 l, respectivel y. Median Cmaxat the same dose levels were 78.3, 97.5, 82.6 and 
294.9 ng/ml respectivel y, and median AUC infwere 967, 1772, 1392 and 6057 h*ng/ml 
respectivel y.
Plitidepsin AUC infand Cmaxvalues increased with dose, although dose-proportionality 
of plitidepsin in blood was not proven, most probably due to the limited sample size for 
all dose levels except for 5 mg/m2and a high interpatient variability . 
The effect of age, weight and body  surface area (BSA) on the pharmacokinetics of 
plitidepsin inblood were inconclusive. There were no statistically  significant gender 
effects.
[IP_ADDRESS].2 Excretion of Plitidepsin
Urinary  excretion of unchanged compound is a minor elimination route, with average 
recoveries of 2 -5% over 48 hours and maximum values below 15%. The major routes of 
elimination have not as yet been determined.
CL_0092 5.[ADDRESS_772356]-C-001-09There were no correlations between kinetic parameters and variations in hepatic and 
renal function in the population analy sis of adult phase I results.
1.4 INFORMATION ON STUDY DRUG:DEXAMETHASONE
Please refer to the Dexamethasone Drug Information , provided as a separate document , 
for further information on dexamethasone.
1.[ADDRESS_772357] shown either additive or 
synergistic antitumor activity . It is equall y important to avoid agents with overlappi[INVESTIGATOR_587113]. 
[IP_ADDRESS] Plitidepsin
Plitidepsin (Aplidin®) is a novel anticancer compound that has shown activity  as single 
agent in a recentl y completed phase II study  in relapsed/refractory  MM patients (51). In 
a first stage, this trial explored the objective response to plitidepsin at 5 mg/m2as a 3-
hour i.v. infusion administered every  two weeks (q2wk ), with 10% of 21 evaluable 
patients having a PR and,additionally ,14% of patients having clinically  meaningful 
disease stabilization (SD ≥ 3 months) ,with a median TTP of 2.3 months. Based on 
preclinical results that showed additive to synergistic effects of 
dexamethasone/plitidepsin combination (30), in a second stage of this phase IItrial, 
patients who experienced suboptimal response (SD or PD) after three to four plitidepsin 
infusions were allowed to receive oral dexamethasone 20 mg daily  on Days 1 through 4 
q2wk (160 mg total monthly dose) added to plitidepsin. In this cohort of patients, 28% 
of the 18 evaluable patients had an objective response and TTP was significantl y 
prolonged to 4.2months .Asimilar overall safety  profile was found ,although with a
slight increase in muscular events (mostl y myalgia and reversible CPK increa se) and a 
mild decrease in grade 3-4 transaminases increase. Of note, as much as two thirds of 
these patients hadpreviously  received bortezomib and thalidomide or lenalidomide and 
HDT and PBSC-T, whereas all patients had steroids as part of a prior therap y, with a 
median of four prior lines of systemic treatments. Although thetrial design had 
limitations that preclude dcomparison between cohorts, both regimens were well 
tolerated and show edclinical activity  in this heavily  pretreated population for which
limited clinical options were available. The addition ofdexamethasone after three to 
four cycles of plitidepsin did not change dramatically  the response (some disease 
stabilizations werefound in patients who were progressing on plitidepsin alone ,and on e 
patient who was stable respon ded after dexamethasone addition ), but responses 
appeared to be more durable and steeped . Therefore, it seems logical to add 
dexamethasone to plitidepsin upfront in order to optimize any synergistic effect that 
may occur clin ically  to achieve a better and longer disease control. 
CL_0092 5.[ADDRESS_772358] commonly  used regimens being high-dose dexamethasone alone (53), melphalan 
and prednisone (8, 54),vincristine, doxor ubicin, and dexamethasone (VAD) (55, 56),
thalidomide, lenalidomide plus dexamethasone (57-59),and bortezomib plus 
dexamethasone. Moreover, dexamethasone can be used as monotherap y as well, the 
dose and regimen being typi[INVESTIGATOR_1306] y around 20-40 mg on Days 1-4, 9-12, and 17-20 of a 
28-to 35-day cycle for a total of 240-480 mg per cycle (53),although adverse reactions 
may be observed including principall y endocrine axis suppression, serious infection s
derived from clinicall y relevant immunosuppression, and confusion or mood changes 
including acute psychosis. In fact, dose of dexamethasone has recently raised some 
concerns particularl y after the ECOG 4A03 study .The Eastern Cooperative Oncolog y 
Group, compared the administration of low er doses of d examethasone ( 40 mg d 1, 8, 15, 
and 22 p.o.q4wk, for a total monthly  dose of 160 mg) plus lenalidomide with high -dose
dexamethasone at the usual dose (40 mg d 1-4, 9-12, and 17-20 p.o.q4wk, for a total 
monthly  dose of 480 mg) plus the same lenalidomide regimen, and reported a 
significant improvement in overall survival with a better safet y profile for the lower 
dose arm (60). A second study with lenalidomide plus dexamethasone in the 
relapsed/refractory  setting showed that patients who had dose reductions of 
dexamethasone have shown a significantly  higher overall response rate, including a 
higher complete response (CR) , PFS and improved median overall survival, when 
compared to those who received dexamethasone at the assigned dose, with adverse 
events rates comparable between both groups (61). Finall y, and based on data from last 
available publications on dexamethasone and borte zomib combinations (62),
dexamethasone administered at reduced doses(20mg) the same day and the day after 
bortezomib infusion up to a total dose of 160 mg/cy cle, has been associated with a 
bette r safety  profile while maintaining the same level of activity .
2OBJECTIVES
2.1 PRIMARY OBJECTIVE
To compare the efficacy  ofplitidepsin with dexamethasone vs.dexamethasone 
alone , as measured by [CONTACT_16625] ,in patients with relapsed /refractory MM.
2.2 SECONDARY OBJECTIVES
To evaluate t umor response according to the IMWG criteria (Appendix 5).
To assess duration of response ( DR)and overall survival ( OS).
To assess efficacy  in patients who undergo crossover from dexamethasone alone to 
plitidep sin and dexamethasone combination.
To characteriz eand compar e the safet y profile on both arms in this population.
To characteriz ethe PK and pharmacokinetic/pharmacod ynamic (PK/PD) 
relationship.
3OVERALL STUDY DESIGN
This is a prospective, open -label, two -arm, 2:1 randomized phase III study . The efficacy 
of plitidepsin in combination with dexamethasone (Arm A) vs.dexamethasone alone 
CL_0092 5.[ADDRESS_772359]-C-001-09(Arm B) will be studied by  [CONTACT_587174] (Appendix 5 ),and the evaluation of secondary  efficacy  endpoints. 
Patients in the control arm (dexamethasone alone, Arm B) who have documented 
disease progression according to the Investigator’s criteria after a minimum of eight 
weeks from randomization shouldbe offered crossover to combination arm(plitidepsin 
+ dexamethasone, Arm A) upon Sponsor agreement .
An Independent Review Committee (IRC), consisting of medical specialists directly 
involved in the care of MM patients ,but not being investigators or subinvestigator sin 
this trial,will review all efficacy  data and will assign the date of progression/censoring 
and objective response according to their independent evaluation . This IRC will be 
blinded to treatment arm allocation and identity  of the cases reviewed (Section 5.6).
An Independent Data Monitoring Committee (IDM C), including specialists in MM and in 
medical statistics , will review the results of the analy sis performed by [CONTACT_69852]. Then, the I DMC wi ll advise the Sponsor about the study  conduct .
Operational details for the above mentioned IRC and IDMC will be detailed in the 
corresponding charters.
4PATIENT DEFINITION
4.1 STUDY POPULATION
A total of approximately 250 patients will be randomized in a 2:1 ratio (combination : 
dexamethasone alone) .
An early  futility  analysis will be performed with data from 40patients evaluable for 
response in Arm A. 
Patients without valid disease evaluation during treatment will not be replaced for the 
main anal ysis, and wi ll be anal yzed as per ITT according to randomization.
4.2 PATIENT ELIGIBILITY
4.2.1 Inclusion criteria
A patient is eligible for enrolment if all of the following inclusion criteria are met :
1.Age ≥ 18 y ears.
2.ECOG PS ≤ 2(see Appendix 2 ).
3.Life expectancy  ≥ 3 months.
4.Patient spreviously  diagnosed with multiple myeloma based on IMWG diagnostic 
criteria (see Appendix 4).
5.Patients must have relapsed or relapsed and refractory multiple myeloma (MM)
(Appendix 5) after at least three , but not more than six, prior therapeutic regimens 
for MM, including induction therapy  and stem cell transplant in candidate patie nts, 
which will be considered as only one regimen.
CL_0092 5.[ADDRESS_772360] received previous bortezomib -containing and lenalidomide -
containing regimens (or thalidomide where lenalidomide is not available), unless 
unable to tolerate either of them .
7.Patients must have measurable disease defined as: 
a)For secretory  MM: any quantifiable serum monoclonal protein value and, 
where applicable, urine light -chain excretion ≥ 200 mg/24 hours.
b)For oligo or non-secretory  MM: presence of soft tissue (not bone) 
plasmacy tomas ,as determined by [CONTACT_587175] [i.e., magnetic resonance imaging (MRI), computed 
tomograph y (CT) -scan], and/orby [CONTACT_587176] (sFLC): involved FLC level ≥ 10 mg/dl provided the serum 
FLC ratio is abnormal .
8.At least two-week washout period since the end of last therapy (six weeks if 
previous nitrosoureas -containing regimen) , given recovery  to grade ≤ 1 from any 
non-hematological related adverse event (AE) derived from previous treatment 
(excluding alopecia) .
9.Adequate BM, renal, hepatic, and metabolic function (assessed ≤ 7 days before 
inclusion in the study ):
a) Absolute neutrophil count (ANC) ≥ 1.0 x 109/l(≥ 0.5 x 109/lif due to 
extensive and documented BM disease involvement by ≥ 50% of pla sma 
cellsin BM biopsy ).
Screening of ANC should be independent of granulocy te-and 
granulocy te/macrophage -colony  stimulating factors (G-CSF and 
GM-CSF) support for at least one week and of pegy lated G-CSF 
for at least two weeks.
b) Platelet count ≥ 50 x 109/l(≥ 25 x 109/lif due to extensive and 
documented BM disease involvement).
c) Hemoglobin ≥ 8.5g/dl.
Patients may receive red blood cells(RBC) and/or erythropoietin 
(EPO) and/or platelets transfusions in accordance with 
institutional guidelines.
d) Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) 
≤ 3.0x the upper limit of normal (ULN).
e) Total bilirubin ≤ 1.[ADDRESS_772361] bilirubin ≤ 1.[ADDRESS_772362] when total 
bilirubin is above the upper limit of normal.
f) Calculated creatinine clearance (CrCl) ≥30 ml/minute (by [CONTACT_587177]´s formula) (Appendix 3 ).
g) Creatine phosphokinase (CPK) ≤ 2.5 x UL N.
h) Albumin ≥ 2.5 g/dl.
10.Left ventricular ejection fraction (LVEF) by [CONTACT_6751] (ECHO) or multiple -
gated acquis ition scan (MUGA) above the lower limitof normal (LLN) .
CL_0092 5.[ADDRESS_772363] agree to use a medically  acceptable method 
of contraception throughout the treatm ent period and for six months after 
discontinuation of treatment. 
12.Voluntarily  signed and dated written informed consent prior to any specific study 
procedure.
4.2.2 Exclusion criteria
A patient will not be eligible for this study  if any of the following exclus ion criteria are 
met: 
1.Concomitant diseases/conditions:
a)History  or presence of angina, myocardial infarction, clinically  relevant valvular 
heart disease , cardiac amyloidosis or congestive heart failure within the last 12 
months .
b)Symptomatic arrhy thmia (excluding anemia -related sinusal tachycardia grade 
≤ 2)or any arrhythmia requiring ongoing treatment, and/or prolonged QT-QTc 
grade ≥ 2; or presence of unstable atrial fibrilation. Patients with stable atrial 
fibrillation on treatment are allowed provided they  do not meet any  other cardiac 
or prohibited d rug exclusion criterion.
c)Active uncontrolled infection.
d)Morphologic alor cytologic alfeatures of myelodysplasia and/or post-
chemotherap y aplasia on BM assessment.
e)Myopath y > grade 2 or any clinical situation that causes significant and 
persistent elevation of CPK (>2.[ADDRESS_772364] in two different determinations 
performed one week apart).
f)Known human immunodeficiency  virus (HIV) infection (HIV testing is not 
required unless infection is clinically  suspected).
g)Known active hepatitis B or C virus (HBV or HCV) infe ction.
h)Limitation of the patient’s ability  to comply  with the treatment or follow -up 
requirements.
i)Any other major illness that, in the I nvestigator’s judgment, will substantially  
increase the risk associated with the patient’s participation in this study .
j)Peripheral neuropath y > grade 2.
2.Women who are pregnant or breast feeding.
3.Concomitant medications that include corticosteroids, chemotherap y, or other 
therap y that is or may  be active against MM, within two weeks prior to Cy cle 1 Day 
1. Concurrent cortic osteroids are allowed, provided they are administered at an 
equivalent prednisone dose of ≤ 10 mg daily , as premedication for blood products
only.
4.Known history  of peptic ulcer and/or major upper gastrointestinal bleeding epi[INVESTIGATOR_587114]/or related to prior steroid -based 
therap y.
CL_0092 5.[ADDRESS_772365]-C-001-095.Relevant history  of mood -disturbances changes associated with previous steroid -
based therap y.
6.Disease -related s ymptomatic hy percalcemia despi[INVESTIGATOR_51495] .
7.Known hypersensitivi ty to any involved study drug or any of its formulation 
components.
5PLAN OF STUDY
5.1 PATIENT PARTICIPATION
Patients will receive the study  treatment for as long as it is considered beneficial for the 
patient (see Section 5.2). Patients will be evaluated at scheduled visits in up to three study  
periods: 
Pre-treatment: from the signature [CONTACT_587220].
Treatment: up to [ADDRESS_772366] treatment discontinuation. An end-of-treatment visit will be 
performed within 30 days (± two days) after last dose administration , unless the patient 
starts any new antitumor therap y outside this clinical trial, in which case the end-of-
treatment visit should be performed immediate ly before the start of the new therap y 
(ideally  the day  before or the same day ).
Follow -up:After treatment discontinuation, patients will be followed every  four weeks 
until resolution of toxicities if any. Patients who discontinued treatment without 
progression will be followed every  four weeks until disease progression orother 
antitumor therap ywhichever occurs first. After progression, all patients will be 
followed every  three months for survival until death ,or until the date of study 
termination, whi chever occurs first. 
Study  termination date is defined as the date in which 80% of death events occurred, [ADDRESS_772367] randomized patient, or IDMC recommendation 
(whichever occurs first).
Note: Two years after the last patient accrual, on 19 May 2017, the final OS analysis was done 
based on a total of 195 death events (i.e., 76.5% of the 255 randomized patients): 123 events in 
Arm A (plitidepsin plus dexamethasone) and 72 events in Arm B (dexamethasone). Then, the 
duration of this study is prolonged for six additional months, until 19 November 2017 , in order 
to continue follow -up in the alive patients , and then to be able to reach the pre -specified total of 
80% of death events (approximately 204 death events) or even more .If the required death 
events are not achieved on [ADDRESS_772368] treatment dose . Those patients 
in the control arm (Arm B) who crossed over to the combination arm (Arm A) after 
disease progression will be considered on-treatment for the duration of their whole 
CL_0092 5.[ADDRESS_772369]-C-001-09treatment (dexamethasone alone + dexamethasone in combination with plitidepsin) and 
during [ADDRESS_772370]. 
Specificall y, treatment will continue until:
Disease progression (except for those patients treated with dexamethasone alone 
and eligible to be offered crossover to combination therap y).
Unacceptable toxicity .
Intercurrent illness of sufficient magnitude to preclude safety  continuation of the 
study .
Patient refusal, and/or non compliance with study  requirements .
Protocol deviation with an effect on the risk/benefit ratio of the clinical trial
(Section 5.3).
Treatment delay  >2 weeks from the theoretical treatment date (except in case of 
clear clinical benefit, with the Sponsors’ approval) .
Requirement of > [ADDRESS_772371] not be re -treated in the context of this study  at any  time. For 
follow -up activities, please refer to Section 5.13.
5.3 PROTOCOL DEVIATION S
A protocol deviation is defined as any departure from what is described in the protocol 
of a clinical trial approved by [CONTACT_14498]/I nstitutional Review 
Board (IEC/IRB) and Competent Authorities. Therefore, it applies to deviations related 
to patient inclusion and clinical procedures (e.g., assessments to be conducted or 
parameters to be determined), and also to other procedures described in the protocol that 
concern the Good Clinical Practice (GCP) guidelines or ethical issues (e.g., issues 
related to obtaining the patients’ Informed Consent, data reporting, the responsibilities 
of the Investigator, etc.).
Deviations with no effects on the risk/benefit ratio of the clinical trial (such as minimal 
delay s in assessments or visits) will be distinguished from those that might have an 
effect on this risk/benefit ratio, such as:
Deviations that might affect the clinical trial objectives, such as those involving the 
inclusion/exclusion criteria (which could mean that the patient is not eligible for the 
trial) and those having an effect on patient evaluability .
Deviations that might affect the patient’s well-being and/or safet y, such as an 
incorrect dosing of the investigational medicinal product (plitideps in) due to not 
following dose adjustment specifications or an incorrect preparation of the 
medication.
CL_0092 5.[ADDRESS_772372]-C-001-09Deviations related to the following of GCP guidelines as described in the protocol 
and regulations in force, such as deviations when obtaining the Inform ed Consent or 
not following the terms established for reporting Serious Adverse Events, etc.
The Investigators may suggest to the Sponsor the authorization of certain protocol 
deviations, especially  if they  are related to the inclusion/exclusion criteria o r if they  may 
have an effect on the evaluability  of the patients. As a general rule, NO deviations that 
may have an effect on the risk/benefit ratio of the clinical trial will be authorized. All 
protocol deviations considered particularl y relevant, which are related to ethical issues, 
fulfillment of GCP guidelines and trial procedures, will be notified to the pertinent 
IEC/IRB and, if pertinent, to the relevant authorities as established by  [CONTACT_427].
5.4 REPLACEMENT OF PATIEN TS
The stud y anal yses will be performed in the study  population of all randomized patients. 
As detailed above (see Section 4.1), those patients not evaluable for response will not be 
replaced and they will be included in the final analy ses. 
Patients not evaluable for response :
A patient evaluable for response should have measurable disease at baseline and 
should have completed at least one full cycle of treatment or have received two 
incomplete cycles followed by [CONTACT_587178], unless the patient 
had been withdrawn from the study  due to early disease progression or drug-related 
toxicity , in which case the patient will be considered as “early  progression” or 
“treatment failure”, respectively . 
Patients will be non-evaluable if there is aprotocol deviation resulting in an 
impossibility  of drawing conclusions about the efficacy  of the stud y therapy.
These non-evaluable patients will be included in the general safety  analysis (if 
appropriate) and in planned efficacy  anal yses.
Patients witho ut valid disease evaluation during treatment will not be replaced for the 
main analy sis and will be analyzed as ITT in either randomized arm. All randomized 
patients will be evaluable for the primary  endpoint (PFS) in an ITT anal ysis.
The early  futility  analysis will be mainly  based on the efficacy  data of the first [ADDRESS_772373] of the study .
5.5 DURATION OF THE CLINICAL TRIAL
Protocol submission: 1Q2010 .
Planned start date (f irst patient onstudy ): 2Q2010 .
Complete enrollment : 60months ( 2Q2010 -2Q201 5).
Planned study  termination date: itwill be set after the occurrenc e of 80% of death 
events, 24months after accrual of the last randomized patient , or IDMC 
recommendation (whichever occurs first). 
Note: Two years after the last patient accrual, on 19 May 2017, the final OS analysis was done based 
on a total of 195 death events (i.e., 76.5% of the 255 randomized patients): [ADDRESS_772374]-C-001-09(plitidepsin plus dexamethasone) and 72 events in Arm B (dexamethasone). Then, the duration of this 
study is prolonged for six additional months, until 19 Novem ber 2017 , in order to continue follow -up 
in the alive patients ,and then to be able to reach the pre-specified total of 80% of death events 
(approximately 204 death events) or even more.If the required death events are not achieved on 19 
November 2017, the study might be furth erextended by [CONTACT_587145].
The futility  analysis is foreseen after 40 patients evaluable for response are recruited in 
Arm A , approximately  12 months after the recruitment start.
All patients on active treatment at the date of study  termination will be offered to 
continue receiv ingplitidepsin -based treatment off-study  according to the Investigator’s
criteria and upon Sponsor agreement .
5.6 INDEPENDENT REVIEW AND DATA MONITORING COMMITTEE S
An Independent Review Committee (IRC), consisting of medical specialists directly 
involved in the care of MM patients, but not being investigators or subinvestigators in this 
trial, will review all efficacy data and will assign the date of progression/censoring and 
objective response according to their independent evaluation. This IRC will be blinded to 
treatment arm allocation and identity  of the cases reviewed .
Pertinent clinical or laboratory  records [protein M measurements in blood and urine and/or 
serum free light chain s(sFLC) measurements in patient samples will be centrali zed for 
adequate monitoring and auditing purposes] and original copi[INVESTIGATOR_587115], 
whenever appropriate, are to be made available by [CONTACT_587179].
An Independent Data Monitoring Committee (IDM C), inclu ding specialists in MM and in 
medical statistics , will review the results of the analy sis performed by [CONTACT_69852]. Then, the I DMC will advise the Sponsor about the study  conduct .
A futility  analysis will be performed when data from the [ADDRESS_772375] of the study  using 
the protocol -specified efficacy criteria for study  continuation in addition to the evaluation 
of safety  profile in both treatment arms.
Operational details for the above mentioned IRC and IDMC will be detailed in the 
corresponding charters.
5.7 PRE-TREATMENT ASSESSMENTS
During the pre-treatment period, and after signing the informed consent, patients should 
undergo a series of investigations to determine their eligibility  for the study (Table 3).
Table 3. Pre-treatment period
PRE -TREATMENT INVESTIGATIONS TIME
History and clinical 
examinationWritten informed consent signed by [CONTACT_102].
Demographic data.Prior to any study -specific procedure.
Within twoweeks prior to registration.
CL_0092 5.[ADDRESS_772376]-C-001-09PRE -TREATMENT INVESTIGATIONS TIME
Medical history includes: 
Date and stage at first diagnosis.
Previous specific treatments (radiotherapy, 
chemotherapy, immunotherapy and
investigational agents ), with dates; best response 
and date of progression or relapse.
Com plete physic al examination, including weight , 
height and BSA . 
Assessment of signs and symptoms.
Intercurrent events, concomitant diseases and 
treatments .
Baseline PS (ECOG ), vital signs (heart rate, BP, 
temperature).Repeat vital signs and PS (ECOG) on 
first infusion.
Repeat complete physical examination 
and sign sand symptoms assessment 
prior to firstinfusion, if treatment will 
be administered > [ADDRESS_772377] .
Biochem istry Biochem istry A :AST, ALT, total bilirubin, direct 
bilirubin (in case total bilirubin is above ULN),
AP, creatinine ,calculated creatinine clearance 
(Cockcroft and Gault´s formula; see Appendix 3 ), 
glucose, serum electrolytes (Na+, K+, Mg++, 
Ca++), CPK (CPK -MB fraction should be 
measured only if CPK is abnormally high) and 
troponin I.
Biochem istry B : Uric acid, LDH , total proteins, 
albumin
Coagulation test s:PT, PTT andINR.Within oneweek prior to registration .
Repeat prior to firstinfusion, if 
treatme nt will be administered more 
than [ADDRESS_772378], if 
applicableSerum HCG Within oneweek prior to registration .
Cardiac assessment ECG: It should allow rhythm definition (at least 30 
seconds of duration).
Troponin I.
LVEF assessment by [CONTACT_12079].Within oneweek prior to registration .
Within one week prior to registration.
Within twoweeks prior to registration .
Local Serum protein Serum protein electrophoresis, immunoglobulins 
quantification, M -protein identifica tion and 
quantification, serum free light chains ( sFLC) , 
sFLC ratio and immunofixation (complete protein 
panel). Within four weeks prior to 
registration .
Repeat on first infusion prior to 
treatment in the Central Lab on Day 1 
of Cycle 1 .
Local Urine pro tein Urine immunoelectrophoresis and 
immunofixation.Within four weeks prior to registration
(up to twoadditional days of tolerance 
window ).
Repeat on first infusion prior to 
treatment in the Central Lab on Day [ADDRESS_772379]-C-001-09PRE -TREATMENT INVESTIGATIONS TIME
Radiological tum or 
assessment only in 
case of soft tissue 
plasmacytom a(s)
present at baselineWithin four weeks prior to 
registration .
Skeletal evaluation May bedone using CT -scan or X -ray, provided the 
same procedure is used throughout the study.Within four weeks prior to registration
(+1 w eek tolerance) .
BSA: body surface area; PS-ECOG: performance status according to Eastern Cooperative Oncology Group; BP: blood pressure; WBC: white 
blood cells; AST: aspartate aminotransferase; ALT: alanine aminotransferase; ULN: upper limit of  normal; AP: alkaline phosphatase CPK: 
creatine phosphokinase; CPK -MB: serum CPK isoenzymes (found In cardiac muscle); CT: computed tomography; LDH: lactate 
dehydrogenase; PT: prothrombin time ,PTT: partial thromboplastin time , INR: international normalized ratio ;ECG: electrocardiogram; LVEF: 
left ventricular ejection fraction; ECHO: echocardiogram; MUGA: multiple -gated acquisition scan; HCG: human chorionic gonadotropin; FLC: 
free light chain ; D, day; C, cycle.
5.8 PATIENT REGISTRATION
After ensuring that the patient meets all eligibility  criteria and has given written 
informed consent, he/she can be registered in the study  by [CONTACT_587180] (IVRS, ICOPhone™). Authorized site staff will be provided 
with a personal user ID and PIN Code to access the system. To start the randomization 
process, the site responsible should dial the country -specific phone numbe r supplied in 
the IVRS Manual (given as a separate document). The sy stem will require the following 
information to be provided: patient number (six digits: four digits for site code, pre-
assigned, plus two numbers assigned consecutively  for every  site’s patients), date of 
birth, ECOG -PS score, Durie -Salmon stage at first diagnosis and planned treatment date 
(the planned treatment date must be seven day s or less from the Randomization date). A 
confirmation report will be sent via e-mail once the randomizatio n call will end, listing 
the above information plus the treatment arm the patient has been assigned to. The 
aforementioned patient number should be used on all future documentation and 
correspondence referring this patient .
A patient who has been treated prior to registration will not be accepted for the study  at 
a later date.
5.9 PATIENT ASSIGNMENT TO TREATMENT GROUP
See Section 5.10 Patient Randomization .
5.10 PATIENT RANDOMIZ ATION
Eligible patients will be stratified according to their ECOG -PS score (0 and 1 vs.2) and 
Durie -Salmon stage (I/IIvs.III) and then randomized using a 2:1 randomization 
procedure to Arm A (plitidepsin in combination with dexamethasone) or Arm B 
(dexamethasone alone). Randomization will be used to avoid bias in the assignment of 
subjects to treatment, andto increase the likelihood that known and unknown subject 
attributes (e.g.,demographics and baseline characteristics) are evenly  balanced across 
treatment groups. 
Randomization of patients should occur as close in time as possible before 
administration of the first dose of study  drug(s) and must occur within [ADDRESS_772380] atwo-thirds chance of getting 
Arm A (plitidepsin in combination with dexamethasone) and a one-third chance of 
getting Arm B (dexamethasone alone). The random permuted blocks method will be 
used; the size of the blocks in the randomization list will be fixed and not accessible to 
the investigators. To select the blocks, a uniform (0, 1) variable with a random seed will 
be used.
5.11 EVALUATION DURING TREATMENT
Table 4. Evaluation during treatment
TREATMENT INVESTIGATIONS TIME
Clinical 
examinationPhysical exam including weight , height
and BSA.
PS(ECOG ), vital signs (heart rate, BP, 
body temperature).
Concomitant treatments.On D1 of each cycle before study drug 
administration .
On D1 and D15 of every c ycle before 
study drug administration.
Throughout the study.
Hem atology Differential WBC, hemoglobin , 
hematocrit and platelets.On D1 and D15 of every cycle b efore
study drug administration ,with a 
window  of -2 days.
If CTCAE grade ≥ [ADDRESS_772381] every 2 -3 days in the 
case of grade 4 non -febrile 
neutropenia and everyday in case of 
grade 4 febrile neutropenia.
Biochem istry Biochem istry A: AST, ALT, total 
bilirubin, direct bilirubin (in case total 
biliru bin is above ULN) , AP, creatinine
(calculated creatinine clearance by 
[CONTACT_311867]´s formula; see 
Appendix 3 ), glucose, serum  electrolytes 
(Na+, K+,Mg++, Ca++), CPK , (CPK -MB 
fraction should be measured only if CPK 
is abnormally high) and troponin I*. On D1 and D15 of every cycle b efore
study drug administration ,with a 
window  of -2 days.
If CTCAE grade ≥ [ADDRESS_772382](s) should be assessed at 
least every 2 -3 day s until recovery. 
Biochem istry B: Uric acid, LDH , total 
proteins, albumin .
Coagulation test s: PT, PTT andINR.On D1 of every cycle, except on D1 of 
Cycle 1, and with a window  of -[ADDRESS_772383] Serum HCG Repeat if applicable ;always prior to 
study drug administration .
Adverse Events Throughout the study.
Cardiac 
assessmentECG: It should allow rhythm definition 
(at least 30 seconds of duration).
Troponin I*.
LVEF assessment by [CONTACT_12079].Before each study drug 
administration , symmetrically in both 
arms.After the first two cyc les, ECG
will be done only onD1 of each cycle.
Every 12 weeks, with a window of ± [ADDRESS_772384] 100 patients receiving both 
plitidepsin and dexamethasone (Arm A). A total of [ADDRESS_772385] three 
infusions [infusions 1 and 2 of Cycle 
1 (Days 1 and 15), and infusion 1 of 
cycle 2 (Day 1)] using a sparse 
sampling schedule (see details in 
Table 5)
Central Lab 
Serum proteinPatients with secretory MM will be 
followed w ith serum electrophoresis, 
immunoglobu lins quantification and M 
protein quantification in the Central Lab 
starting on Day 1 of Cycle 1 ; patients 
with oligo or non -secretory MM, w ill be 
followed w ith sFLC ratio, in case it has 
been abnormal at study entry; in case of 
M protein disappearance, 
immunofixation will be done to confirm 
CR, and if CR is confirmed, sFLC ratio 
will be performed, to determine sCR.All protein assays will be done 
symmetrically every fourweeks ( i.e., 
Day 1 of every 4 -week cycle, with a 
window  of ±2 days) in both treatment
arms, irrespectively of treatment 
delays or omissions .
Central Lab Urine 
proteinOnly if Bence -Jones proteinuria is 
present at entering the study , in the 
Central Lab starting on Day 1 of Cycle 1.Every four weeks (with a window  of ±
2 days )symmetrically in both 
treatment arms, irrespectively of 
treatment delays or omissions.
Serum β -2 
microglobulin Every 8 weeks (with a window of ±2 
days).
Bone m arrow In all patients while in treatment, BM 
evaluation is mandatory at screening and 
in case of CR (inclu ding flow cytometry 
or immunohistochemistry, to 
demonstrate the presence of clonal 
plasma cells, only in those patients with 
presumed CR).
In patients with non -secretory MM it 
must be repeated 6 w eeks later to 
confirm response or as clinically 
indicated.When serum protein indicates CR.
Radiological 
tumor assessment 
only in case of 
measurable soft 
tissue 
plasm acytom aEvery 8 weeks (with a window of 2 
weeks) orif response is observed or if 
clinically indicated.
Skeletal evaluation May be done using CT -scan or X -ray, 
provided the same procedure is used 
throughout the study.If clinical symptoms suggest new  
bone lytic lesion.
* In case of serum troponin I increase, an ECG and ECHO will be performed as soon as possible, as well as further studies if judged 
necessary by [CONTACT_239938]. Any increase of troponin I ≥ ULN together with evidence of cardiac damage by [CONTACT_587181]/MUGA will be followed accordingly by a cardiologist and the patient will immediately and definitively discontinue study 
treatment.
PS-ECOG: Eastern Cooperative Oncology Group; BSA: body surface area; BP: blood pressure; WBC: white blood cells; CTCAE: 
National Cancer Institute Common Terminology Criteria for Adverse Events; AST: aspartate aminotransferase; ALT: alanine 
CL_0092 5.[ADDRESS_772386]-C-001-09TREATMENT INVESTIGATIONS TIME
aminotransferase ; ULN: upper limit of  normal; AP: alkaline phosphatase; CPK: creatine phosphokinase; CPK -MB: serum CPK 
isoenzymes (found in cardiac muscle); CT: computed tomography; LDH: lactate dehydrogenase; PT: prothrombin time, PTT: partial 
thromboplastin time, INR: international normalized ratio; ECG: electrocardiogram; LVEF: left ventricular ejection fraction; ECHO: 
echocardiogram; MUGA: multiple -gated acquisition scan; PK: pharmacokinetics; HCG: human chorionic gonadotropin; BM: bone 
marrow; FLC: free light chain ; CR: complete response; MM: multiple myeloma ; sCR, stringent complete response ; D, day .
Note: One patient was still undergoing treatment on 19 May 2017 . However, as the primary 
endpoint of the study (progression -free survival) was fulfilled, and this exten ded follow -up is 
focused only on survival, no information such as central laboratory data or images will be sent 
for independent review. Nevertheless, laboratory determinations or images will be done locally, 
if clinically indicated, in order to perform tu mor assessment.    
5.12 EVALUATION AT THE ENDOFTREATMENT
The end-of-treatment visit will be scheduled 30 days (±two days) after the 
administration of the last dose of the study  therapy , unless another anticancer treatment 
is started before. In thatcase, the end-of-treatment visit should be performed 
immediately  before the start of the new therap y (ideally  the day  before or the same day ). 
At the time of patient discontinuation (regardless of the reason), the same complete 
work -up done before study  entry  will be repeated. 
Physical examination ,weight and height.
ECOG performance status.
Vital signs.
Hematology and coagulation tests .
Biochemistry  (A and B).
ECG: I t should allow rhythm definition (at least 30 seconds of duration)
LVEF assessment by  [CONTACT_587182] A.
Safety  assessment (AEs).
Serum protein : serum protein electrophoresis, immunoglobulins quantification, 
M-protein identification and quantification , and serum sFLC if indicated.
Urine protein : Onl y if Bence -Jones proteinuria is present at entering the st udy.
Serum β-2 microglobulin : only if the patient discontinues treatment without 
documented disease progression.
Bone marrow (if clinically indicated).
Radiological tumor assessment only in case of soft tissue plasmacy toma present 
at entering the stud y.
Skeletal evaluation.
Concomitant t reatments .
Adverse events must be assessed for [ADDRESS_772387] study  drug administration will 
be reported. Beyond this period of time, onlythose suspected to be treatment -related 
SAEs will be reported (Section 9.2.2 ).
CL_0092 5.[ADDRESS_772388]. Study  termination date is 
defined as the date in which 80% of death events occurred, [ADDRESS_772389] randomized patient, or IDMC recommendation (which ever occurs first).
Note: Two years after the last patient accrual, on 19 May 2017, the final OS analysis was done 
based on a total of 195 death events (i.e., 76.5% of the 255 randomized patients): 123 events in 
Arm A (plitidepsin plus dexamethasone) and 72 events in Arm B (dexamethasone). Then, the 
duration of this study is prolonged for six additional months, until 19 November 2017 , in order 
to continue follow -up in the alive patients ,and then to be able to reach the pre -specified total of 
80% of death events (approximately 204 death events) or even more .If the required death 
events are not achieved on [ADDRESS_772390] be followed after the tim e of therapy 
discontinuation until the event or its sequel resolve or stabilize at a level acceptable to 
the Investigator and the clinical monitor or his/her designated representative. After 
treatment discontinuation, patients will be followed every  four weeks until resolution of 
toxicities, if any .
Additional parameters and/or increased frequency of observations should be performed 
at the Investigator’s discretion and according to the nature of the observed AEs. When 
available, autops y data should be provi ded.
The f ollow -up visits willbe performed b y phone only if the patient is unable to go to the 
study  center owing to the seriousness of his/her disease. This will only apply to patients 
who are followed up after discontinuing treatment due to disease prog ression.
6PHARMACOKINETICS
Plitidepsin pharmacokinetics (PK) will be evaluated in at least 100 patients receiving 
both plitidepsin and dexamethasone (Arm A)at selected sites. Patients will be sampled 
during Days [ADDRESS_772391] mlof blood 
will be discarded to avoid the dilution of the sample with the solution used to keep it 
perm eable.
Four -ml blood samples will be collected in sodium heparin tubes. Sample tubes will be 
gentl y inverted several times to assure adequate mixing with the heparin and the blood 
(without centrifugation) should be transferred to the provided polypropylenetubes and 
stored at-20ºC until the shippi[INVESTIGATOR_587116] . The tubes will be provided 
by [CONTACT_587183].
A total of [ADDRESS_772392] three infusions (infusions 1 
and 2 of Cy cle 1, and infusion 1 of Cy cle 2) at t he time points detailed in Table 5.
Table 5. Sampling points for pharmacokinetic evaluations.
Sample 
numberCycle Infusion Time
(from  start of each 
infusion)Time*
(relative to EOI)
[ADDRESS_772393] before EOI
11 2 1 4 h One hour after EOI
12 2 1 6 h Three hours after EOI
13 2 1 ~336 Two weeks after EOI**
*The length of the infusion is three hours.
**Previous to second infusion of the second cycle.
EOI: end of infusion.
The accurate recording of actual dosing and sampling times is much more important 
than the strict adherence to the scheduled times.
Once all samples from a patient have been collected they should be shipped to the 
central laboratory  for pharmacokinetics as soon as possible, ideall y the next shippi[INVESTIGATOR_587117]. The time span between the moment the last PK sample for a patient has been 
collected and the shipment of all the samples from this patient to the central lab should 
not exceed twomonths.
CL_0092 5.[ADDRESS_772394]-C-001-09Samples will be identified with the following data: study  reference, patient number , 
sample number, date and time of collection. At all time the confidentiality  of patient’s 
data will be maintained.
A manual of instructions for sample collection, labeling , storage, and shipment will be 
provided as a separate docu ment .
7TREATMENT
7.1 STUDY MEDICATIONS
For information regarding dexamethasone please refer to Dexamethasone Drug 
Information, provided as a separate document . For detailed instructions regarding 
plitidepsin inventory , handling, reconstitution, dilution, storag e, accountability  and 
disposal, please refer to the updated Aplidin®Preparation Guide for Infusion, also 
provided as separate document.
Commercially  available oral dexamethasone formulation will be provided by [CONTACT_429].
7.1.1 Quantitative and Qualitative Co mposition
[IP_ADDRESS] Plitidepsin
Plitidepsin will be supplied as a powder and solvent for concentrate for solution for 
infusion . The 2-mg vial should be reconstituted with a 4-ml ampoule of reconstitution 
solution. The composition of reconstitution solution is Cremop hor EL/Ethanol/Water 
for injection, 15%/15%/70% (v/v/v).
7.2 ADMINISTRATION OFSTUDY MEDICATION
The administration of each study  medication will be as follows:
Arm A :
a)Dexamethasone: 40 mg orally  on Day 1, 8, 15 and 22 every four weeks 
(q4wk )at least one hour before plitidepsin infusion.
b)Plitidepsin: 5 mg/m2intravenousl y (i.v.) diluted to a total volume of 250 ml 
in 0.9% saline (or 5% glucose )via a central venous catheter (suggested) or 
diluted to a total volume of 500 ml in 0.9% saline (or 5% glucose )via a 
peripheral line. Infusion will be performed through a pump device over three 
hours (fixed rate) on Day 1 and 15 q4wk.
Arm B: 
a)Dexamethasone: 40 mg orally  on Day 1, 8, 15 and 22 q4wk .
A cy cle is defined as a four -week period.
7.3 CRITERIA FOR TREATMEN T CONTINUA TION AND RETREATMENT
Patients may be treated with additional cycles of plitidepsin and dexamethasone or 
dexamethasone alone, as long as no unacceptable toxicity  and/or disease progression is 
documented (see Section 5.2).
CL_0092 5.[ADDRESS_772395]-C-001-09Complete blood counts, blood chemistries and other tests will be done prior to starting 
the next treatment cycle (please refer to Section 5.7and Section 5.[ADDRESS_772396] of 
tests to be done before each drug administration and/or initiation of a new treatment 
cycle).
Table 6lists the minimum requirements needed to re-expose the patient to the study 
drug(s) in each group. Other factors might be considered critical by [CONTACT_737]. In 
this case, these factors should be appropriatel y documented in the patient’s record and 
on the CRF, and discussed with the Sponsor.
If the criteria listed inTable 6are not met on the day of the next planned dose, 
administration of the study  drug(s) should be delay ed. The criteria for treatment 
administration should be reevaluated weekl y. The new cycle will start upon recovery  to 
the values listed in th ose tables, for Day 1.
A maximum cy cle delay  of two weeks is allowed for recovery  from drug -related AEs. If 
no recovery  was found after the two-week delay , the patient should discontinue the 
treatment, except —upon Sponsor’s agreement —in cases of obvious patient benefit in 
continuing the treatment according to the investigator’s criteria. 
Before the administration of each dose (retreatment), patients must fulfill the baseline 
criteria defined in Table 6.
Table 6. Criteria for continuation of treatment
Criteria for continuation of 
treatm entPlitidepsin
(Arm  A)Dexamethasone
(Arm  A and B)
Day 1a and 15bDay 1aand15
ANC 1.0  x109/l or return to baseline 
values if extensive BM involvement -
Plate lets 50  x 109/l or return to baseline 
values if extensive BM involvement-
Hem oglobin 8.5g/dl 8.5 g/dl
Direct bilirubin if total bilirubin 
is above the upper normal limit1.0x ULN -
AST/ALT Grade 2 -
Muscular toxicity (m yalgia, 
muscular we akness, CPK 
increase)Grade 2 ≤ Grade 2
Other non -hematological drug -
related AEs (except for 
increased GGT and/or AP , not 
optim ally treated nausea and 
vomiting or hypertension , 
alopecia)c≤ Grade 1 ≤ Grade [ADDRESS_772397]-C-001-09Criteria for continuation of 
treatm entPlitidepsin
(Arm  A)Dexamethasone
(Arm  A and B)
Day 1a and 15bDay 1aand15
ECG, ECHO/ MUGAdSame as baseline Same as ba seline
a.If a patient does not meet the requirements for treatment continuation on Day 1 of the following cycle ,the 
infusion of study drugs will be withh eld until recovery or for a maximum of 1 4days. After this period, if delay is 
due to toxicity assessed as related to study drug, a dose decrease of 20% is mandatory; up to a maximum of two 
individual dose reductions are allowed. Patients needing additional dose reductions must be withdrawn from the 
trial.
b.If a patient does not meet the requirements for treatment continuation on Day 15,the administration of plitidepsin
will be omitted. Patients requiring frequent dose omissions may have a dose reduction of 20% upon Investigator 
and Sponsor agreement. In no case more than two dose reductions are allow ed
c.Any grade accepted for increased GGT and/or AP, and up to grade 2 peripheral neuropathy.
d.Tobe performed every three months unless more frequent assessments are clinically indicated.
AEs: adverse event(s); ANC: absolute neutrophil count; AP: alkaline phosphatase; BM: bone marrow; AST/ALT: 
aspartate aminotransferase/alanine aminotransferase; CPK: creatine phosphokinase; GGT: -glutamyltranspeptidase; 
ECG: electrocardiogram; ECHO/MUGA: echocardiogram/multiple -gated acquisition scan.
7.4 DOSE REDUCTION CRITERIA
Patients experienc ingfrequent dose omissions and/or unacceptable toxicity , defined as
less than 50% compliance with treatment schedule ,and/or 
grade ≥ 3 febrile neutropenia ,or 
grade 4 neutropenia and infection ,or 
grade 4 neutropenia lasting > 7 days(except for patients with extensive BM 
involvement) ,and/or 
grade 4 thrombocy topenia (except for patients with extensive BM involvement) ,
and/or
grade 4 thrombocy topenia with grade ≥3 bleeding (in patients with extensive 
BM involvement), and/or
any grade ≥ 3 clinical lyrelevant non-hematological toxicity  other than non-
optimally  treated nausea and vomiting, diarrhea lasting < 48 hours and/or grade 
≥ 3 asthenia/fatigue lasting < 5 day s
may continue treatment after reducing 20% of the dose of plitidepsin (first reduction to 
4 mg/m2, and second reduction to 3.2 mg/m2), upon Sponsor agreement, if patient 
benefit is perceived. 
Dexamethasone doses are to be reduced by 50%, up to a maximum of two consecutive 
dose reductions (first one, 20 mg Days 1,8,15 and 22, and second, 20 mg Days 1 and 15 
of each 28 -day cycle), if a patient experience smuscular toxicity  of grade ≥ 3 (weakness, 
myalgia and/or CPK elevations), or drug-related grade ≥ 3 fatigue, or mood 
disturbances or agitation of grade ≥ 2 or grade ≥ [ADDRESS_772398] 
gradePlitidepsin Dexamethasone
Less than 50% compliance 
with treatm ent scheduleDecrease to 4 
mg/m2, then to 3.2 
mg/m2No reduction
Febrile neutropenia≥ 3 Decrease to 4 
mg/m2,then to 3.2 
mg/m2No reduction
Neutropenia lasting > 7 days
(except for patients with 
extensive BM involvem ent)4 Decrease to 4 
mg/m2, then to 3.2 
mg/m2No reduction
Thrombocytopenia
(except for patients with 
extensive BM involve ment )4 Decrease to 4 
mg/m2, then to 3.2 
mg/m2No reduction
Thrombocytopenia with 
grade ≥ 3 bleeding 
(in patients with extensive 
bone m arrow involvem ent)4 Decrease to 4 
mg/m2, then to 3.2 
mg/m2No reduction
Any clinically relevant 
and/or non -hematolo gical 
toxicity (except non -
optim ally treated nausea and 
vomiting, diarrhea < 48 
hours and/or 
asthenia/fatigue lasting < 5 
days)≥ 3 Decrease to 4 
mg/m2, then to 3.2 
mg/m2No reduction
Muscular toxicity (weakness, 
myalgia and/or CPK 
elevations) ≥ [ADDRESS_772399] epi[INVESTIGATOR_1865]: 
decrease to 4 
mg/m2, then 
reduce 
dexamethasone; if 
toxicity recurs, 
reduce to 3.2 
mg/m2First reduce plitidepsin; if 
persistence, decrease 
dexamethasone to 20 mg Days 
1,8,15,22 of each cycle; if 
toxicity recurs, decrease  again 
plitidepsin and, if persistence, 
then decrease dexamethasone 
dose to 20 mg Days 1 and 15 of 
each cycle. T wo dose reductions 
are allow ed for either agent (only 
for muscular toxicity).
Mood disturbances/agitation≥ [ADDRESS_772400] reduction to 20 mg Days 
1,8,15,22 of each cycle, then to 
20 mg Days 1 and 15 of each 
cycle.
Fluid retention≥ [ADDRESS_772401] reduction to 20 mg Days 
1,8,15,22 of each cycle, then to 
20 mg Days 1 and 15 of each 
cycle.
Once a dose reduction has been implemented, dose will not be re-escalated thereafter . 
No more than two dose reductions (of either compound, if required) are allowed. 
Patients need ingadditional dose reduction s must be withdrawn from the trial. 
7.[ADDRESS_772402] be recorded on the patient's CRF.
In addition, reasonable efforts will be made to determine all treatments received by [CONTACT_587184]. This information must be documented 
in the concomitant therapy Section of the CRF .
Cardiac safet y of plitidepsin will be monitored with ECG ,LVEF and troponin I 
measurement during the trial. Some drugs may prolong QT Cinterval duration. These 
drugs are allow ed as concomitant medication, and the investigators should be aware of 
this potential event.
Close monitoring of patients taking oral anticoagulants is required.
7.5.1 Prophylactic Medication
1.Arm A: 
All patients must receive the following proph ylactic medication 20 -30 minutes before 
infusion of plitidepsin:
Ondansetron 8 mg i.v. or equivalent (granisetron 3 mg i.v. preferred when 
available ).
Diphenhy dramine hydrochloride 25 mg i.v. or equivalent, and
Ranitidine 50 mg i.v. or equivalent.
Oral metoclopramide and/or extended oral ondansetron (or their equivalents) may  be 
used as per Investigator’s criteria /institutional guidelines (63).
2.Arm B: No proph ylactic medication specified.
7.5.2 Allowed Medication s/Therapi[INVESTIGATOR_014]
1.Platelet and red cells transfusions .
2.Erythropoietin.
3.Bisphosphonates during the study  according to the ASCO guidelines (64).
4.Therapi[INVESTIGATOR_587096]/or emergent medical conditions not 
specificall y forbidden as per protocol elsewhere.
CL_0092 5.[ADDRESS_772403]-C-001-095.Antiemetics (excluding steroids) according to institutional or ASCO guidelines (65).
6.Granulocy te colon y stimulating factor (G-CSF)/granulocy te-macropha ge colon y 
stimulating factor (GM -CSF) and/or blood derived products transfusions, according 
to institutional or ASCO guidelines (66, 67) .
7.Palliative local radiation of a plasmacy toma . The irradiated lesion will then not be 
considered an area of measurable/evaluable disease.
8.Systemic and/or local therapi[INVESTIGATOR_587097], particularl y in the case of 
diarrh ea or skin toxicity .
9.Patients in the plitidepsin + dexamethasone arm who develop grade ≥ 2 muscular 
toxicity  may be empi[INVESTIGATOR_587118] L-carnitine at a total daily  amount of
up to 3 g, divided into three doses, until it decreases to grade ≤ 1.
10.Adequate analgesic medication, including opi[INVESTIGATOR_587119].
11.Drugs known to prolong QT interval and/or induce Torsades de Pointes should be 
avoided whenever possible (see Appendix 7 , drugs labeled as 1 ).
7.5.3 Prohibited Medication s/Therapi[INVESTIGATOR_014]
1.Concomitant administration of an y other antineoplastic therap y.
2.Other investigational agents.
3.Immunosuppressive therapi[INVESTIGATOR_014], except single bolus hy drocortisone used eventually  as 
treatment for h ypersensitivity  reactions, if required.
4.Primary  prophy laxis with colony -stimulating factors ,such as G -CSF and GM -CSF.
7.5.[ADDRESS_772404] supervision of the I nvestigator.
8STUDY EVALUATIONS
8.1 EFFICACY 
Primary
PFS, according to IRC assessment, as per intention -to-treat (ITT) anal ysis.
CL_0092 5.[ADDRESS_772405]-C-001-09Secondary 
Objective RR .
Best overall response including rate of minor response (MR) or better (according to 
the IMWG criteria) (Appendix 5).
RR to combination treatment in patients who crossed over after progression on 
dexamethasone alone .
Time -to-event endpoints: DRandOS.
Intrapatient response and PFS comparison of patients who crossed over from 
dexamethasone alone (Arm B )to plitidepsin plus dexamethasone combination ( Arm 
A).
The primary  study analysis will be based on externall y assessed PFS data in the ITT 
efficacy population , defined as all patients ra ndomized to either treatment arm.
PFS will be calculated from randomization to the first evidence ofPD (IMWG criteria) 
or death due to any cause. If the patient receives further antitumor therapy  before PD 
and within the timeframe expected for first follo w-up, PFS will be censored on the date 
of the last disease assessment prior to the administration of this antitumor therapy . If the 
patient is lost to follow -up for the assessment of progression, or has more than one 
missing follow -up between the date of last tumor assessment and the date of 
progression, death or further antitumor therapy , the PFS will be censored at the date of 
last valid tumor assessment before the missing evaluations.
DR will be calculated from the date of first documentation of response to the date of 
disease progression or death .The same censoring rules described above for PFS 
calculation will be also considered for DR.
OS isdefined as the time from the date of randomization to the date of death or last 
contact.
An external IRC,blind ed to treatment arm,will assign a progression or censoring date 
for each patient based on laboratory  data and radiologic and bone marrow assessments 
when required andevaluation of all relevant clinical information , according to a 
predefined algorithm provided in a separate charter. Both IRC and Investigator’s 
assessment will be used for the determination of RR, DR and PFS.
By [CONTACT_8345], disease response will be assessed every  four weeks symmetrically  across 
treatment arms irrespectively  of treatment delays or omissions . Disease assessments 
(e.g., serum or urine M protein, serum FLC) and evaluation of extent of disease will be 
done within two weeks before randomization and every  four weeks thereafter in the 
absence of PD while on treatment. If disease progress ion has not occurred at treatment 
termination, then disease assessments should continue every  four weeks until evidence 
of disease progression, start of subsequent anticancer treatment, or death, whichever 
occurs first. 
PFS and objective tumor response wi ll be assessed symmetricall y across treatment arms 
every  four weeks while on treatment, irrespectively  of dose omissions or delay s,
according to IMWG criteria .Centralized laboratory  reports and copi[INVESTIGATOR_436388], 
MRI  (in case of soft tissue plasmacy toma) and any other documented means to evaluate 
tumor response or progression should be available for IRC review.
CL_0092 5.[ADDRESS_772406] one dose of thestudy 
treatment . Safet y will be evaluated in each arm separatel yaccording to the actual 
treatment received.
AEs will be graded according to National Cancer Institute Common Terminology 
Criteria for Adverse Events (CTCAE), version 4.
8.[ADDRESS_772407] of the concomitant 
administration of dexamethasone on the plitidepsin PK and the relationship between the 
plitidepsin PK exposure and toxicity /efficacy  parameters will be evaluated.
9ADVERSE EVENTS REPOR TING
9.1 DEFINITIONS
9.1.1 Adverse Event 
An adverse event (AE) is any untoward medical occurrence in a patient or a clinical 
investigation patient administered a pharmaceutical product which does not necessaril y 
have a causal relationship with this treatment. 
An AE can therefore be any unfavorable and unintended sign (e.g., an abnormal 
laboratory  finding), or a disease temporally  associated with the use of a medicinal 
product, whether or not considered related to t he medicinal product.
Any event involving adverse drug reactions, illnesses with onset during the study  or 
exacerbations of pre-existing illnesses should be recorded, including but not limited to 
clinically  significant changes in physical examination findi ngs and abnormal objective 
test findings (e.g., x-ray, ECG). The criteria for determining whether an abnormal 
objective test finding should be reported as an AE are as follows:
The test result is associated with clinically  significant sy mptoms, and/or
The test result leads to a change in the study  dosing or discontinuation from the 
clinical trial, significant additional concomitant drug treatment or other therap y, 
and/or
The test result leads to any of the outcomes included in the definition of a SAE, 
and/o r
The test result is considered to be clinicall y relevant by [CONTACT_737].
9.1.2 Serious Adverse Event (SAE)
A Serious Adverse Event (SAE) is an y adverse experience occurring at an y dose that:
Results in death (is fatal),
Is life -threatening,
Requires or pro longs inpatient hospi[INVESTIGATOR_059],
Results in persistent or significant disability  or incapacit y,
CL_0092 5.[ADDRESS_772408]-C-001-09Is a congenital anomal y or birth defect, or
Is medicall y significant.
Is any suspected transmission of an infectious agent via a medicinal product.
Medical and scientific judgment should be exercised in deciding whether expedited 
reporting is appropriate in other situations such as an important medical event that may 
not be immediately  life-threatening or result in hospi[INVESTIGATOR_587120].
[IP_ADDRESS] Death
Death as such is the outcome of a SAE and should not be used as the SAE term itself. 
Instead ,the cause of death should be recorded as the SAE term. When availa ble, the 
autopsy  report will be provided to the Sponsor.
Grade 5 should be used for events which lead immediately  and directl y to death, and 
grade 4 should be used with outcome death for events which lead to death after a longer 
time period, and that may  also be linked to additional morbidities.
[IP_ADDRESS] Life Threatening Event
Any event in which the patient was at risk of death at the time of the event; it does not 
refer to an event which hy pothetically  might have caused death if it were more severe.
[IP_ADDRESS] Hospi[INVESTIGATOR_587121] H ospi[INVESTIGATOR_587122] (or prolongation of hospi[INVESTIGATOR_059]) that occurs or 
worsens during the course of a patient’s participation in a clinical trial must be reported 
as a SAE unless exempted from SAE reportin g (see Section 9.2.2 ). Prolongation of 
hospi[INVESTIGATOR_436408]/required for the initial admission, as determined by [CONTACT_12244] r or 
treating ph ysician.
Hospi[INVESTIGATOR_436409]: 
a)Reasons described in protocol (e.g., study  drugadministration, protocol -required 
intervention/investigations, etc). However, events requiring hospi[INVESTIGATOR_587123] a result of a complication of therapy 
administration or clinical trial procedures will be reported as SAEs.
b)Hospi[INVESTIGATOR_436411], practical or social
reasons, in absence of an AE.
c)Pre-planned hospi[INVESTIGATOR_602]: any pre-planned surger y or procedure must be 
documented in the source documentation. Only  if the pre-planned surgery needs to 
be performed earlier due to a worsening of the condition, should this event 
(worsened condition) be repo rted as a SAE. 
Other situations that MUST NOT be considered as hospi[INVESTIGATOR_436412]:
d)An emergency visit due to an accident where the patient is treated and discharged.
CL_0092 5.[ADDRESS_772409]-C-001-09e)When the subject is held 24 hours for observation and finally  is not admi tted.
f)Planned treatments at sites not associated to a hospi[INVESTIGATOR_587124] (i.e., laser ey e surgery, arthroscopy , etc).
9.1.3 Unlisted /Unexpected Adverse Event
An AE, the nature or severity  of which is not consistent with the applicable reference 
safet y information.
The Sponsor will use as the reference safety information for the evaluation of 
listedness/expectedness the following documents:
The current Investigator’s Brochure (IB)for any PharmaMar study  drug without 
a marketing authorization or used outside the conditions of its marketing 
authorization.
The summary  of product characteristics (SPC) or its national equivalent [i.e., 
U.S. package inserts (USPI )] for non-PharmaMar study  drugs used within the 
conditions of its marketing authorization. For dexamethasone the expectedness 
will be assessed against the safety  sections in the label maintained at 
http://www.drugs.com/pro/dexamethasone.html.
9.1.[ADDRESS_772410].
9.1.5 Adverse Events Related to Study Drugs
An AE is considered related to a study  drug/ investigational medicinal product (IMP) if 
the Investigator assessment of causal relationship to the study  drug is “Y” (see below) . 
The Investigator will assess the causal relationship of each of the study drugs to the 
SAE.
The Sponsor may also consider related to the study  drug those events for which the 
Investigator assesses the causal relationship with the study  drug as “Uk” when it cannot 
rule out a role of the study drug in the event. Refer to Section 1 0.1.6 for causality  scale.
9.1.6 Expedited Reporting
The Sponsor is responsible for the appropriate expedited reporting of suspected unlisted 
/ unexpected and related serious adverse reactions (S[LOCATION_003]R s), including the following 
events of special interest: misuse, overdose , medication error and abuse, to the 
Competent Authorities. The Sponsor will also report all SAEs , including those which
are unliste d / unexpected and related to the study  drug(s), to the Investigators and to the 
Independent Ethics Committees/I nstitutional Review Boar ds(IECs/IRBs) according to 
the current legislation unless otherwise required and documented b y the IECs/I RBs.
CL_0092 5.[ADDRESS_772411] provide an assessment of causal relationship of each of the 
clinical trial study  drugs (including combination and comparator products) to the SAE 
according to the following scale:
Y There is a reasonable possibility  that the study  drug(s) caused the SAE
N There is no reasonable possibility  that the study drug(s) caused the SAE 
and other causes are more probable.
Uk Only  to be used in special situations where the Investigator has 
insufficient information (i.e. the patient was not seen at his/her centre) if 
none of the above can be used.
9.[ADDRESS_772412] dose of study 
drug(s)or until the start of a new antitumor therapy , whichever occurs first. All AEs 
suspected to be related to study  drug(s)must be followed after the time of therapy 
discontinuation until the event or its sequelae resolve or stabilize at an acceptable level 
to the I nvestigator and the Sponsor.
All AEs, including misuse, overdose and abuse must be recorded using medical 
terminology  in the source document and the CRF. Whenever possible the Investigator 
will record the main diagnosis instead of the signs and symptoms normally  included in 
the diagnoses. 
Investigators must assess severity  (grade) of the event following NCI-CTCAE v. 4and 
assign relationship to each study  drug; pursue and obtain information adequate both to 
determine the outcome and to assess whether it meets the criteria for classification as a 
SAE requiring immediate notification to PharmaMar or its designated representative. 
The Investigator must provide any relevant information as requested by [CONTACT_587185].
Abnormal laboratory  tests occurring during the study  are AEs, but they should be 
collected onl y in the AE section of the CRF in some cases :
Is ass ociated with clinically  significant s ymptoms, and/or
Leads to a change in study  dosing or discontinuation from the study , significant 
additional concomitant drug treatment or other therap y, and/or
Leads to an y of the outcomes included in the definition of a SAE.
The test result is considered to be a clinicall y relevant by [CONTACT_737].
Otherwise laboratory  results should be reported in the corresponding section of the CRF 
(e.g. biochemistry , hematology ).
CL_0092 5.[ADDRESS_772413] dose of study 
drug(s)or until the start of a new antitumor therapy , whichever occurs first . Bey ond this 
period of time, only those SAEs suspected to be related need to be reported. 
Nonetheless, the Sponsor will evaluate any safety  information that is spontaneousl y 
reported b y an Investigator bey ond the time frame specified in the protocol.
Exemptions from SAE REPORTING:  Events of “disease progression” even if they 
fulfill any  seriousness criterion (i.e. ,fatal, requiring hospi[INVESTIGATOR_12191], etc) are exempted from 
SAE reporting and will only  be reported in the applicable CRF page (s).
All SAEs (as defined above ) regardless of treatment group or relationship to study  
drug/IMP must be reported immediately  and alway s within 24 hours to the PharmaMar 
Pharmacovigilance Department by [CONTACT_6791] ([PHONE_9082]) or telephone ([PHONE_12208] 
6054). Out of office hours (GMT), assistance on SAE reporting can be obtained by 
[CONTACT_587186] [PHONE_12209] 49 .  
The preferred reporting metho d is by [CONTACT_587187] “Serious Adverse Event 
Form” provided by [CONTACT_587188] . An initial report by [CONTACT_587189] a 
completed SAE form the investigational staff within one working day .
All SAEs suspected to be related to the study  drug(s) must be followed until the event or
its sequelae resolves or stabilizes at an acceptable level by [CONTACT_587190]/her designated representative.
9.2.[ADDRESS_772414] information on 
pregnancies occurring during clinical trials, in which exposure to the study  drugs at any 
moment of the pregnancy , via either maternal or paternal exposure is suspected.
Therefore, pregnancy and suspected pregnancy (including a positive pregnancy  test 
regardless of age or disease state) of a female patient or the female partner of a male 
patient occurring while the patient is on study  drug, or within 30 days of the patient’ s 
discontinuation v isit, is considered an immediately reportable event.
The Investigator will report the following events immediately  and alway s within 
[ADDRESS_772415] knowledge:
Any occurrence of a pregnancy  where any kind of exposure to the drug( s)is 
suspected
Possib le exposure of a pregnant woman [this could involve a partner of a male 
patient or a pregnant female who came in contact [CONTACT_587191](s )]
All reports of elevated/ questionable or indeterminate beta human chorionic 
gonadotrophins (βhCGs)
CL_0092 5.[ADDRESS_772416]-C-001-09Immediately  after detecting a case of suspected pregnancy  in a female clinical trial 
patient, the decision on her continued participation in the clinical trial will be jointly  
taken by [CONTACT_28138], the Investigator and the Sponsor , with the patient’ s best 
interest in mind. A decision to continue the pregnancy  will require immediate 
withdrawal from the trial. If the trial is blinded, the Investigator will open the blind 
whenever the treatment information is needed for the management of the patient.
Any pregnancy , suspected pregnancy , or positive pregnancy  test must be reported to 
PharmaMar Pharmacovigilance immediatel y by [CONTACT_587192]. In the case of pregnancy  of the female partner of a trial Patient the Investigator 
will obtain her informed consent to provide the information by [CONTACT_587193] b y the Sponsor who will also advise the Investigator in these situ ations.
The Investigator will follow the pregnancy  until its outcome, and must notify 
PharmaMar Pharmacovigilance the outcome of the pregnancy  within [ADDRESS_772417] 
knowledge as a follow -up to the initial report .
For any event during the pregnancy , whic h meets a seriousness criterion (including fetal 
or neonatal death or congenital anomaly ), the Investigator will also follow the 
procedures for reporting SAEs (complete and send the SAE form to PharmaMar 
Pharmacovigilance by [CONTACT_31950] 24 hours of the Investigator ’s knowledge of the 
event). 
All neonatal deaths that occur within [ADDRESS_772418] 
to causality , as SAEs. In addition, any infant death at any time thereafter that the 
Investigator suspects is related to the exposure to the study  drug(s) should also be 
reported to PharmaMar Pharmacovigilance by [CONTACT_31950] 24 hours of the 
Investigators’  knowledge of the event.
10STATISTICA L METHODS
10.1 SAMPLE SIZE
1.Arm A(plitidepsin plus dexamethasone combination): approxima tely 167
patients.
2.Arm B (dexamethasone single agent): approximately  83patients.
The number of patients randomized in the trial has beencalculated based on PFS 
estimates obtained from the previous phase II study  (APL -B-014-03). 
Approximately 210progres sion or death events would be needed in thistrial to detect a 
HR of 0.625 in favor of the combination arm (equivalent to an increase of 60% in PFS, 
i.e., from 10 to 16 weeks , from 12 to 19.2 weeks, from 16 to 25.6 weeks , etc. )with 90% 
power and 1-sided 2.5% significance level. As a preliminary  hypothesis, it is estimated 
that up to [ADDRESS_772419]-C-001-0910.2 STATISTICAL ANALYSIS
10.2.1 Demographics
Descriptive statistics (mean, median, standard deviation and95% confidence interval, 
range of value, frequencies and percentages) will be used. Tables by [CONTACT_587194].
Comparative study  with descriptive methods will be done to check that patients’ 
baseline characteristics are similar betwe en treatment groups 
10.2.2 Safety 
Patients are evaluable for general safet y if they  received any stud y treatment . Safety  will 
be evaluated in each arm separately according to the actual treatment received.
AEs will be graded according to CTCAE , version 4.0.
Descriptive statistics will be employ ed to characterize the profiles of drug-related 
adverse event s, drug-related deaths, SAE and drug-related treatment discontinuation. 
Tables b y randomization group will be displayed.
10.2.3 Efficacy Analysis
[IP_ADDRESS] Early Futility Analys is
An early  futility  analysis will be performed when information from 40 patients in Arm 
A are evaluable for response. A response rate (IMWG criteria) of at least 30% (12 or 
more responses by [CONTACT_587195] ) will be taken as threshold for continuation of the study. 
A minimum response rate of 30% has been considered as clinically  significant in this 
setting. This result will ensure that the lower limit of the exact binomial 95% 
Confidence Interval for the response rate will be greater than 15% (95% CI in case of 12 
responses would be 16.6% -46.5%).
However, the information from all randomized patients in both arms at that time will be 
used by [CONTACT_587196] y profile and to provide the Sponsor with a 
recommendation for the further study  conduct. No claim for superiority  in efficacy  will 
be formulated in this interim analysis and no alpha -spending for the analy sis of PFS is 
foreseen.
[IP_ADDRESS] Patients’ Evaluability for Response 
All patients who have completed at least one evaluable cycle or who have receive d two 
uncompleted cycles followed by [CONTACT_587197] (± one week) after treatment onset, will be considered evaluable for response. In 
addition, any eligible patients who receive at least one treatment cycle or have received 
two uncompleted cycles and experience disease progression or die due to progressive 
disease prior to response evaluation will be considered evaluable for response and will 
be categorized as an “early  progression”. 
CL_0092 5.[ADDRESS_772420]-C-001-09Patients withdrawn due to drug-related toxicity  without any tumor assessments after the 
start of study  treatment will be considered as “treatment failures”.
Patients withdrawn due to significant clinical deterioration of unknown reason, 
hypersensitivity  reactions, or refusal to contin ue on study  for any reason or unrelated 
AEs without any disease assessments after the start of study  treatment will be 
considered not evaluable for efficacy  and their response will be categorized as “non 
evaluable”.
Binomial estimates with exact 95% CIs will be calculated for the analysis of response 
rate. Randomized patients not evaluable for response will be excluded from the 
denominator exclusively  for the futility  analysis but will be included in all final efficacy 
analyses.
[IP_ADDRESS] Final PFS Analysis and Inte rim OS analysis
The final PFS analysis will be performed when at least 210 progression or death events 
are observed.
The PFS assessed by [CONTACT_300425] (IRC) will be used for the 
primary  analysis, while the Investigator assessment will beused for the secondary 
analysis of PFS.
The unstratified log rank test will be used to compare the PFS of Arm A and Arm B.
Secondary  time-to-event endpoints (DR, OS) will be analyzed according to the Kaplan -
Meier method and compared between treatment groups using the log-rank test. A 
stratified log-rank test for the main endpoint (PFS) will be performed as supportive 
analysis.Both the IRC and Investigator’s assessments will be used.
Counts and percentages, with their corresponding exact 95% confidence intervals, will 
be calculated for the RR(IMWG criteria and, separatel y, minor response). The Fisher’s 
exact test will be used to compare the response rates of the Arm A and B.
[IP_ADDRESS] Evaluation of Overall Survival
Although the study  is powered for the evaluation ofthe main endpoint, PFS, two
analyses of OS will be performed to ascertain if a trend in OS is observed in favor of the 
experimental arm. An interim analysis of OS will be performed concomitantly  with the 
final PFS analy sis (see Section [IP_ADDRESS] ). Afinal anal ysis of OS will be performed when 
80% of death events (approximately  200 death events) have occurred or [ADDRESS_772421].At the interim OS analyses, the 
significance level determined by [CONTACT_941] O’Brien -Fleming boundary  with overall 2.5% 1-
sided significance level will be used.
Note: Two years after the last patient accrual, on 19 May 2017, the final OS analysis was done 
based on a total of 195 death events (i.e., 76.5% ofthe 255 randomized patients): 123 events in 
Arm A (plitidepsin plus dexamethasone) and 72 events in Arm B (dexamethasone). Then, the 
duration of this study is prolonged for six additional months, until 19 November 2017 , in order 
to continue follow -up in t he alive patients , and then to be able to reach the pre -specified total of 
80% of death events (approximately 204 death events) or even more .If the required death 
CL_0092 5.[ADDRESS_772422] of 
crossover by [CONTACT_587198] (68).
[IP_ADDRESS] Other Analyses of Efficacy
Efficacy  parameters versus baseline covariates will be analy zed and appropriate tests
will be used (i.e., the Fisher exact test and logistic regression for categorical variables, 
the log -rank test or Cox regression for time -to-event variables, etc.).
Exploratory  intrapatient compar ison of response and PFS (before and after crossover) 
will be performed for patients who switch from Arm B to Arm A after disease 
progression.
10.2.[ADDRESS_772423] of dexamethasone on the plitidepsin pharmacokinetics will be evaluated by 
[CONTACT_587199] “Objective Function” of the population model after the 
inclusion of a shift variable on every  relevant PK parameter. Bayesian estimation of the 
individual PK parameters will be correlated with toxicity  and response outcomes. 
Logistic regression will be used for dichotomic or categorical outcomes, such as 
response/no response or toxicity  grade. For continuous outcomes, such as transaminase 
values, linear regression will be applied. The influence of the plitidepsin PK on time to 
event variables, such as PFS, will be evaluated using Cox regression.
10.3 INTERIM ANALYSIS
Protocol -specified analy ses are foreseen at the time of the futility  evaluation 
(approximately  40 evaluable patients for response in Arm A), final PFS analy sis (main 
endpoint, approximately  210 progression or death events ) and follow -up evaluation of 
OS when 80% ofdeath events (approximately  200 death events) have occurred or [ADDRESS_772424] . Accrual will be on-
hold while data for the futility  anal ysisis being assessed .
Note: Two years after the last patien t accrual, on 19 May 2017, the final OS analysis was done 
based on a total of 195 death events (i.e., 76.5% of the 255 randomized patients): 123 events in 
Arm A (plitidepsin plus dexamethasone) and 72 events in Arm B (dexamethasone). Then, the 
duration of this study is prolonged for six additional months, until 19 November 2017 , in order 
to continue follow -up in the alive patients ,and then to be able to reach the pre -specified total of 
80% of death events (approximately 204 death events) or even more .If the required death 
events are not achieved on [ADDRESS_772425] their 
origin in the Declaration of Helsinki and will be consistent with Good Clinical Practice 
(GCP) and applicable regulatory  requirements.
Study  personnel involved in conducting this trial will be qualified by  [CONTACT_8640], training 
and experience to perform their respective ta sk(s).
The study  will be conducted in compliance with the protocol. The protocol, any 
amendments and the patient informed consent will receive Institutional Review Board 
(IRB)/Independent Ethics Committee (IEC) approval/favorable opi[INVESTIGATOR_587125] n. 
The decision of the IEC/IRB concerning the conduct of the study  will be made in 
writing to the Investigator and a copy of this decision will be provided to the Sponsor 
before commencement of the study .
The Investigator and/or the Sponsor is/are respons ible for keepi[INVESTIGATOR_436419]/I RB 
informed of significant new information about study  drug.
All protocol amendments will be agreed upon b y the Sponsor and the Investigator.
Administrative changes of the protocol are minor corrections and/or clarifications that 
have no impact on the way  the study  is to be conducted . 
11.[ADDRESS_772426] ING
The study  will be monitored by  [CONTACT_587200]/or the Contract Research Organization (CRO) clinical 
trial monitor (if applicable).
During site visits, the study  monitor should revise original patient records, drug 
accountability  records and document retention (study  file). Additionally , the monitor 
should observe study  procedures and will discuss any  problem with the Investigator.
The Investigator should allocate adequate time for these visits.  The Investigator should 
also ensure that the monitor is given direct access (as perICH GCP Guideline, Sections 
4.9.7 and 6.10) to source documents (i.e., hospi[INVESTIGATOR_436420], original laboratory 
records, appointment books, etc.) of the patient which support data entered in the CRFs, 
as defined in the ICH GCP Guideline, Sections 1.[ADDRESS_772427] an onsite 
audit visit to the centers at an ytime (ICH guideline glossary  Section 1.6).
CL_0092 5.[ADDRESS_772428] provide the patient 
with a copy  of the consent form and written fully information about the study  in 
language that is non -technical and easily  understood. The Investigator should allow time 
necessary  for the patient or the patient's legally acceptable representative to inquire 
about the details of the study ; then, the informed consent must be freely signed and 
personall y dated by [CONTACT_587201] .  The patient shou ld receive a copy  of the 
signed informed consent and any other written information provided to study  patients 
prior to patient's participation in the trial.
During a patient's participation in the trial, any updates to the consent form and any 
updates to t he written information will be provided to the patient.  
If there is a need to obtain new consent from the patients, the Investigator, or a person 
designated by [CONTACT_737], should inform the patient of any new information 
relevant to the patient's willingness to continue participation in the study , before 
obtaining the written consent.
11.4 CONFIDENTIALITY /PATIENTS IDENTIFICAT ION
The collection and processing of personal data from subjects enrolled in this study  will 
be limited to those data that are nec essary  to investigate the efficacy , safety , quality , and 
utility  of the investigational medicinal product used in this study . It is the Investigator’s 
responsibility  that sufficient information appertaining to the identity  of the patients will 
be retained.
The trial monitor, Sponsor’s auditor, IRB/IEC, or Competent Authorities should have 
direct access to all requested trial related records and agree to keep the identity  of study 
patients confidential.
The data must be collected and processed with adequate precautions to ensure 
confidentiality  and compliance with applicable data privacy  protection laws and 
regulations.
11.5 CASE REPORT FORMS
Case report forms (CRFs) will be used for recording all data for each patient. It is the 
responsibility  of the Investigato r to ensure that the CRFs are properl y and completely 
CL_0092 5.[ADDRESS_772429] been admitted into the study .
The patient’s source documentation is the physician's patient records, and as such, they 
should be maintained at the study  site. 
The data collected in the CRF will be entered into the Sponsor databases that comply  
with the Spanish Act which implements the Directive 95/46/EC of the European 
Parliament and of the Council of [ADDRESS_772430] to the processing of personal data. 
11.6 INSURANCE
The Sponsor will provide insurance or indemnity  in accordance with the applicable 
regulatory  requirements.
11.7 RECORDS RETENTION 
The Investigator/Institution shou ld maintain trial documents according to ICH Topic E6 
Section [ADDRESS_772431] for publication or 
otherwise publicly  disclose information concerning the studied IMP(s), the Sponsor 
must be provided with at least [ADDRESS_772432] number of patients with information finall y available for data 
analysis. Relevant Sponsor’s personnel who have fully  participated in the study  must be 
considered for co -authorshi p of the publication.
CL_0092 5.[ADDRESS_772433]-C-001-0912REFERENCES
1. National_Cancer_Institute. Information about MM and other plasma cell 
neoplasms: treatment, clinical trials, research, and statistics. 
wwwcancergov/cancertopi[INVESTIGATOR_1102]/ty pes/m yeloma. (27/01/09).
2. Harous seau JL, Drey ling M. Multiple myeloma: ESMO clinical 
recommendations for diagnosis, treatment and follow -up. Ann Oncol. 2008 
May;[ADDRESS_772434] 2:ii55 -7.
3. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. 
Correlation of measured myeloma cellmass with presenting clinical features, 
response to treatment, and survival. Cancer. 1975 Sep;36(3):842 -54.
4. Greipp PR, San Miguel J, Durie BG, Crowley  JJ, Barlogie B, Blade J, et al. 
International staging system for multiple myeloma. J Clin Oncol. 2005 May 
20;23(15):3412 -20.
5. Hari PN, Zhang MJ, Roy V, Perez WS, Bashey A, To LB, et al. Is the 
international staging system superior to the Durie -Salmon staging system? A 
comparison in multiple myeloma patients undergoing autologous transplant. 
Leukemia. 20 09 Aug;23(8):1528 -34.
6. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and 
response assessment of multiple my eloma. Leukemia. 2009 Jan;23(1):3 -9.
7. Fermand JP. Initial therap y for multiple myeloma: role of stem cell 
transplant ation. ASCO Educational Book. 2008:375 -9.
8. Combination chemotherapy versus melphalan plus prednisone as treatment for 
multiple myeloma: an overview of 6,633 patients from 27 randomized trials. 
Myeloma Trialists' Collaborative Group. J Clin Oncol. 1998 Dec;16(12):3832 -
42.
9. Facon T, Mary  JY, Hulin C, Benboubker L, Attal M, Pegourie B, et al. 
Melphalan and prednisone plus thalidomide versus melphalan and prednisone 
alone or reduced -intensity  autologous stem cell transplantation in elderly 
patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. [ADDRESS_772435] 6;370(9594):1209 -18.
10. Hulin C, Facon T, Rodon P, Pegourie B, Benboubker L , Doy en C, et al. Efficacy 
of melphalan and prednisone plus thalidomide in patients older than 75 years 
with newl y diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol. 2009 
Aug 1;27(22):3664 -70.
11. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpi[INVESTIGATOR_83868] O, Kropff 
M, et al. Bortezomib plus melphalan and prednisone for initial treatment of 
multiple my eloma. N Engl J Med. 2008 Aug 28;359(9):906 -17.
12. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. 
Antitumor activity  of thalidomide in refractory  multiple myeloma. N Engl J 
Med. 1999 Nov 18;341(21):1565 -71.
13. Knight R. IMiDs: a novel class of immunomodulators. Semin Oncol. 2005 
Aug;32([ADDRESS_772436] 5):S24 -30.
CL_0092 5.[ADDRESS_772437]-C-001-0914. Jagannath S, Barlogie B, Berenson JR, Singhal S, Alexanian R, Srkalovic G, et 
al. Bortezomib in recurrent and/or refractory  multiple myeloma. Initial clinical 
experience in patients with impared renal function. Cancer. 2005 Mar 
15;103(6):1195 -200.
15. Bross PF, Kane R, Farrell AT, Abraham S, Benson K, Brower ME, et al. 
Approval summary  for bortezomib for injection in the treatment of multiple 
myeloma. Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3954 -64.
16. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, 
et al. Bortezomib or high -dose dexamethasone for relapsed multiple my eloma. N 
Engl J Med. 2005 Jun 16;352(24):2487 -98.
17. Kane RC, Farrell AT, Sridhara R, Pazdur R. [LOCATION_002] Food and Drug 
Administration approval summary : bortezomib for the treatment of progressive 
multiple myeloma after one prior therap y. Clin Cancer Res. 2006 May 
15;12(10):[ADDRESS_772438];13(10):[ADDRESS_772439] 
cancer cells via alteration of glutathione homeostasis, Rac1 GTPase activation, 
and MKP -1 phosphatase downregulation. Cell Death Differ. 2006 
Nov;13(11):1968 -81.
20. Erba E, Bassano L, Di Liberti G, Mura dore I, Chiorino G, Ubezio P, et al. Cell 
cycle phase perturbations and apoptosis in tumour cells induced by  [CONTACT_587202]. Br J 
Cancer. 2002 May  6;86(9):1510 -7.
21. Cuadrado A, Gonzalez L, Suarez Y, Martinez T, Munoz A. JNK activation is 
critical for Aplidin -induced apoptosis. Oncogene. 2004 Jun 10;23(27):4673 -80.
22. Broggini M, Marchini SV, Galliera E, Borsotti P, Taraboletti G, Erba E, et al. 
Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial 
growth factor (VEGF) secretion and blocks VEGF -VEGFR -1 (flt-1) autocrine 
loop in human leukemia cells MOLT -4. Leukemia. 2003 Jan;17(1):[ADDRESS_772440] 24;21(49):7533 -44.
24. Cuadrado A, Garcia -Fernandez LF, Gonzalez L, Suarez Y, Losada A, Alcaide 
V, et al. Aplidin induces apoptosis in human cancer cells via glutathi one 
depletion and sustained activation of the epi[INVESTIGATOR_3506], Src, 
JNK, and p38 MAPK. J Biol Chem. 2003 Jan 3;278(1):[ADDRESS_772441] Inhibiting Cell Cy cle and Inducing 
Apoptosis via Rac1/c -Jun NH2 -Terminal Kinase Activation in Human 
Melanoma Cells 10.1124/jpet.107.132662. J Pharmacol Exp Ther. 2008 March 
1, 2008;324(3):[ADDRESS_772442]-C-001-0926. Moneo V, Serelde BG, Leal JF, Blanco -Aparicio C, Diaz -Uriarte R, Aracil M, et 
al. Levels of p27(kip1) determine Aplidin sensitivity . Mol Cancer Ther. 2007 
Apr;6(4):[ADDRESS_772443];16(10):1667 -74.
28. Taraboletti G, Poli M, Dossi R, Manenti L, Borsotti P, Faircloth GT, et al. 
Antiangiogenic activit y of aplidine, a new agent of marine origin. Br J Cancer. 
2004 Jun 14;90(12):2418 -24.
29. Sasak H. The cytotoxic effects of Aplidin in a brad spectrum of human tumor 
types using the MTS proliferation assay . Cambridge, MA, [LOCATION_003]: PharmaMar 
Inc; 2004. Report No.: P[LOCATION_003] -SR007.
30. Mitsiades CS, Ocio EM, Pandiella A, Maiso P, Gajate C, Garay oa M, et al. 
Aplidin, a marine organism -derived compound with potent antimy eloma activity 
in vitro and in vivo. Cancer Res. 2008 Jul 1;68(13):5216 -25.
31. Radl J, De Glopper ED, Schuit HR, Zurcher C. Idiopathic paraproteinemia. II. 
Transplant ation of the paraprotein -producing clone from old to young 
C57BL /KaLwRij mice. J Immunol. 1979 Feb;122(2):609 -13.
32. Caers J, Menu E, De Raeve H, Lepage D, Van Valckenborgh E, Van Camp B, et 
al. Antitumour and antiangiogenic effects of Aplidin in the 5TMM syngeneic 
models of multiple my eloma. Br J Cancer. 2008 Jun 17;98(12):1966 -74.
33. Herr I, Gassler N, Friess H, Buchler MW. Regulation of differential pro-and 
anti-apoptotic signaling by  [CONTACT_446499]. Apoptosis. 2007 Feb;12(2):271 -91.
34. Zhang C, Wen ger T, Mattern J, Ilea S, Frey C, Gutwein P, et al. Clinical and 
mechanistic aspects of glucocorticoid -induced chemotherap y resistance in the 
majority  of solid tumors. Cancer Biol Ther. 2007 Feb;6(2):278 -87.
35. Schaaf MJ, Cidlowski JA. Molecular mechanism s of glucocorticoid action and 
resistance. J Steroid Biochem Mol Biol. 2002 Dec;83(1 -5):37 -48.
36. Schmidt S, Rainer J, Riml S, Ploner C, Jesacher S, Achmuller C, et al. 
Identification of glucocorticoid -response genes in children with acute 
lymphoblastic l eukemia. Blood. 2006 Mar 1;107(5):2061 -9.
37. Adamson PC, Barrett JS. All dex'ed out with nowhere to go? J Clin Oncol. 2008 
Apr 20;26(12):1917 -8.
38. Zhou J, Cidlowski JA. The human glucocorticoid receptor: one gene, multiple 
proteins and diverse responses . Steroids. 2005 May -Jun;70(5 -7):[ADDRESS_772444] CW. Recent insights into the mechanism of glucocorticosteroid -
induced apoptosis. Cell Death Differ. 2002 Jan;9(1):6 -19.
40. Planey  SL, Litwack G. Glucocorticoid -induced apoptosis in lymphocy tes. 
Bioc hem Biophy s Res Commun. 2000 Dec 20;279(2):307 -12.
41. Kofler R. The molecular basis of glucocorticoid -induced apoptosis of 
lymphoblastic leukemia cells. Histochem Cell Biol. 2000 Jul;114(1):[ADDRESS_772445] and glucocorticoid resistance in 
lymphoblastic leukemia. Curr Mol Med. 2003 Dec;3(8):707 -17.
43. Oh HY, Namkoong S, Lee SJ, Por E, Kim CK, B illiar TR, et al. Dexamethasone 
protects primary  cultured hepatocy tes from death receptor -mediated apoptosis 
by [CONTACT_587203]. Cell Death Differ. 2006 Mar;13(3):512 -23.
44. Tissing WJ, Meijerink JP, den Boer ML, Pi[INVESTIGATOR_3689] R. Molecular determinants of 
glucocorticoid sensitivity  and resistance in acute lymphobla stic leukemia. 
Leukemia. 2003 Jan;17(1):17 -25.
45. Machuca C, Mendoza -Milla C, Cordova E, Mejia S, Covarrubias L, Ventura J, 
et al. Dexamethasone protection from TNF -alpha -induced cell death in MCF -7 
cells requires NF-kappaB and is independent from AKT. BMC Cell Biol. 
2006;7:9.
46. Matthews JG, Ito K, Barnes PJ, Adcock IM. Defective glucocorticoid receptor 
nuclear translocation and altered histone acety lation patterns in glucocorticoid -
resistant patients. J Allergy  Clin I mmunol. 2004 Jun;113(6):1100 -8.
47. Ito K, Yamamura S, Essilfie -Quay e S, Cosio B, Ito M, Barnes PJ, et al. Histone 
deacety lase 2-mediated deacety lation of the glucocorticoid receptor enables NF-
kappaB suppression. J Exp Med. 2006 Jan 23;203(1):7 -13.
48. Ito K, Barnes PJ, Adcock IM. Glucocort icoid receptor recruitment of histone 
deacety lase 2 inhibits interleukin -1beta -induced histone H4 acetylation on 
lysines 8 and 12. Mol Cell Biol. 2000 Sep;20(18):[ADDRESS_772446];15(4 -5):347 -50.
50. Faircloth G, Grant W, Nam S, Jimeno J, Meely  K, Rinehart KL. Aplidine is a 
Novel, Marine Derived Depsipeptide with In Vivo Antitumor Activity. Am 
Assoc Ca Res. 1998;39:227.
51. Mateos MV, Cibeira MT, Richardson PG, Blade J, Prosper F, Oriol A, et al. 
Final Results of a Phase II Trial with Plitidepsin (Aplidin) Alone and in 
Combination with Dexamethasone in Patients with Relapse d/Refractory 
Multiple Myeloma. 50th American Societ y of Hematology Annual Meeting; 
2008; San Francisco, CA, [LOCATION_003]; 2008. p. Poster Board III -782.
52. Joan Bladé DS, Donna Reece, Jane Apperley , Bo BJörkstrand, Gösta Gahrton, 
Morie Gertz, Sergio Giralt, Sundarr Jagannath, David Vesole. Criteria for 
evaluation disease response and progression in patients with multiple myeloma 
treated by [CONTACT_5019]-dose therap y and haematopoietic stem cell transplantation. 
British Journal of Haematology . 1998;102(5):1115 -23.
53. Alexani an R, Dimopoulos MA, Delasalle K, Barlogie B. Primary 
dexamethasone treatment of multiple myeloma. Blood. 1992 Aug 15;80(4):887 -
90.
54. Rajkumar SV, Gertz MA, Kyle RA, Greipp PR. Current therap y for multiple 
myeloma. May o Clin Proc. 2002 Aug;77(8):[ADDRESS_772447]-C-001-0955. Sonneveld P, Suciu S, Weijermans P, Beksac M, Neuwirtova R, Solbu G, et al. 
Cyclosporin A combined with vincristine, doxorubicin and dexamethasone 
(VAD) compared with VAD alone in patients with advanced refractory  multiple 
myeloma: an EORTC -HOVON rando mized phase III study  ([ZIP_CODE]). Br J 
Haematol. 2001 Dec;115(4):895 -902.
56. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple 
myeloma refractory  to alkylating agents. N Engl J Med. 1984 May 
24;310(21):1353 -6.
57. Anagnostopoulos A, Weber D, Rankin K, Delasalle K, Alexanian R. 
Thalidomide and dexamethasone for resistant multiple my eloma. Br J Haematol. 
2003 Jun;121(5):[ADDRESS_772448]-line 
therap y with thalidomide and dexamethasone in preparation for autologous stem 
cell transplantation for multiple myeloma. Haematologica. 2004 Jul;89(7):826 -
31.
59. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or 
with dexamethasone for previously  untreated multiple myeloma. J Clin Oncol. 
2003 Jan 1;21(1):16 -9.
60. Rajkumar SV, Jacobus S, Callander N, Fonseca R, Vesole D, Williams MV, et 
al. Randomized trial of lenalidomide plus high-dose dexamethasone versus 
lenalidomide plus low-dose dexamethasone in newl ydiagnosed myeloma 
(E4A03), a trial coordinated by [CONTACT_587204]: 
Analy sis of response, survival, and outcome wi. J Clin Oncol (Meeting 
Abstracts). 2008 May  20, 2008;26(15_suppl):8504 -.
61. Miguel JFS, Dimopoulos M, Weber D, Olesn yckyj M, Yu Z, Zeldis J, et al. 
Dexamethasone Dose Adjustments Seem To Result in Better Efficacy  and 
Improved Tolerability  in Patients with Relapsed/Refractory  Multiple Myeloma 
Who Are Treated with Lenalidomide/Dexamethasone (MM009/010 Sub-
Analy sis). ASH Annual Meeting Abstracts. 2007 November 16, 
2007;110(11):2712 -.
62. Richardson P, Jagannath S, Raje N, Jakubowiak A, Lonial S, Ghobrial I, et al. 
Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) in Patients with 
Relapsed or Relapsed/Refractory  Multiple Myeloma (MM): Preliminary  Results 
of a Phase II Study . ASH Annual Meeting Abstracts. 2007 November 16, 
2007;110(11):2714 -.
63. Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery  LW, et al. 
Recommendations for the use of antiemetics: evidenc e-based, clinical practice 
guidelines. American Society  of Clinical Oncology . J Clin Oncol. 1999 
Sep;17(9):2971 -94.
64. Kyle RA, Yee GC, Somerfield MR, Flynn PJ, Halabi S, Jagannath S, et al. 
American Societ y of Clinical Oncology  2007 clinical practice guideline update 
on the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2007 Jun 
10;25(17):[ADDRESS_772449]-C-001-0965. Kris MG, Hesketh PJ, Somerfield MR. American Society  of Clinical Oncology 
Guideline for Antiemetics in Oncology : Update 2006. J Clin Oncol. 
2006 ;24:2932 -47.
66. Update of recommendations for the use of hematopoietic colony -stimulating 
factors: evidence based clinical practice guidelines. American Society  of 
Clinical Oncology . J Clin Oncol. 1996;14(6):1957 -19.
67. American Societ y of Clinical Onco logy. Recommendations for the use of 
hematopoietic colony stimulating factors: evidence -based, clinical practice 
guidelines. J Clin Oncol. 1994;12(11):[ADDRESS_772450] Theor y 
Meth. 1991;20(8):[ADDRESS_772451]-C-001-0913APPENDICES
APPENDIX 1:CLINICAL MANAGEMENT OF HYPERSENSITIVITY REACTIONS TO 
PLITIDEPSIN®
• If Severe/life threatening reactions (NCI CTCAE v 4≥ grade 3)
Patients must have at least one of the following:
-Cardiovascular symptoms : hypertension ≥ 160/100 mmHg or tachycardia ≥ 
120bpm or hypotension (systolic pressure <90mmHg) requiring vasopressor 
therapy, or anaphylactic shock or
-Respi[INVESTIGATOR_23908] :Angioedema, generalized wheezing and/or respi[INVESTIGATOR_587126] (pulse gasometry with < 92% O 2saturation at 
ambient air).
Then:
1) Immediatel y stop infusion. A trained physician must clinically  assess the 
patient.
2) If pulse gasometry  < 92% O2saturation at ambient air, consider immediately 
O2 mask ±bronchodilators (i.e., generalized wheezing).
3) Administer diphenhydramine 50 mg i.v. or equivalent, and hydrocortisone 
100 mg up to a maximum of 300 mg i.v.
4) Add epi[INVESTIGATOR_238] ( adrenaline) if clinicall y indicated. 
Do not re -start infusion. Withdraw the patient from the study.
Event should be reported as a serious adverse event. Send an SAE form by [CONTACT_236947] [ADDRESS_772452]-C-001-09CLINICAL MANAGEMENT OF HYPERSENSITIVITY REACTIONS TO PLITIDEPSIN®
(CONT .)
If Mild to Moderate reactions/not life threatening (NCI CTCAE v 4.0 ≤ grade 2)
Patients may  have an y of the following: 
-Mild to moderate : facial and/or trunk flushing, rash and/or pruritus and/or mild 
dyspnea (shortness of breath) and/or coughing and/or chest discomfort.
BUT NONE of the previous severe/life threatenin g criteria.
Then:
1) Immediatel y stop infusion and assess vital signs and pulse gasometry . Ideall y 
a trained ph ysician must clinically  assess the patient.
2) Check if premedication was administered properly  (if not, administer it as per 
protocol and re-start infusion similarly  as before, withholding it a minimum of 
30 minutes after premedication was given) .
3) If symptoms persist after stoppi[INVESTIGATOR_348025] ,give additional diphenhy dramine, 
50 mg i.v. or equivalent, and hy drocortisone 100 mg bolus i.v. or equiv alent.
4) Reassess s ymptoms and vital signs after 30 minutes.
4.A-If normal or improving, then infusion could be re-started at 1/3 (one 
third) of the initial drip rate during the first hour, and then, infusion rate 
could be increased according to toleranc e. The decision about retreating the 
patient or not should be taken according to Investigator’s judgment on 
benefit/risk balance. Any further infusions should be initiated at this reduced 
rate and should be given with prophy lactic premedication as per protocol. If 
no hypersensitivity  reactions are observed, the rate of infusion to be applied 
could be set back to the initial one.
4.B-If there is no sign of improvement of symptoms after [ADDRESS_772453] be taken by [CONTACT_587205]:
-Eventually  repeat medication (anti-H1and/or corticoids) if necessary 
and/or wait up to one hour for s ymptoms to resolve.
-Omit infusion until resolution (< two weeks) (in this case further 
infusions might start at a reduced rate, according to 4.A
-Withdraw the patient from study . 
-Report the event as a serious adverse only if it fulfil ls any of the 
seriousness criteria indicated in the SAE section of the protocol.
CL_0092 5.[ADDRESS_772454]-C-001-09APPENDIX 2:PERFORMANCE STATUS (ECOG)
Grade ECOG*
0 Fully active, able to carry on all pre-disease performance 
without restriction
1 Restricted in physically strenuous activity but ambulatory 
and able to carry out work of a light or sedentary 
nature, e.g., light house work, office wor k
2 Ambulatory and capable of all self-care but unable to 
carry out any work activities. Up and about more 
than 50% of waking hours
3 Capable of only limited self-care, confined to bed or chair 
more than 50% of waking hours
4 Completely disabled. Cannot carry on any self-care. 
Totally confined to bed or chair
5 Dead
*As published in Am. J. Clin. Oncol 5:649 -655, 1982 : Oken, M.M., Creech, R.H., Tormey, D.C., Horton, 
J., Davis, T.E., McFadden, E.T., Carbone, P.P.: Toxicity And Response Criteria Of The Eastern 
Cooperative Oncology Group. 
CL_0092 5.[ADDRESS_772455]-C-001-09APPENDIX 3:COCKCROFT AND GAULT ’S FORMULA 
For calculating creatinine clearance :
[(140 -age (y ears)) x weight (Kg)]
Creatinine clearance (ml/min)  =      x G1
72 x serum creatinine ( mg/dl)
[(140 -age (y ears)) x weight (Kg)]
Creatinine clearance (ml/min)  =      xG1
72 x serum creatinine (mol/l) x 0.0113
1G(Gender)= 0.85 if Female; 1 if Male.
Reference:
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. 
Nephron. 1976;16(1):[ADDRESS_772456]-C-001-09APPENDIX 4:DIAGNOSTIC CRITERIA 
Multiple myeloma:
All three criteria must be met, except as noted:
1)Clonal bone marrow plasma cells ≥ 10% .
2)Presence of serum and/or urinary  monoclonal protein (except in patients with true 
non-secretory  multiple my eloma) .
3)Evidence of end-organ damage that can be attributed to the underly ing plasma cell 
proliferative disorder, specificall y
-Hypercalcemia: serum calcium > 11.5 mg/100 ml or
-Renal insufficiency :serum creatinine > 1.73 mmol/l
-Anemia: normochromic, normocy tic with a hemoglobin value of > 2 g/100 ml 
below the lower limit of normal or a hemoglobin value o f 10 g/100 ml
-Bone lesions: ly tic lesions, severe osteopenia or pathologic fractures .
Reference s: 
The International Myeloma Working Group. Criteria for the classification of 
monoclonal gammopathies, multiple myeloma and related disorders: a report of the 
International M yeloma Working Group. Br J Haematol 2003; 121: 749 –757.
Rajkumar SV, Kyle RA. Multiple myeloma: diagnosis and treatment. Mayo Clinic 
Proc 2005; 80: 1371 –1382.
CL_0092 5.[ADDRESS_772457]-C-001-09APPENDIX 5:INTERNATIONAL MYELOMA WORKING GROUP UNIFORM RESPONS E 
CRITERIA FOR MULTIPL E MYELOMA 
(Anderson KC, Kyle RA, Rajkumar SV, Stewart AK, Weber D, Richardson P. 
Clinically  relevant end points and new drug approvals for myeloma. Leukemia 
2008; 22: 231 –239).
Complete response (CR)
-Negative immunofixation of serum and urine ,and
-Disappearance of an y soft tissue plasmacy tomas, and
-<5% plasma cel ls in bone marrow .
Stringent complete response (sCR)
CR as defined above plus
-Normal FLC ratio ,and
-Absence of clonal cells in bone marrow by [CONTACT_318610] .
Very good partial response (VGPR)
-Serum and urine M-component detect able by [CONTACT_159444] > 90% or greater reduction in serum M-component plus urine 
M-component o f 100mg per 24 h .
Partial response (PR)
-≥ 50% reduction of serum M protein and reduction in 24 -h urinary  M protein by 
≥ 90% or to < 200mg per 24 h.
-If the serum and urine M protein are unmeasurable, a > 50% decrease in the 
difference between involved and uninvolved FLC levels is required in place of 
the M protein criteria.
-If serum and urine M protein are unmeasurable, and serum free light assay  is 
also unmeasurable, ≥ 50% reduction in bone marrow plasma cells is required in 
place of M protein, provided baseline percentage was > 30% .
-In addition to the above criteria, if present at baseline, ≥ 50% reduction in the 
size of soft tissue plasmacy tomas is also required .
Stable disease (SD) 
-Not meeting criteria for CR, VGPR, PR or progressive disease
CL_0092 5.[ADDRESS_772458]-C-001-09Progressive disease (PD)
Increase of 25% from lowest response value in any  one or more of the following:
-Serum M -component (absolute increa se must be ≥ 0.5 g/100 ml) and/or
-Urine M -component (absolute increase must be ≥ 200mg per 24 h) and/or
-Only  in patients without measurable serum and urine M-protein levels: the 
difference between involved and uninvolved FLC levels (absolute increase must 
be > 100 mg/l)
-Bone marrow plasma cell percentage (absolute % must be ≥ 10%)
-Definite development of new bone lesions or soft tissue plasmacy tomas or 
definite increase in the size of existing bone lesions or soft tissue plasmacy tomas
-Development of hyperca lcemia (corrected serum calcium > 11.5 mg/100 ml) 
that can be attributed solely  to the plasma cell proliferative disorder
Note: clarification to IMWG criteria for coding CR and VGPR in patients in whom the 
only measurable disease is by [CONTACT_128758]: CR in such patients is defined as a 
normal FLC ratio of 0.26–1.65 in addition to CR criteria listed above. VGPR in such 
patients is defined as a > 90% decrease in the difference between involved and 
uninvolved free light chain (FLC) levels.
All response categories (CR, sCR, VGPR and PR) require two consecutive assessments 
made at any time before the institution of any new therap y; complete, PR and SD 
categories also require no known evidence of progressive or new bone lesions if 
radiographic studies were per formed.
Radiographic studies are not required to satisfy  these response requirements. Bone 
marrow assessments need not to be confirmed. 
For progressive disease, serum M-component increases of ≥ 1 gm/100 ml are sufficient 
to define relapse if starting M -component is ≥ 5 gm/100ml.
Additional response criteria for specific disease stages
(Anderson KC, Kyle RA, Rajkumar SV, Stewart AK, Weber D, Richardson P. Clinically 
relevant end points and new drug approvals for myeloma. Leukemia 2008; 22: 231 –239).
Definition of relapsed myeloma and relapsed and refractory myeloma
-Relapsed myeloma : at least one prior regimen, and not meeting criteria for 
relapsed and refractory  myeloma
-Relapsed and refractory myeloma : relapse of disease while on salvage 
therap y, or progression within [ADDRESS_772459] recent therapy
Minor response (MR) in patients with relapsed refractory myeloma
-≥ 25% but < 49% reduction of serum M protein and reduction in 24 h urine M 
protein by  50–89%, which still exceeds [ADDRESS_772460]-C-001-09-In addition to the above criteria, if present at baseline, 25–49% reduction in the 
size of soft tissue plasmacy tomas is also r equired
-No increase in size or number of l ytic bone lesions (development of compression 
fracture does not exclude response)
CL_0092 5.[ADDRESS_772461]-C-001-09APPENDIX 6:STAGING SYSTEMS
Durie -Salmon Staging Criteria
Stage Durie -Salmon Criteria ISS Criteria
I All of the following:
Hem oglobin value >10 g/ dl
Serum calcium value norm al or ≤12 
mg/dl
Bone x-ray, norm al bone structure 
(scale 0) or solitary  bone plasmacytom a 
only
Low M-component production rate
—IgG value <5 g/ dl; IgA value <3 g/ dl
Bence Jones protein <4 g/24 hß2-M <3.5 and Albumin ≥3.5
II Neither stag e I nor stage III Neither stage I nor stage III
III Oneor more of the following:
Hem oglobin value <8.5 g/ dl
Serum calcium value >12 mg/ dl
Advanced lytic bone lesions (scale 3)
High M -component production rate
—IgG value >7 g/ dl; IgA value >5 g/ dl
—Benc e Jones protein >12 g/24 hß2-M >5.5
Durie -Salmon sub classifications (either A or B)
A: Relatively normal renal function (serum creatinine value <2.0 mg/ dl
B: Abnormal renal function (serum creatinine value ≥2.0 mg/ dl
New International Staging System 
Stage Criteria Median Survival (months)
    I Serum ß2 -microglobulin < 3.5 mg/L 62
Serum albumin 3.5 g/ dl
    II Not stage I or III* 44
    III Serum ß2 -microglobulin 5.5 mg/L 29
* There are two categories for stage II: serum ß2-microglobulin < 3.5 mg/l but serum 
albumin < 3.5 g/dl; or serum ß2-microglobulin 3.5 to < 5.5 mg/l irrespective of the 
serum albumin level.
CL_0092 5.[ADDRESS_772462]-C-001-09APPENDIX 7:LISTS OF DRUGS THAT PROLONG THE QT INTERVAL AND/OR INDUCE 
TORSADES DE POINTES VENTRICULAR ARRHYTHMIA
Source:  www.azcert.org
Because the evidence for risk of TdP is often imperfect, AZCERT, inc. has divided the 
drugs into four groups based on their anal ysis of the evidence:
1.Risk of TdP: Substantial evide nce supports the conclusion that these drugs prolong 
QT intervals and have a risk of TdP when used as directed in labeling.
2.Possible risk of TdP: Substantial evidence supports the conclusion that these drugs 
can cause QT prolongation but there is insuffici ent evidence that the drugs, when 
used as directed in labeling, have a risk of causing TdP.
3.Conditional risk of TdP: Substantial evidence supports the conclusion that these 
drugs prolong QT and have a risk of developi[INVESTIGATOR_587127].
A note about brand names :drugs are listed with up to two common brand names. 
There are many more brand names for some of the common drugs, such as 
pseudoephedrine and erythromy cin. It is also important to look at the list of active drugs 
in medic ines that contain a combination of drugs such as Zyrtec-D®, which contains 
pseudoephedrine.
Generic Name
(Brand Nam e)Drug Class / Clinical Usage Comments Risk 
List
Alfuzosin (Uroxatral®) Alpha1 -blocker/benign prostatic 
hyperplasia2
Amantadine ( Symmetrel®)Dopaminergic/anti -viral/anti -
infective/Parkinson's disease2
Amiodarone (Cordarone®)Anti-arrhythmic/abnormal heart 
rhythmFemales>Males,TdP risk 
regarded as low1
Amiodarone (Pacerone®)Anti-arrhythmic/abnormal heart 
rhythmFemales>Males,T dP risk 
regarded as low1
Amisulpride (Solian®and 
others)Antipsychotic, atypi[INVESTIGATOR_587128] -not 
available in U.S.3
Amitriptyline (Elavil®) Tricyclic 
antidepressant/depressionRisk of TdP w ith overdosage3
Arsenic trioxide 
(Trisenox®)Anti-cancer/leukemia1
Artenimol + pi[INVESTIGATOR_14961] 
(Eurartesim®)Anti-malarial/ Not available in U.S.2
Astemizole (Hismanal®) Antihistamine/allergic rhinitis No longer available in U.S. 1
Atazanavir (Reyataz®) Protease inhibitor/HIV 2
Azithromycin 
(Zithromax®)Antibiotic/bacterial infection1
Bedaquiline (Sirturo®) Anti-infective/drug -resistant 
TuberculosisBlack Box for QT2
Bepridil (Vascor®) Anti-anginal/heart pain Females>Males 1
Chloral hydrate (Noctec®)Sedative/sedation/insomnia 2
Chlo roquine (Aralen®) Anti-malarial/malaria infection [ADDRESS_772463]-C-001-09Generic Name
(Brand Nam e)Drug Class / Clinical Usage Comments Risk 
List
Chlorpromazine 
(Thorazine®)Anti-psychotic/anti -
emetic/schizophrenia/nausea1
Ciprofloxacin (Cipro®) Antibiotic/bacterial infection Drug interaction risk -metabolic 
inhibitor3
Cisapride (Propulsi d®) GI stimulant/heartburn No longer available in U.S. 1
Citalopram (Celexa®) Anti-depressant/depression 1
Clarithromycin (Biaxin®)Antibiotic/bacterial infection 1
Clomipramine 
(Anafranil®)Tricyclic 
Antidepressant/depression3
Clozapi[INVESTIGATOR_050] (Clozar il®) Anti-psychotic/schizophrenia 2
Desipramine (Pertofrane®)Tricyclic 
Antidepressant/depressionRisk of TdP w ith overdosage3
Diphenhydramine 
(Benadryl®)Antihistamine/allergic rhinitis, 
insomniaRisk of QT increase/TdP in 
overdosages3
Diphenhydram ine 
(Nytol®)Antihistamine/allergic rhinitis, 
insomniaRisk of QT increase/TdP in 
overdosages3
Disopyramide (Norpace®)Anti-arrhythmic/abnormal heart 
rhythmFemales>Males1
Dofetilide (Tikosyn®) Anti-arrhythmic/abnormal heart 
rhythmFemales > Males1
Dolasetron (Anzemet®) Anti-nausea/nausea, vomiting 2
Dom peridone (Motilium®)Anti-nausea/nausea Not available in U.S. 1
Doxepin (Sinequan®) Tricyclic 
Antidepressant/depression3
Dronedarone (Multaq®) Anti-arrhythmic/ atrial fibrillation 2
Droperido l (Inapsine®) Sedative; anti-nausea/anesthesia 
adjunct, nausea1
Eribulin (Halaven®) Anti-cancer/metastatic breast 
neoplasias2
Erythromycin (E.E.S.®) Antibiotic;GI stimulant/bacterial 
infection; increase GI motilityFemales>Males1
Erythromycin 
(Erythrocin®)Antibiotic;GI stimulant/bacterial 
infection; increase GI motilityFemales>Males1
Escitalopram (Cipralex®)Anti-depressant/ major 
depression/ anxiety disorders1
Escitalopram (Lexapro®)Anti-depressant/ major 
depression/ anxiety disorders1
Famotidine (Pepcid®) H2-receptor antagonist/ peptic 
ulcer/ GERD2
Felbamate (Felbatrol®) Anti-convulsant/seizure 2
Fingolimod (Gilenya®) Immunosuppressant/ multiple 
sclerosis2
Flecainide (Tambocor®) Anti-arrhythmic/abnormal heart 
rhythm1
Fluconazole (Diflucan®) Anti-fungal/fungal infection Drug interaction risk -metabolic 
inhibitor. Can also increase QT 
at high doses -800 mg/day3
Fluoxetine (Sarafem®) Anti-depressant/depression 3
Fluoxetine (Prozac®) Anti-depressant/depression 3
Fosca rnet (Foscavir®) Anti-viral/HIV infection 2
Fosphenytoin (Cerebyx®)Anti-convulsant/seizure 2
Galantamine (Reminyl®)Cholinesterase inhibitor/ 
dementia, Alzheimer's3
CL_0092 5.[ADDRESS_772464]-C-001-09Generic Name
(Brand Nam e)Drug Class / Clinical Usage Comments Risk 
List
Gatifloxacin (Tequin®) Antibiotic/bacterial infection Oral/I.V. forms no longer 
available in U.S. and Canada, 
only ophthalmic2
Gem ifloxacin (Factive®) Antibiotic/bacterial infection 2
Granisetron (Kytril®) Anti-nausea/nausea and vomiting 2
Halofantrine (Halfan®) Anti-malarial/malaria infection Females>Males 1
Haloperidol (Hal dol®) Anti-psychotic/schizophrenia, 
agitationTdP risk w ith I.V. or excess 
dosage1
Ibutilide (Corvert®) Anti-arrhythmic/abnormal heart 
rhythmFemales>Males1
Iloperidone (Fanapt®) Antipsychotic, 
atypi[INVESTIGATOR_2855]/ schizophrenia2
Imipram ine (Norfranil®) Tricyc lic 
antidepressant/depressionTdP risk w ith excess dosage3
Indapamide (Lozol®) Diuretic/stimulate urine & salt 
loss2
Isradipi[INVESTIGATOR_050] (Dynacirc®) Anti-hypertensive/high blood 
pressure2
Itraconazole (Sporanox®)Anti-fungal/fungal infection Drug interact ion risk -metabolic 
inhibitor3
Ketoconazole (Nizoral®)Anti-fungal/fungal infection Prolongs QT & Drug interaction 
risk -metabolic inhibitor.3
Lapatinib (Tykerb®) Anti-cancer/breast cancer, 
metastatic2
Lapatinib (Tyverb®) Anti-cancer/breast cance r, 
metastatic2
Levofloxacin (Levaquin®)Antibiotic/bacterial infection 2
Levomethadyl (Orlaam®)Opi[INVESTIGATOR_48489]/pain control, 
narcotic dependenceNot available in U.S.1
Lithium (Eskalith®) Anti-mania/bipolar disorder 2
Lithium (Lithobid®) Anti-mania/bipolar disorder 2
Mesoridazine (Serentil®)Anti-psychotic/schizophrenia 1
Methadone (Dolophine®)Opi[INVESTIGATOR_48489]/pain control, 
narcotic dependenceFemales>Males1
Methadone (Methadose®)Opi[INVESTIGATOR_48489]/pain control, 
narcotic dependenceFemales>M ales1
Mirtazapi[INVESTIGATOR_050] (Remeron®)Anti-depressant/ 2
Moexipril/HCTZ 
(Uniretic®)Anti-hypertensive/high blood 
pressure2
Moxifloxacin (Avelox®) Antibiotic/bacterial infection 1
Nicardipi[INVESTIGATOR_050] (Cardene®) Anti-hypertensive/high blood 
pressure2
Nilotini b (Tasigna®) Anti-cancer/ leukemia 2
Nortriptyline (Pamelor®)Tricyclic 
Antidepressant/depression3
Octreotide (Sandostatin®)Endocrine/acromegaly, carcinoid 
diarrhea2
Ofloxacin (Floxin®) Antibiotic/bacterial infection 2
Olanzapi[INVESTIGATOR_050] (Zyprexa®) Antipsychotic, 
atypi[INVESTIGATOR_2855]/ schizophrenia, bipolarCom bo c fluoxetine: Symby[CONTACT_276200]2
Ondansetron (Zofran®) Anti-emetic/nausea and vomiting 2
Oxytocin (Pi[INVESTIGATOR_31933]®) Oxytocic/ labor stimulation 2
Paliperidone (Invega®) Antipsychotic, 
atypi[INVESTIGATOR_2855]/ schizophrenia2
CL_0092 5.[ADDRESS_772465]-C-001-09Generic Name
(Brand Nam e)Drug Class / Clinical Usage Comments Risk 
List
Paroxetine (Paxil®) Anti-depressant/depression 3
Pentamidine (NebuPent®)Anti-infective/pneumocystis 
pneumoniaFemales>Males1
Pentamidine (Pentam®) Anti-infective/pneumocystis 
pneumoniaFemales>Males1
Perflutren lipid 
microspheres (Definity®)Imaging contrast 
agent/ echocardiography2
Pi[INVESTIGATOR_3924] (Orap®) Anti-psychotic/Tourette's tics Females>Males 1
Probucol (Lorelco®) Antilipemic/ hypercholesterolemia No longer available in U.S. 1
Procainamide (Pronestyl®)Anti-arrhythmic/abnormal heart 
rhythm1
Procainamide (Procan®) Anti-arrhythmic/abnormal heart 
rhythm1
Protriptyline (Vivactil®) Tricyclic 
antidepressant/depression3
Quetiapi[INVESTIGATOR_050] (Seroquel®) Anti-psychotic/schizophrenia 2
Quinidine (Quinaglute®) Anti-arrhythmic/abnormal heart 
rhythmFemales>Males1
Quinidine (Cardioquin®)Anti-arrhythmic/abnormal heart 
rhythmFemales>Males1
Quinine sulfate 
(Qualaquin®)Anti-malarial/ malaria or leg 
cram psTdP w ith overdose or drug -drug 
or drug food interaction3
Ranolazine (Ranexa®) Anti-anginal/chronic angina 2
Risperidone (Risperdal®)Anti-psychotic/schizophrenia 2
Ritonavir (Norvir®) Protease inhibitor/HIV 3
Roxithromycin* (Rulide®)Antibiotic/bacterial infection *Not available in U.S. 2
Sertindole (Serdolect®) Antipsychotic, atypi[INVESTIGATOR_2855]/ anxiet y, 
schizophreniaNot available in U.S.2
Sertindole (Serlect®) Antipsychotic, atypi[INVESTIGATOR_2855]/ anxiety, 
schizophreniaNot available in U.S.2
Sertraline (Zoloft®) Anti-depressant/depression 3
Sevoflurane (Ulane®) Anesthetic, general/anesthesia Label warning f or patients with 
congenital long QT or patients 
taking QT prolonging drugs1
Sevoflurane (Sojourn®) Anesthetic, general/anesthesia Label warning for patients with 
congenital long QT or patients 
taking QT prolonging drugs1
Solifenacin (VESIcare®) muscari nic receptor 
anatagonist/treatment of 
overactive bladder3
Sotalol (Betapace®) Anti-arrhythmic/abnormal heart 
rhythmFemales>Males1
Sparfloxacin (Zagam®) Antibiotic/bacterial infection No longer available in U.S. 1
Sunitinib (Sutent®) Anti-cancer/RCC , GIST 2
Tacrolimus (Prograf®) Immunosuppressant/Immune 
suppression2
Tamoxifen (Nolvadex®) Anti-cancer/breast cancer 2
Telithromycin (Ketek®) Antibiotic/bacterial infection 2
Terfenadine (Seldane®) Antihistamine/ allergic rhinitis No longer ava ilable in U.S. 1
Thioridazine (Mellaril®) Anti-psychotic/schizophrenia 1
Tizanidine (Zanaflex®) Muscle relaxant/ 2
Trazodone (Desyrel®) Anti-depressant/ depression, 
insomnia3
CL_0092 5.[ADDRESS_772466]-C-001-09Generic Name
(Brand Nam e)Drug Class / Clinical Usage Comments Risk 
List
Trim ethoprim -Sulfa 
(Septra®or Bactrim®)Antibiotic/bacterial infection Also available in DS (double 
strength)3
Trim ipram ine 
(Surmontil®)Tricyclic 
Antidepressant/depression3
Vandetanib (Caprelsa®) Anti-cancer/ thyroid cancer 1
Vardenafil (Levitra®) Phosphodiesterase 
inhibitor/vasodilator2
Venlafaxine (Effexor®) Anti-depressant/depression 2
Voriconazole (VFend®) Anti-fungal/anti -fungal 2
Ziprasidone (Geodon®) Anti-psychotic/schizophrenia [ADDRESS_772467]-C-001-09APPENDIX 8:QTC SUBSTUDY PROTOC OL
An Uncontrolled, Open -label, Substudy within APL -C-001-09 Clinical Study 
(ADMYRE) in Patients with Relapsed/Refractory Multiple Myeloma, Evaluating 
the Potential Effects of Plitidepsin on the QT Intervals of the Electrocardiogram.
1. INTRODUCTION
Plitidepsin showed no relevant cardiac toxicity  during preclinic al/toxicology  studies. 
However, other cyclic depsipeptides have been linked to increased cardiac toxicity , and 
thus a retrospective study  of the cardiac adverse events [e.g., rhythm abnormalities, 
myocardial injury  events, electrocardiogram (ECG) alteratio ns] that occurred in all 
patients treated with single -agent plitidepsin was conducted. This study  showed that the 
frequency  of these events was not different to that reported in the age-matched healthy 
population, thereb y suggesting that plitidepsin has a safe cardiac risk profile in cancer 
patients. [1]
1.1.  SUBSTUDY RATIONALE
An undesirable propert y of some drugs is their ability  to delay  cardiac repolarization, an 
effect that can be measured as prolongation of the QT interval on the surface 
electrocardiogr am (ECG). The QT interval represents the duration of ventricular 
depolarization and subsequent repolarization, and is measured from the beginning of the 
QRS complex to the end of the T wave. A delay  in cardiac repolarization creates an 
electroph ysiological environment that favors the development of cardiac arrhythmias, 
most clearl y torsades de pointes (TdP), but possibly  other ventricular tachy arrhy thmias 
as well. TdP is a polymorphic ventricular tachy arrhy thmia that appears on the ECG as 
continuous twistin g of the vector of the QRS complex around the isoelectric baseline. A 
feature of TdP is pronounced prolongation of the QT interval in the supraventricular 
beat preceding the arrhy thmia. TdP can degenerate into ventricular fibrillation, leading 
to sudden death. While the degree of QT prolongation is recognized as an imperfect 
biomarker for proarrh ythmic risk, in general there is a qualitative relationship between 
QT prolongation and the risk of TdP, especially  for drugs that cause substantial 
prolongation ofthe QT interval. Because of its inverse relationship to heart rate, the 
measured QT interval is routinely  corrected by  [CONTACT_587206] a less heart 
rate-dependent value known as the QTc interval. It is not clear, however, whether 
arrhythmia development is more closely  related to an increase in the absolute QT 
interval or QTc. Most drugs that have caused TdP clearly  increase both the absolute QT 
and the QTc (hereafter called QT/QTc). Documented cases of TdP (fatal and nonfatal) 
associated with the use of a drug have resulted in the withdrawal from the market of 
several drugs and relegation of other drugs to second -line status. Because prolongation 
of the QT/QTc interval is the ECG finding associated with the increased susceptibilit y 
to these arrhythmias, an adequate premarketing investigation of the safety  of a new 
pharmaceutical agent should include rigorous characterization of its effects on the 
QT/QTc interval .[2]
CL_0092 5.[ADDRESS_772468] marker of the risk of 
proarrh ythmia. [3]
Patients with refractory  malignancies and expected reduced survival could justifiably  be 
excused from the burden of time-matched baseline ECG values and separate 
administration of a positive control. [4]
Therefore, this substudy  will be conducted in patients who may benefit from the 
anticancer activity  of plitidepsin at the recommended dose, such as those enrolled in 
clinical trial APL -C-001-09. The potential effects of a 5 mg/m2 plitidepsin dose given as 
a 3-hour intravenous infusion on the QTc interval duration will be assessed when the 
patient is treated with plitidepsin for the first time (Day  1 of Cycle 1). In order to detect 
any delayed drug effect on the QTc interval, these investigations will be repeated at the 
second infusion of plitidepsin (Day  15 of Cycle 1), when the drug is expected to reach 
the stead y state in spi[INVESTIGATOR_587129] ’slong terminal half-life in blood ,approximately 
[ADDRESS_772469] advanced 
age, concomitant medical problems and prior QT-prolonging chemotherapy .[5]For this 
reason, an intrapatient standard deviatio n of 18 milliseconds is assumed. To reduce 
intrapatient variability  due to measurement error, it has been recommended that the 
baseline QTc be rigorously  investigated and be expressed as the mean of multiple 
electrocardiogram assessments. [6]For this purpose, two sets of triplicate ECG tracings 
recorded before plitidepsin administration will be considered baseline assessments: one 
set before and one after prophy lactic medication administration on Day s [ADDRESS_772470]-C-001-091.3.DNA COLLECTION RATIONALE
Genetic variation can be an important contributory  factor to interindividual differ ences 
in QT/QTc changes to drug exposure. The collection of an additional sample will allow 
for genetic evaluation of mutations associated with ion channelopathies in case marked 
drug-related changes of the QT/QTc interval are observed. Details are provide d in 
Section 7.4 QT-Related Poly morphisms Assessment.
2. OBJECTIVES
Based on the aforementioned scientific background, the primary  objective of the present 
substudy  is to assess the potential effects of plitidepsin administered at a therapeutic 
dose on the duration of the QT/QTc interval, measured by [CONTACT_397910], in patients with 
relapsed/refractory  multiple my eloma.
Secondary  objectives are:to evaluate QTc changes over the treatment period; to 
characterize the plitidepsin (real and estimated) whole blood concen tration/QTc 
relationship (or PK/PD relationship); and to explore related ECG parameters.
3. OVERALL SUBSTUDY DESIGN
This is an uncontrolled, open -label, substudy within APL-C-001-09 clinical trial 
(ADMYRE) in patients with relapsed/refractory multiple myeloma, evaluating the 
potential effects of plitidepsin on the QT/QTc intervals of the ECG.
Patients will be enrolled as needed to ensure at least 36 evaluable patients with 
evaluable ECG data .
Patients will be admitted to the study  site on Days 1 and 15 (atleast 2 hours before 
plitidepsin administration) until completion of the pharmacokinetic (PK) blood sample 
collection scheduled at three hours after EOI. After completing all other baseline 
assessments on Days [ADDRESS_772471] one hour prior to the start of 
the plitidepsin infusion (SOI ).
Patients will be administered the proph ylactic medication at [ADDRESS_772472] the stud y site. Patients will be asked to:
-keep calm and relaxed until the next day (i.e., at 21 hours after EOI), when the 
ECG recorder will be rem oved.
-remain in a supi[INVESTIGATOR_587130] 10 minutes before 6, 9 and 21 hours after EOI . 
Specific times will be reminded (see section 4.4 Patient’s Card)
CL_0092 5.[ADDRESS_772473] 30 minutes before the next PK 
blood sample collection (i.e., 3 hours after EOI). The activities of patients at the study  
site will be modified to avoid strenuous effort or emotional excitement.
An additional blood sample (10 mL) may be collected on Day 1 prior to treatment to 
allow for genetic evaluation of mutations associated with ion channelopathies, in case 
marked drug-related changes of the QT/QTc interval are observed. Participation in the 
QT-related poly morphisms assessment is optional.
Details on the timing of the treatment and assessments are given in the substudy ’s 
Schedule of Assessments and Procedures (see below) .
4. PATIENT DEFINITION
4.1. SUBSTUDY POPULATION
Patients will be enrolled in the substudy  as needed to ensure that at least [ADDRESS_772474] completed all required assessments (see Section 5.1).
The inclusion and exclusion criteria for enrolling patients in this substudy  are described 
in the following sections.
4.2.PATIENT ELIGIBILITY
4.2.1. Inclusion Criteria
In order to be enrolled in the substudy , patients must satisfy  the following criteria at 
screening for the main study :
1.Patient included in the clinical study  APL-C-001-09 and randomized to the 
experimental arm (plitidepsin + dexamethasone).
2.Patient with voluntarily  signed and dated informed consent to participate in the 
QT substudy .
3.A 12-lead ECG consistent with normal cardiac conduction and function, 
showing:
Sinus rhy thm.
Pulse rate between 45 and 100 bpm.
QRS interval <1 20 ms.
PR interval <[ADDRESS_772475] infusion, ≤ grade 1:
Ionic Ca++: 1.0 –1.5 mmol/L .
K+: 3 –5.5 mmol/L .
Mg++: 0.5 –1.23 mmol/L.
4.2.2. E xclusion Criteria
Patients who meet any of the following criteria will be excluded from participating in 
the substudy :
1.Has heart rhythm disturbances (e.g. atrial fibrillation), unusual T wave and U 
wave (if present) morphology , personal or famil y history  of Long QT Sy ndrome, 
ECG findings of complete left bundle branch block, permanent ventricular 
pacemaker, or Brugada Sy ndrome .
2.Has any skin condition likely  to interfere with ECG electrode placement, or a 
history  of breast implant or thoracic surgery  likely  to cause abnormality  in 
electrical conduction.
3.Prior exposure to anthracy clines at a cumulative dose of doxorubicin or 
equivalent greater than 450 mg/m².
4.Patients who at screening are on medication that is known to prolong the QT 
interval (refer to Appendi x 7 of the main protocol). Patients must have been off 
these medications for a minimum of [ADDRESS_772476] refrain from joggi ng, strenuous exercises of all ty pes, and sunbathing from 
48 hours before Days 1 and 15 until after the end of the continuous ~24-hour 
ECG recording on Day s 1 and 15.
2.May not consume beverages containing alcohol from 24 hours before Days 1 
and 15 until after the end of the continuous ~24-hour ECG recording on Days [ADDRESS_772477] refrain from using any methy lxanthine -containing products, (e.g., 
chocolate bars or beverages, coffee, tea, or colas) from 48 hours before Days 1 
and 15 until after the end of the continuous ~24-hour ECG recording on Days [ADDRESS_772478] meals during their stay at the study  site. Meals 
will not contain spi[INVESTIGATOR_587131] (i.e., black pepper, hot peppers, wasabi, etc). 
Excessive food consumption will not be permitted.
4.4.PATIENT’S CARD
The Investigator will provide the patient with a card listing all prohibited activities and 
substances during the substudy . This card will contain blank spaces for the Investigator 
to write down the specific times of the ECG timepoints at 6, [ADDRESS_772479] remember to tell the patient that he/she must remain in a supi[INVESTIGATOR_587132] [ADDRESS_772480] completed the substudy  if he/she has evaluable 
ECG data . 
5.2.WITHDRAWAL/DISCONTINUATION FROM THE SUBSTUDY
A patient will be withdrawn from the substudy  for any  of the following reasons:
-Withdrawal of substudy  ICF.
-The patient does not comply  with the substudy  requirement s, including inclusion 
criteria, exclusion criteria, and prohibitions and restrictions.
Patients who withdraw from the substudy  will be replaced as needed in order to ensure 
that at least 36 evaluable patients complete the substudy .
5.3. WITHDRAWAL FROM QT-RELATED POLYMORPHISMS
ASSESSMENT ONLY
A patient may withdraw his/her consent for the QT-related polymorphisms assessment 
while being evaluable for the substudy . In such a case, collected blood samples will be 
destroy ed. To initiate the sample destruction process, the Investigator must notify  the 
Sponsor’s center contact [CONTACT_587207]. In turn, the Sponsor’s center 
contact [CONTACT_587208]. If requested, the 
Investigator will receive written confirmatio n from the Sponsor/central lab that the 
sample has been destro yed.
6. TREATMENT
6.1.PROPHYLACTIC MEDICATION
During the substudy  (Cycle 1 of main study ), all patients must receive the following 
prophy lactic medication at 20-30 minutes before infusion of p litidepsin:
CL_0092 5.[ADDRESS_772481]-C-001-09Palonosetron 0.25 mg i.v. (tropi[INVESTIGATOR_14960] 5 mg i.v. could be considered if 
palonosetron is not available).
Dexchlorpheniramine 5 mg i.v. or chlorpheniramine 10 mg i.v., 
(dexchlorpheniramine 6 mg p.o. or chlorpheniramine 10-15 mg p.o. could be 
considered, if i.v. formulations are not available) .
Ranitidine 50 mg i.v. or cimetidine 300 mg i.v.
Oral aprepi[INVESTIGATOR_587133]’s criteria/institutional guidelines. 
Metoclopramide should be avoided.
The use of alternative prophy lactic medi cations should be discussed in advance with the 
Sponsor.
6.2.PROHIBITED MEDICATIONS/THERAPI[INVESTIGATOR_587134]/or induce torsades de pointes are prohibited 
(refer to Appendix 7 of the main protocol). Patients must have been off these
medications for a minimum of 48 hours prior to plitidepsin administration on Days 1 
and 15.
7. SUBSTUDY EVALUATIONS
7.1.SUBSTUDY PROCEDURES
The substudy ’s Schedule of Assessments and Procedures summarizes the frequency  and 
timing of continuous ECG recor der placement for pharmacod ynamic (PD) assessments 
and PK and QT -related poly morphisms sample collection.
A [ADDRESS_772482] consented to 
participate in the QT -related poly morphisms assessment of the subs tudy.
7.2.PHARMACOKINETIC EVALUATIONS
Plitidepsin PK assessment in patients participating in the substudy  will be the same as 
the one conducted on patients in Arm A of the main study . Please refer to the main 
study  protocol, Section 6.2.
7.3.PHARMACODYNA MIC EVALUATIONS
Patients will wear a continuous ECG recorder on Days 1 and 15, from prior to 
prophy laxis administration to 21 hours after EOI. This ECG recorder will be provided 
by [CONTACT_587209]’s MYSTUDY PORTALTM. 
Registration details will be provided to the site coordinator at each participating site.
The ECG recorder will be set in place once all safet y assessments scheduled for the 
main study  (i.e., vital signs, blood sample extraction for laboratory  tests, and EC G) have 
been conducted.
CL_0092 5.[ADDRESS_772483]-C-001-09On Day 1 and Day 15, serial ECGs with stable resting heart rate will be extracted from 
the continuous recording in triplicate (three 10 -second digital ECGs in close succession) 
within a 10 minute (±5min) window at each scheduled time point of the ECG 
assessments:
Pre-proph ylaxis (Predose 1), post -proph ylaxis and prior to SOI (Predose 2) *, 
1.[ADDRESS_772484] before the end of infusion (EOI)*, 0.5, 1*, 3*, 6, 9, and 21 
hours after EOI.
*Triplicate ECGs will be extracted prior to the corresponding PK blood sample 
collection.
Patients will remain in the same comfortable supi[INVESTIGATOR_21683] [ADDRESS_772485] -party, central ECG 
laboratory  (for triplicate ECG extraction at the scheduled time window, measurement of 
intervals, diagnostics of abnormalities and review of ECG waveform morphology ). 
Quality  assurance procedures will be used to ensure high precision and consistency  of 
QT interval measurements.
For the triplicate ECGs collected at each time point, the average of the three 
measurements for each ECG parameter will be considered for all listing and statistical 
analyses described below. 
7.3.1. QT Correction Methods
QT will be corrected for heart rate using the following methods:
Primary : Fridericia’s correction method (QTcF). [7]
Secondary : Bazett’s correction method (QTcB). [8]
7.3.2. Pharmacodynamic Endpoints
In principle, for each patient and each postdose time point on Day 1 and Day 15, 
baseline QTc intervals will be the mean of the Predose 1 and Predose 2 QTc values for 
that patient on Day  1.
If the mean Predose 2 QTc value of all evaluable patients is ≥[ADDRESS_772486] of prophylactic medication on QTc cannot be 
ruled out; therefore, individual Predose 2 QTc values will be considered as the baseline 
values.
The change from baseline (ΔQTc) will be calculated using the corresponding baseline 
QTc values. Specificall y:
ΔQTc at time t: Difference in QTc betw een scheduled time point t and 
baseline.
CL_0092 5.[ADDRESS_772487]-C-001-09The primary  pharmacody namic (PD) endpoint will be ΔQTc at each scheduled time 
point. ΔQTc will be summarized where QTc is derived using both the QTcF and QTcB 
correction methods whereb y QTc denotes a general notatio n of corrected QT using 
either method.
7.4.QT-RELATED POLYMORPHISMS ASSESSMENT
A 10 mL blood sample will be collected on Day 1 from patients who consented to take 
part in the QT-related polymorphisms assessment of the substudy  at the time point 
indicated in the substudy ’s Schedule of Assessments and Procedures (see below) . 
Participation in the QT -related pol ymorphisms assessment is optional.
A manual of instructions for sample collection, labeling, storage, and shipment will be 
provided as a separate docum ent (Instruction Manual for the Collection, Labeling, 
Storage and Shipment of Pharmacokinetic Samples).
If a patient shows marked drug-related changes of the QTc interval and a genetic cause 
is suspected, that individual sample will be anal yzed.
Genes currently hypothesized to potentially  be relevant to irregular QT/QTc intervals 
such as KCNE1, KCNE2, KCNH2, KCNQ1 and SCN5A will be considered for 
genot ypi[INVESTIGATOR_007].
When the ECG database will be locked, if no marked drug-related changes are 
observed, all samples for QT-related polymorphisms assessment from the substudy  will 
be destro yed.
7.4.1. Confidentiality of Samples for QT -related Polymorphisms Assessment
PharmaMar shall comply  with the Directive 95/46/EC of the European Parliament and 
of the Council of [ADDRESS_772488]. Sponsor personnel whose responsibilities require 
access to personal data agree to keep the identity  of substudy  patients confidential.
Samples will be stored until the ECG database has been locked, when the decision on 
whether it is necessary  to rule out mutations associated with ion channelopathies, is 
made.
7.5. 12 -LEAD ECG ACQUISITION
ECGs will be obtained digitally  using a Mortara Instrument (Milwaukee, WI, [LOCATION_003]) H-
12+ ECG continuous [ADDRESS_772489] is received by [CONTACT_587210]. ECGs to be used in the analy sis 
will be selected by [CONTACT_587211] y using a high-resolution manual on-screen caliper semiautomatic method with 
annotations. In this trial using pre-treatment ECGs as the baseline, the H-12+ recording 
CL_0092 5.[ADDRESS_772490] 
EOI in order to obtain the baseline ECGs as detailed below.
ECGs for the treatment day s will be obtained as triplicate (3) 12 -lead ECGs at each time 
point which will be downloaded from the H-12+ flash card approximately  one minute 
apart on Day 1 and Day 15.  On Day 1 and Day 15, baseline ECGs will be extracted (in 
triplicate) pre-prophy laxis (Predose 1), post-prophy laxis and prior to SOI (Predose 2).  
On Day  1 and Day  15, triplicate ECGs will be extracted at the following time points: 1.[ADDRESS_772491] flash memory  cards provided to the site. The patient’s unique 
identification number and demog raphic information will be recorded for each card. ERT 
will generate a 10-second, 12-lead digital ECG at each time point specified in the 
protocol. If targeted ECG time points are artifactual and of poor quality , ERT will 
capture anal yzable 10 -second ECGs as close as possible to the targeted time points.
Digital ECGs will be transmitted to ERT’s validated data management system, 
EXPERT. Interval duration measurements will be collected using computer assisted 
caliper placements on three consecutive beats. Trained analysts will then review all 
ECGs for correct lead and beat placement and will adjudicate the pre-placed algorithm 
calipers as necessary  using the proprietary  validated electronic caliper system applied 
on a computer screen. A cardiologist will then verify  the interval durations and perform 
the morphology  analysis, noting any T-U wave complex that is compatible with an 
effect on cardiac repolarization. 
The ECG analysis will be conducted in Lead II, or in Lead V5 if Lead II is not 
analyzable. If Lead V5 is not analy zable then Lead V2 will be used, followed by [CONTACT_587212] . ECG readers will be blinded to patient identifiers, 
and visit. All ECGs for a given patient will be analyzed by [CONTACT_336601]. Quality 
Assurance reports for inter-and intra-observer variability  will be produced by [CONTACT_587213].
On-screen measurements of the RR, PR, QRS, and QT interval durations will be 
performed and variables for QTcF, QTcB, and heart rate (HR) will be obtained by [CONTACT_302712]:
Interval measurements will be obtained by  [CONTACT_117843]: 
Three (3) RR mean RR I nterval is reported.
Three (3) PR mean PR I nterval is reported.
Three (3) QRS mean QRS Width is reported.
Three (3) QT mean QT Interval is reported.
The following calculations will be made from the interval measurements:
CL_0092 5.[ADDRESS_772492]-C-001-09Three (3) QTcF measurements -QTc correction by [CONTACT_469414]’s formula
QTcF1 = QT1/3RR1
QTcF2 = QT2/3RR2
QTcF3 = QT3/3RR3
Mean QTcF = (QTcF1 + Q TcF2 + QTcF3)/3
Three (3) QTcB measurements -QTc correction by [CONTACT_581139]’s formula
QTcB1 = QT1/ RR1
QTcB2 = QT2/ RR2
QTcB3 = QT3/ RR3
Mean QTcB = (QTcB1 + QTcB2 + QTcB3)/3
Three (3) Heart Rate measurements
HR1 = 60 / RR1 
HR2 = 60 / RR2 
HR3 = 60 / RR3 
Mean HR = (HR1 + HR2 + HR3)/3
Each fiducial point (onset of P wave, onset of Q wave, offset of S wave, and offset of T 
wave) will be electronically  marked. The original ECG waveform and such annotations 
will be saved separatel y in XML  format for independent review.
8. STATISTICAL METHODS
A non-inferiorit y limit of 20 ms will be used for the comparison of the effects of 
plitidepsin on the QT/QTc intervals.
8.1. SAMPLE SIZE
Using a standard deviation of 18 ms in a sample size of 36 evaluable patients, the 
probability  that the upper limit of the one-sided 95% confidence interval (CI) for the 
difference in mean QTc between each time point and baseline (ΔQTc) will fall below 20 
ms is 80%, when the true difference in means equals [ADDRESS_772493] anal ysis of variance (ANOVA) model will be fitted with the QTc data as 
the dependent variable and intervention (baseline vs. postdose), scheduled time point t 
of measurement (where t will be baseline, 1.[ADDRESS_772494] before the EOI, 0.5, 1, 3, 6, 
9and 21 hours after EOI) and treatment period (Day  1 and Day 15) as fixed effects and 
patient as a random effect. Using the estimated least square means and intrapatient 
variance obtained from this model, a one-sided 95% CI will be calculated for the 
CL_0092 5.[ADDRESS_772495]-C-001-09difference in mean QTc between baseline and each scheduled time point t. Non-
inferiority  will be concluded if at each scheduled time point the upper -limit of the one-
sided 95% CI  falls below 20 ms.
Mean ECG parameters (QT, QTc, RR, heart rate, QRS, and PR) and corresponding 
changes from baseline will be listed and summarized descriptively  by [CONTACT_7206] t. Plots 
of mean QTc changes from baseline (ΔQTc) vs. the scheduled time point t will be 
prepared.
The incidence count and percentage of patients with QTc increase from baseline 
(ΔQTc) >30-60 ms and >60 ms will be tabulated for each time point t, age and gender. 
The incidence count and percentage of patients with any postdose QTc values >450 ms 
and >480 ms, will be tabulated for each time point t, and gender. Patients with QTc 
values >500 ms will be listed.
The incidence count of patients with PR >200 ms, QRS >120 ms, heart rate >100 bpm
and <[ADDRESS_772496] segment (e.g. flat, depressed, 
elevated) and T wave (i.e. present or absent) and U wave (e.g. flattened, inverted, 
biphasic and notched) will be reported.
8.3. PHARMACOKINETIC /PHARMACODYNAMIC ANA LYSES
The PK/PD analyses will be based on data collected from the scheduled time points of 
ECG measurement and:
1.their corresponding whole blood plitidepsin concentration.
2.their estimated whole blood plitidepsin concentration at the corresponding ECG 
time point by  [CONTACT_587214].
Evaluable patients (i.e., those who have evaluable ECG data) who withdraw before 
completing both days (i.e., Days 1 and 15) will be included in these analy ses. Plots of 
individual QTc changes from baseline (ΔQTc) vs. the corresponding plitidepsin blood 
concentrations will be prepared to explore any concentration -effect relationship for 
plitidepsin.
The concentration –QTc relationship will be assessed  using a linear mixed effects 
analysis of the relationship between ΔQTc data and plitidepsin concentration according 
to the equation: ΔQTc = α + β*[plitidepsin], where inter-individual variability  will be 
estimated for both intercept (α) and slope (β). The effect of treatment period (i.e. Day 1 
or Day 15) on slope and intercept will also be evaluated. If the intercept term is not 
significant, the model will be re-fit with a zero intercept term. The predicted value of 
ΔQTc (along with 90% CI) will be estimated at the mean maximum plasma (Cmax) 
values of plitidepsin.
Additionally , in a complementary  PK/PD analysis, the relationship between QTc and 
plitidepsin whole blood concentration will be assessed using linear mixed effect 
modeling to estimate t he maximal change (mean and upper 95% confidence limit) in the 
QTc associated with therapeutic concentrations of plitidepsin.
CL_0092 5.[ADDRESS_772497]-C-001-099. REFERENCES
1. Soto-Matos, A., et al., Plitidepsin has a safe cardiac profile: a comprehensive 
analysis. Mar Drugs, 2011. 9(6): p. 1007 -23.
2. E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic 
Potential for Non-Antiarrhythmic Drugs. Guidance for Industry. , F.a.D.A. U.S. 
Department of Health and Human Services, Center for Drug Evaluation and 
Research, Center for Biologics Evaluation and Research, ICH. , Editor Oct. 
2005.
3. Morganroth, J., R.R. Shah, and J.W. Scott, Evaluation and management of 
cardiac safety using the electrocardiogram in oncology clinical trials: focus on 
cardiac repolarization (QTc interval). Clin Pharmacol Ther, 2010. 87(2): p. 
166-74.
4. Rock, E.P., et al., Assessing proarrhythmic potential of drugs when optimal 
studies are infeasible. Am Heart J, 2009. 157(5): p. 827 -36, 836 e1.
5. Mason, J.W., et al., Electrocardiographic reference ranges derived from 79,743 
ambulatory subjects. J Electrocardiol, 2007. 40(3): p. 228 -34.
6. Varterasian, M., et al., Consideration of QT/QTc interval data in a phase I study 
in patients with advanced cancer. Clin Cancer Res, 2004. 10(17): p. 5967 -8; 
author repl y 5968 -9.
7. Fridericia, L.S., Die Systolendauer im Elektrokardiogramm bei normalen 
Menschen und bei Herzkranken. Acta Medica Scandinavica, Stockholm, 1920. 
57: p. 469 -486.
8. Bazett, H., An analysis of the time-relationship of electrocardiograms. Heart, 
1919. 70: p. [ADDRESS_772498]-C-001-09SCHEDULE OFASSESSMENTS AND PROCEDURES
PROCEDURE ScreeningDay 1 Cycle 1 Day 15 Cycle 1
-2 hours-30 minpredose0+3 hours 
(just before EOI)+4 hours 
(1-h after EOI)+4.5 hours 
(1.5-h after EOI)+6 hours 
(3-h after EOI)-2 hours-30 minpredose0+3 hours 
(just before EOI)+4 hours 
(1-h after EOI)+4.5 hours
(1.5-h after EOI)+6 hours 
(3-h after EOI)
Written substudy -specific informed consentBefore any
procedures- - - - - - - - - - - - - - - -
Written IC for QT -related polymorphisms assessment * -14  to  0 - - - - - - - - - - - - - - - -
Review of substudy -specific inclusion/exclusion criteria -14  to  0 - - - - - - - - - - - - - - - -
Patient admission at the study site and Holter placement ** -  - - - - - - -  - - - - - - -
Intravenous prophylaxis medication - - - - - - - - - - - - - - -
Blood sample (10 mL) for QT -related polymorphisms - - -  - - - - - - - - - - - -
PK blood sample (4 mL) - - -  -   -  - - -   - 
Plitidepsin treatment - - - -  - - - - - - - - - - -
Meal - - - - - - -  - - - - - - -  -
*Patient participation in QT -related polymorphisms assessment is optional. Sample w ill be collected on Day 1.
**The ECG recorder will be set in place once all safety assessments scheduled for the main study (i.e., vital signs, blood samp le extraction for laboratory 
tests, and ECG) have been conducted.
ECG, electrocardiogram ; EOI, end of infusion; IC, Informed Consent; PK, pharmacokinetics.